TrialID,url,Scientific_title,Conditions,Interventions,Public_title,Source_registry,Date_registration_format,Date_enrollment_format,Day_inferred,Study_type,Study_design,Phase,Target_size,Primary_sponsor,Countries,Bridging_flag,Retrospective_flag,Date_registration,Date_enrollment,Last Refreshed on,Acronym,Date registration3,Export date,Source Register,Recruitment_status,other records,Inclusion agemin,Inclusion agemax,Inclusion gender,Contact Firstname,Contact Lastname,Contact Address,Contact Email,Contact Tel,Contact Affiliation,Inclusion Criteria,Exclusion Criteria,Primary outcome,results date posted,results date completed,results url link,Bridged type,results yes no,Date_registration3_format
ACTRN12620000588998,https://anzctr.org.au/ACTRN12620000588998.aspx,The safety and efficacy of STC3141 in patient with COVID-19 ARDS require intensive care,COVID-19 infection; <br>COVID-19 infection;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases,"This is a two- stage study.<br> Stage 1:  Patients will receive STC3141 60 mg/hr as an initial infusion rate which was based on phase Ia study in health volunteer and 60mg/hr is the dosage in long term infusion in phase Ia without aPTT increase, followed by a dose increase of 10 mg/hr every 6 hours  until the max infusion rate is 100 mg/hr or the aPTT reaches 1.5 x ULN which ever comes first, then the infusion rate will be fixed in the rest of time. The infusion will continue at this rate for 72 hr. <br>Stage 2: Arm 1 will receive STC3141 with the initial infusion rate decided from Stage 1 by DSMB, the dosage will be adjusted every 6 hours according to subjects’ aPTT as same as stage 1. The target aPTT and Maximum dosage will be based on DSMB recommendation based on data from stage 1. The infusion last up to 120 hours, unless the patients is well enough to be discharged from ICU, or pass away or experienced intolerable adverse event etc.",The safety and efficacy of STC3141 in patient with COVID-19 Acute Respiratory Distress Syndrome,ANZCTR,2020-05-21,2020-05-29,FALSE,Interventional,Purpose: Treatment; Allocation: Randomised controlled trial;,Phase 2,160,Grand Medical Pty Ltd,Australia,FALSE,Yes,21/05/2020,29/05/2020,3 August 2020,NA,20200521,12/3/2020 5:31:55 PM,ANZCTR,NA,No,18 Years,80 Years,Both males and females,NA,NA,NA,NA,NA,NA,"Inclusion criteria: Subjects entering the ICU and presenting with confirmed or suspected COVID-19-related ARDS will be enrolled in the trial.<br>1. Aged 18 to 80 years (inclusive at the time of consent)<br>2. Subjects are diagnosed with moderate to severe ARDS that has been present for less than 3 days<br>3. Meet Berlin Definition<br>1)	Must have a partial pressure of arterial O2 (PaO2)/ fraction of inspired O2 (FiO2)  less than or equal to 200 mmHg on invasive or non-invasive ventilation with the level of positive end-expiratory pressure (PEEP) or continuous positive pressure (CPAP) greater than or equal to 5cmH2O.<br>2)	Bilateral opacities not fully explained by effusion, lobar or lung collapse, or nodules by chest X-ray or CT <br>3)	Respiratory failure not fully explained by heart failure or fluid overload<br>In the opinion of the treating clinicians, likely to survive beyond the day after tomorrow.<br>4. Subjects who are consented<br>","Exclusion criteria: 1. Subjects who have  <55 ml/min/BSA<br>2. Subjects who require ECMO<br>3. Subjects who require a therapeutic dose of heparin or who are receiving oral<br>anticoagulants, or received warfarin, factor Xa inhibitors within last 24 hours<br>4. Subjects who have Absolute Neutrophil Count (ANC) <1000/mL;<br>6. Subjects who have activated Partial Thromboplastin Time (aPTT) >55 s;<br>7. Severe anaemia (haemoglobin;<br>8. Bleeding in the past 24 hours requiring blood transfusion;<br>9. Subjects who have the following chronic organ dysfunction or immunosuppression","Changes in PaO2/FiO2 assessed by arterial blood gases and  ventilator measures[end of infusion in stage 2];Incidence, nature and severity of AEs and SAEs[D10 in stage 1];Incidence of treatment discontinuation due to AEs [D10 in stage 1]",NA,NA,NA,NA,NA,2020-05-21
ACTRN12620000731998,https://anzctr.org.au/ACTRN12620000731998.aspx,Safety and efficacy of a pharmacological strategy using Losartan in hospital patients with COVID-19,COVID-19; <br>COVID-19;Respiratory - Other respiratory disorders / diseases;Inflammatory and Immune System - Other inflammatory or immune system disorders;Infection - Other infectious diseases,"This is a multisite, 3 stage inpatient study of the Angiotensin II Receptor Blocker Losartan for treatment of COVID-19. The three stages will be recruited sequentially. <br><br>In the first stage, 9 participants will be allocated to the active treatment. The first intervention studied will be Losartan 25mg tablet once daily, for 7 days, or their entire admission (whichever is longer).<br><br>Following complete recruitment to the first stage, participants will be allocated to the second stage of the study. In the second stage, 9 participants will start at 25mg Losartan. If hemodynamically stable after 24 hours, they will increase dose to 25mg twice daily for 7 days, or their entire admission (whichever is longer).<br>If not (clinical decision) the participant will stay on 25mg daily for 7 days, or the remainder of for their admission (whichever is longer).<br><br>Following complete recruitment to the first and second stages, participants will be allocated to the third stage of the study. In the third stage, 9 participants will start on 25 mg Losartan daily. If hemodynamically stable after 24 hours, they will increase dose to 25mg twice daily. Then, if hemodynamically stable after further 24 hours, they will increase dose again to 25mg morning and 50mg night. After a further 24 hours, and if the participant is hemodynamically stable, they will increase dose to 50mg twice daily for 7 days, or the remainder of for their admission (whichever is longer).<br><br>For all stages, the dose will be held if the blood pressure systolic reading is less than 100mmHg, and/or a renal function decrease of greater than 30% from baseline is observed, or serum potassium greater than permitted by the institutional upper limit of normal (ULN) occurs. <br><br>Losartan will be restarted at the",Will treating the overwhelming patient response with medications affect COVID-19 mortality?,ANZCTR,2020-07-13,2020-09-01,FALSE,Interventional,Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Safety/efficacy;,Phase 1,36,NSW Health via the Hunter New England Local Health District,Australia,FALSE,Yes,13/07/2020,01/09/2020,20 July 2020,NA,20200713,12/3/2020 5:31:55 PM,ANZCTR,Not Recruiting,No,18 Years,No limit,Both males and females,NA,NA,NA,NA,NA,NA,"Inclusion criteria: Confirmed SARS-CoV-2 infection by any method<br>Current admission as inpatient to hospital ward for management of COVID-19","Exclusion criteria: Current use of RAS agent<br>Known contra-indication to any RAS agent<br>Participation in another clinical trial for COVID-19 or SARS-CoV-2<br>Current or previous admission to ICU for COVID-19 management","To determine the incidence of any treatment emergent AE, using using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Targeted toxicities include hypotension, skin rash. These will be coded at all timepoints by both the clinician and the clinical trial manager in terms of causality.[CTCAE v5.0 will be completed and assessed daily until the patient is no longer on trial, that is 7 days or until discharge, whichever is longer. The primary endpoint will be assessed days 1-7, but in this study all time points will be assessed during analysis.];Incidence of Blood Pressure toxicity, defined as systolic BP readings < 100mmHg that do not return to baseline within 24 hours will be measured as per standard local hospital practice (digital or manual sphygmomanometer), and required to be measured at least daily (once in 24 hours).[The incidence will be assessed daily until patient no longer on trial, that is 7 days or until discharge, whichever is longer. The primary endpoint will be assessed days 1-7, but in this study all time points will be assessed during analysis.]",NA,NA,NA,NA,NA,2020-07-13
ChiCTR2000030944,http://www.chictr.org.cn/showproj.aspx?proj=50199,"An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia",Novel Coronavirus Pneumonia (COVID-19),"Experimental group:On the basis of the current clinical treatment of SNCP, NK cells and MSCs were increased;Control group:current clinical treatment of SNCP;",Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID-19),ChiCTR,2020-03-18,2020-09-01,FALSE,Interventional study,Parallel,1,Experimental group:10;Control group:10;,The Second Affiliated Hospital of Nanchang University,China,FALSE,Yes,2020-03-18,2020-09-01,23 March 2020,NA,20200318,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,4,80,Both,Ye Xiaoqun,NA,"1 Minde Road, Donghu District, Nanchang, Jiangxi, China",511201663@qq.com,+86 0791 86300047,The Second Affiliated Hospital of Nanchang University,"Inclusion criteria: 1. Patients are eligible for inclusion if they meet all of the following criteria within 5-7 days after the first admission to the ICU.<br>2. The patients met the diagnostic criteria of 2019-nCoV pneumonia (new coronavirus infection) pneumonia treatment plan (Fifth version), the National Health Office [2020] No.103.;<br>3. The primary disease is 2019 nCoV infection;<br>4. Respiratory distress, RP >=30 times/unit;<br>5. Under resting state, blood oxygen saturation <=93%;<br>6. PaO2 / FiO2 <=300nnhg (1mmhg = 0.133kpa);<br>7. Imaging data suggest bilateral lesions<br>8. Volunteer to participate in clinical research, understand and sign informed consent.","Exclusion criteria: 1. sNCP caused by other non-viral infections (such as trauma);<br>2. WHO grade III or IV pulmonary hypertension;<br>3. Malignant tumor in lung and other systems;<br>4. Lactating women or screening women with positive blood pregnancy test;<br>5. Idiopathic IgA deficiency;<br>6. Recent cardiovascular and cerebrovascular events (3 months);<br>7. Lung transplanted patients;<br>8. HIV positive patients;<br>9. According to the researcher's judgment, these subjects will be excluded because of some causes, such as any disease, treatment, or laboratory abnormal history or current evidence, which may confound the results of the study, interfere with the subject's participation in the study procedure, or be not in the best interest of the subject's participation in the study.",Changes of serum inflammatory factors;Patient death risk;Drug related adverse reactions and events;,NA,NA,NA,NA,NA,2020-03-18
ChiCTR2000039000,http://www.chictr.org.cn/showproj.aspx?proj=62581,"Randomized, double-blinded, placebo parallel-controlled phase III clinical trial to evaluate the Immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in healthy population aged 18 years and above",Novel coronavirus Pneumonia (COVID-19),placebo group:placebo;vaccine group:vaccine;,A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells),ChiCTR,2020-10-13,2020-09-02,FALSE,Interventional study,Parallel,3,placebo group:300;vaccine group:300;,China National Biotec Group Co.Ltd,Morocco,FALSE,No,2020-10-13,2020-09-02,9 November 2020,NA,20201013,12/3/2020 5:31:55 PM,ChiCTR,Recruiting,No,18,NA,Both,Professeur Abouqal Redouane,NA,"Ibn Sina Hospital, PO Box 25427, Safat, 13115, Kuwait",rabouqal@gmail.com,00212661224739,Ibn Sina Hospital,"Inclusion criteria: 1. Age range: Healthy subjects aged 18 years old and above;<br>2. By asking for medical history and physical examination, the investigator judged that the health condition is well;<br>3. Female subjects of childbearing age are not nursing or pregnant at the time of enrolment (negative urine pregnancy test) and have no family planning within the first 3 months after enrollment. Effective contraceptive measures have been taken within 2 weeks before inclusion;<br>4. During the whole follow-up period of the study, be able and willing to complete the whole prescribed study plan;<br>5. With self-ability to understand the research procedures, the informed consent & voluntarily sign an informed consent form and be able to comply with the requirements of the clinical study protocol.","Exclusion criteria: 1. Confirmed acute cases of SARS-CoV-2 Infection;<br>2. Have a history of SARS, MERS infection (self-report, on-site inquiry);<br>3. Fever (axillary temperature > 37.0 degree C), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination;<br>4. Axillary body temperature > 37.0 degree C before vaccination;<br>5. Previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated SARS-CoV-2 vaccine have occurred;<br>6. Has a history of convulsion, epilepsy, encephalopathy or mental illness or family history;<br>7. With congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;<br>8. With severe liver diseases, severe kidney diseases , uncontrollable hypertension (systolic blood pressure >140 mmHg, diastolic blood pressure > 90 mmHg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases;<br>9. Has been diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;<br>10. With known or suspected diseases include acute respiratory diseases (e.g. influenza like illness, acute cough, sore throat), severe cardiovascular diseases, liver and kidney diseases, and malignant tumors;<br>11. Has a history of coagulation dysfunction (e.g. Coagulation factor deficiency, coagulation disease);<br>12. Receiving anti-TB therapy;<br>13. Patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days);<br>14. Live attenuated vaccine is inoculated within 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination;<br>15. Received blood products within 3 months before this vaccination;<br>16. Received other research drugs within 6 months before this vaccination;<br>17. Other circumstances judged by investigators that are not suitable for this clinical trial;<br>18. Patients with high fever (axillary temperature >=39.0 degree C) lasting for 3 days after the previous dose of vaccine and severe allergic reaction;<br>19. Serious adverse reactions with causal relationship with the previous dose of vaccine;<br>20. Reach the endpoint of a study;<br>21. for the subjects newly identified or newly co-curred which does not meet the inclusion criteria for the first dose or meets the exclusion criteria for the first dose after the previous dose of vaccine is vaccinated, the investigator shall determine whether they should continue to participate in the trial;<br>22. Other reasons for exclusion that investigator believes;<br>23. If any of the following occurs during the trial, the relevant subjects are not required to stop the trial:<br>- Non-specific immunoglobulins were used during the study;<br>- Continuous oral or IV administration of steroid hormones for 14 days;	<br>24. above 18-23 criteria is the exclusion criteria of the second dose.","To evaluate the 4-fold increase rate, GMT and GMI of anti-SARS-CoV-2 neutralizing antibody 28 days after full course of immunization;",NA,NA,NA,NA,NA,2020-10-13
ChiCTR2000030469,http://www.chictr.org.cn/showproj.aspx?proj=50082,A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19),Novel Coronavirus Pneumonia (COVID-19),Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN;,A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19),ChiCTR,2020-03-02,2020-02-27,FALSE,Interventional study,Parallel,0,Control group:48;Experimental group:48;,Shanghai University of TCM,China,FALSE,No,2020-03-02,2020-02-27,9 March 2020,NA,20200302,12/3/2020 5:31:55 PM,ChiCTR,Recruiting,No,18,65,Both,Xiuming Song,NA,"528 Zhanghen Road, Pudong New Area District, Shanghai, China",Xiumingsong@sina.com,+86 13817525012,Shuguang Hospital Affiliated to Shanghai University of T.C.M.,"Inclusion criteria: 1. Real-time fluorescent RT-PCR detection of new coronavirus nucleic acid positive, or viral gene sequencing is highly homologous with known new coronavirus;<br>2. Confirmed as a novel coronavirus pneumonia common and severe patients, meets the diagnostic criteria of the ""novel coronavirus pneumonia diagnosis and treatment plan (trial implementation of the sixth edition)""<br>3. aged 18 to 65 years;<br>4. Learn about the significance of the study before the trial also the possible inconveniences and potential risk.","Exclusion criteria: 1. Patients with mild and critical novel coronavirus pneumonia;<br>2. Acute respiratory disease caused by non- novel coronavirus pneumonia;<br>3. Patients with diabetes and hypertension accompanied by severe primary immunodeficiency disease acquired immunodeficiency syndrome congenital respiratory malformation congenital heart disease pulmonary dysplasia and other diseases;<br>4. Patients with obvious abnormal heart, liver and kidney disease or serious other system diseases such as digestive system urogenital system blood system hemorrhagic disease central nervous system psychiatric diseases in acute stage, and endocrine and metabolic diseases;<br>5. People who are known to be allergic to the ingredients in the research drug, or patients with allergies; <br>6. Women who are breastfeeding, pregnant, or have a positive urine pregnancy test;<br>7. Patients who are participating in other clinical trials or patients who have participated in other drug clinical trials within 1 month;<br>8. Researchers find the patient inappropriate to be involved in the trial.",fever clearance time;Effective rate of TCM symptoms;,NA,NA,NA,NA,NA,2020-03-02
ChiCTR2000030033,http://www.chictr.org.cn/showproj.aspx?proj=49703,A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19),Novel Coronavirus Pneumonia (COVID-19),"Intervention group 1:Oral antiviral oral solution (Xiangxue Pharmaceutical);Intervention group 2:Oral ""Wu-Zhi-Fang-Guan-Fang"" decoction;Control group:Routine quarantine measures;",A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19),ChiCTR,2020-02-21,2020-02-24,FALSE,Interventional study,Parallel,New Treatment Measure Clinical Study,Intervention group 1:276;Intervention group 2:276;Control group:276;,The First Affiliated Hospital of Guangzhou Medical University,Chinese,FALSE,Yes,2020-02-21,2020-02-24,25 February 2020,NA,20200221,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,18,80,Both,Feng WANG,NA,"151 Yanjiang Road, Guangzhou, Guangdong, China",412475734@qq.com,+86 13710801606,The First Affiliated Hospital of Guangzhou Medical University,"Inclusion criteria: 1. Aged 18 to 80 years (inclusive);<br>2. People who had ineffective protection, i.e.:<br>1) living, studying, working together with, or having close contacts with confirmed cases and positive testers, such as working at close distances or sharing the same classroom or living in the same house;<br>2) had close contacts with medical personnel, family members or people who have similar close contact during the diagnosis, treatment, and visits, such as visiting or staying in a closed environment with other patients in the ward and their accompanying staff personnel;<br>3) people who took the same transportation and have close contact with the cases, including carers on the transportation vehicle;<br>4) people traveled together (e.g., family, colleagues, friends, etc.);<br>5) Other passengers or flight attendants who possibly had close contact with confirmed cases and positive testers after investigation and evaluation;<br>3. People who were considered as having close contacts with cases after an assessment by onsite investigators.","Exclusion criteria: 1. The physician decides that participating in this study is not in the best interest of the subject or that there exist a circumstance in which the agreed protocol cannot be safely followed;<br>2. People who have allergic reactions or allergies to antiviral oral solution or Wuzhifangguanfang decoction;<br>3. Those who do not meet the national diagnostic criteria for close contacts of new coronary pneumonia;<br>4. Confirmed cases of new coronavirus pneumonia;<br>5. People with mental disorders who cannot communicate normally;<br>6. Pregnant woman;<br>7. People who do not agree to participate;",Proportion of COVID-19 close contacts who have developed as confirmed cases;,NA,NA,NA,NA,NA,2020-02-21
ChiCTR2000029813,http://www.chictr.org.cn/showproj.aspx?proj=49425,Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19),Novel Coronavirus Pneumonia (COVID-19),"Experimental group:Conventional Treatment & Tanreqing Capsules (oral, 3 capsules at a time, 3 times a day);Control Group:Conventional Treatment;",Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19),ChiCTR,2020-02-14,2020-02-14,FALSE,Interventional study,Parallel,0,Experimental group:36;Control Group:36;,Shanghai Public Health Clinical Center,China,FALSE,Yes,2020-02-14,2020-02-14,17 February 2020,NA,20200214,12/3/2020 5:31:55 PM,ChiCTR,Recruiting,No,18,75,Both,"Hongzhou Lu, Xiaorong Chen",NA,"2901 Caolang Road, Jinshan District, Shanghai",luhongzhou@fudan.edu.cn,+86 18930810088,Shanghai Public Health Clinical Center,"Inclusion criteria: (1) Those who meet the diagnosis of new coronavirus pneumonia and have clinical classification of low and medium;<br>(2) Those who have been diagnosed with TCM as epidemic-closed lungs;<br>(3) Inpatients aged 18 to 75 years, regardless of gender;<br>(4) Voluntarily receive treatment with the drug and sign informed consent. The informed consent process complies with relevant GCP regulations.","Exclusion criteria: (1) Immunodeficiency disease, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months;<br>(2) Preparing pregnant, pregnant and lactating women;<br>(3) Patients with allergies (referring to allergies to two or more medicines, foods or known ingredients in this study);<br>(4) Patients with mental illness, or have no cognitive ability;<br>(5) Patients with an estimated survival time of less than 48 hours from the start of screening;<br>(6) Those who have been intubated or mechanically ventilated at the time of screening;<br>(7) Obvious symptoms of heart, liver, kidney or various other systems, ALT, AST exceed 1.5 times the upper limit of normal value;<br>(8) Believed to be not suitable to participate in clinical trials by investigator.",Time of viral nucleic acid turns negative;Antipyretic time;,NA,NA,NA,NA,NA,2020-02-14
ChiCTR2000030804,http://www.chictr.org.cn/showproj.aspx?proj=51018,Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial,Novel Coronavirus Pneumonia (COVID-19),Exocarpium Citri Grandis Group:Oral Administration of Exocarpium Citri Grandis Phlegm Cough Solution;Placebo Group:Oral Administration of Placebo;,Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial,ChiCTR,2020-03-15,2020-02-01,FALSE,Interventional study,Parallel,4,Exocarpium Citri Grandis Group:64;Placebo Group:64;,Maoming People's Hospital,China,FALSE,No,2020-03-15,2020-02-01,16 March 2020,NA,20200315,12/3/2020 5:31:55 PM,ChiCTR,Recruiting,No,18,75,Both,Hu Linhui,NA,"101 Weimin Road, Maoming, Guangdong, China",hulinhui@live.cn,+86 13580013426,Maoming People's Hospital,"Inclusion criteria: (1) aged between 18 and 75 years old;<br>(2) Common type patients with confirmed COVID-19 according to the diagnostic criteria of ""novel coronavirus Infection Diagnosis and Treatment Plan (Trial 6th Edition)"" issued by the National Health and Safety Commission;<br>(3) Patients and their families voluntarily participated in the study and signed an informed consent form.","Exclusion criteria: (1) Female patients during pregnancy or lactation;<br>(2) Patients with allergy to Exocarpium Citri Grandis preparation, patients with intolerance to the recommended dose of Exocarpium Citri Grandis were previously applied;<br>(3) Patients who are taking part in clinical trials of other drugs;<br>(4) Patients are taking other foods or drugs with antitussive and antiasthmatic effects.<br>(5) There are other serious diseases that may threaten life, such as cancer.",Cough Score;Expectoration score;,NA,NA,NA,NA,NA,2020-03-15
ChiCTR2000030089,http://www.chictr.org.cn/showproj.aspx?proj=49889,"A randomized, open-label, controlled trial for the efficacy and safety of  Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)",Novel Coronavirus Pneumonia(COVID-19),Experimental group:Conventional treatent and adalimumab;Control group:conventional treatment ;,A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19),ChiCTR,2020-02-22,2020-02-28,FALSE,Interventional study,Parallel,4,Experimental group:30;Control group:30;,Shanghai Changzheng Hospital,China,FALSE,Yes,2020-02-22,2020-02-28,25 February 2020,NA,20200222,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,NA,NA,Both,Huji Xu,NA,"415 Fengyang Road, Huangpu District, Shanghai, China",xuhuji@smmu.edu.cn,+86 13671609764,Shanghai Changzheng Hospital,"Inclusion criteria: Subjects who meet the following conditions can become subjects of this study:<br>1. Will sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian;<br>2. Chinese aged >=18 years;<br>3. In accordance with NCP criteria for severe and critical illness, namely ""Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 6)"". Combined with the following epidemiological history, clinical manifestations, and pathogenic examinations to make a comprehensive judgment.<br>4. The course of disease is within 14 days after the onset of illness;<br>5. Will take nasopharyngeal or oropharyngeal swabs before administration.","Exclusion criteria: 1. Patients who are participating in other drug clinical trials;<br>2. Pregnant or lactating women;<br>3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50;<br>4. Expected survival is less than 1 week;<br>5. Patients diagnosed with rheumatic immune related diseases;<br>6. Take orally anti rejection drugs or immunomodulatory drugs for a long time;<br>7. Hypersensitive to adalimumab or any excipients;<br>8. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections",TTCI (Time to Clinical Improvement);,NA,NA,NA,NA,NA,2020-02-22
ChiCTR2000030170,http://www.chictr.org.cn/showproj.aspx?proj=50017,Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19),Novel Coronavirus Pneumonia (COVID-19),"severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;Acute exacerbation NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;",Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19),ChiCTR,2020-02-24,2020-02-15,FALSE,Interventional study,Factorial,0,severe NCP group:8;Acute exacerbation NCP group:8;,Shanghai Public Health Clinical Center,China,FALSE,No,2020-02-24,2020-02-15,25 February 2020,NA,20200224,12/3/2020 5:31:55 PM,ChiCTR,Recruiting,No,50,100,Both,Lu Hongzhou,NA,"2901 Caolang Road, Jinshan District, Shanghai, China",luhongzhou@shphc.org.cn,+86 18930810088,Shanghai Public Health Clinical Center,"Inclusion criteria: (1) Inpatients aged 50 and over, regardless of gender, voluntarily signed informed consent;<br>(2) Persons diagnosed with 2019-nCoV infection: respiratory specimens or blood specimens are tested positive for 2019-nCoV nucleic acid by real-time fluorescent RT-PCR; or respiratory specimens or blood specimens are sequenced for viral genes, which are highly homologous with known 2019-nCoV;<br>(3) Severe NCP group: meets (""New Coronavirus Infected Pneumonia Diagnosis and Treatment Plan (Trial Fifth Edition)"") diagnostic criteria for heavy NCP.<br>(4) NCP group in acute exacerbation period: NCP patients with acute exacerbation period in general to severe and critically severe (for definition of severe and critically severe, see ""Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Fifth Edition)"");<br>Remarks: ""Judgment Criteria for NCP Patients with Acute Exacerbation in General to Severe and Critical Severity""<br>1) Aged 50 years or older;<br>2) Dyspnea (those who inhale oxygen in a mask);<br>3) Combined with basic diseases, such as COPD, diabetes, hypertension, coronary heart disease;<br>4) White blood cell count is less than 4 × 109 / L or has a tendency to decrease continuously;<br>5) Lymphocyte count <1.5x10^9 / L or a trend of continuous decrease;<br>6) Platelet count is less than 150x10^9/L or has a tendency to decrease continuously;<br>7) Hemoglobin has continued to decrease;<br>8) C-reactive protein >=10 mg / L or a trend of continuous increase;<br>9) Procalcitonin >=0.5 ng / mL or a tendency of continuous increase;<br>10) Lactate dehydrogenase >=250 U/L or a trend of continuous increase;<br>11) Aspartate aminotransferase and alanine aminotransferase have a tendency to increase continuously;<br>12) Creatinine >=133 umol/L or a tendency of continuous increase;<br>13) D-dimer >=0.5 mg/L or a trend of continuous increase;<br>14) There is a continuous decrease in serum potassium;<br>15) IL-6 has a tendency to increase continuously;<br>16) Any of IL-2, IL-4, IL-10, TNF, IFN-r, and IL-17A has a tendency to increase continuously;<br>17) Imaging findings consistent with NCP progression.<br>Remarks: (1) If 9 or more of the above 17 items are met, they are judged to be ""normal-to-severe, severely severe NCP patients with acute exacerbation period""; (2) continuous increase or decrease trend: at least 3 consecutive measurements, specific trends Determined by the research doctor; (3) In view of the special circumstances of the NCP, during the trial implementation, the selection criteria of the protocol can be appropriately updated and adjusted according to the clinical progress.","Exclusion criteria: Exclusion criteria for the severe NCP group were the same as those for the acutely exacerbated NCP group:<br>1. Have a history of drug dependence or substance abuse;<br>2. female patients who are pregnant or lactating;<br>3. People with allergies or known allergies to research drugs and excipients;<br>4. In patients with impaired liver function, alanine aminotransferase (ALT) / aspartate aminotransferase (AST) increases more than five times the upper limit of normal;<br>5. Patients with renal impairment (dialysis treatment patients or eGFR <60mL / min);<br>6. Those who meet the diagnostic criteria of ARDS:<br>(1) acute onset;<br>(2) oxygenation index (PaO2 / FiO2) <=200mmHg [1mmHg = 0.133kPa, regardless of the positive end-expiratory pressure (PEEP) level];<br>(3) positive X A chest radiograph showed patchy shadows in both lungs;<br>(4) pulmonary artery incarceration pressure <=18mmHg, or no clinical evidence of increased left atrial pressure.<br>7. Patients with significantly impaired cardiac function: those with A and NYHA heart failure classification = Grade II or LVEF <=lower limit of normal value; those with ECG in leads B and 12 suggesting conduction block or acute myocardial infarction requiring urgent treatment;<br>8. Combining other serious diseases that affect patient survival, such as malignant tumors;<br>9. the use of immunosuppressants or diseases that seriously affect the immune system, such as human immunodeficiency virus infection;<br>10. Combining other infections that are severe and uncontrollable (bacteria, chlamydia, deep fungi, etc.);<br>11. Those with diarrhea> 4 times / day;<br>12. People who have difficulty swallowing oral drugs;<br>13. Situations in which other researchers find it inappropriate to participate in research.",Severe NCP group: Time to clinical improvement (TTCI) [time window: 28 days];Acute exacerbation NCP group: Time to clinical recovery [time window: 28 days] and the ratio of common to severe and critically severe.;,NA,NA,NA,NA,NA,2020-02-24
ChiCTR2000031453,http://www.chictr.org.cn/showproj.aspx?proj=51859,"Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial",Novel Coronavirus Pneumonia (COVID-19),Nintedanib group:Nintedanib;Control group:Placebo;,"Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial",ChiCTR,2020-04-01,2020-04-01,FALSE,Interventional study,Parallel,4,Nintedanib group:40;Control group:40;,"Tongji Hospital of Tongji Medical College, Huazhong Science and Technology University",China,FALSE,Yes,2020-04-01,2020-04-01,6 April 2020,NA,20200401,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,18,70,Both,Xianglin Yuan,NA,"1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China",yuanxianglin@hust.edu.cn,+86 13667241722,Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University,"Inclusion criteria: 1) Aged 18 to 70 years old;<br>2) Infection with new coronavirus pneumonia was confirmed by throat swab nucleic acid test. Patients with severe and critical illness were clinically judged. The symptoms of acute infection have been alleviated after treatment (at least 14 days after onset, no fever for more than 3 days), and the disease is recovering Within three months;<br>3) CT examination of patients with multiple fibrotic shadows in both lungs;<br>4) Blood routine, liver, and kidney functions are within the controllable range: such as the normal upper limit of plasma total bilirubin and creatinine <=1.5 NUL; AST, ALT, LDH <=2 NUL; sufficient hematopoietic function: such as white blood cells >=4.0x10^9/L, platelets >=100x10^9/L;<br>5) Signed informed consent.","Exclusion criteria: 1) Previous history of chronic bronchitis, emphysema, interstitial lung disease or pulmonary heart disease;<br>2) Combining with other serious diseases: such as those who have suffered myocardial infarction and uncontrollable diabetes within 6 months, and are considered unsuitable to participate in the trial;<br>3) People with active peptic ulcer;<br>4) Patients during pregnancy and lactation;<br>5) Patients with mental illness or others who cannot cooperate effectively;<br>6) Researcher judged unsuitable to participate.",FVC;,NA,NA,NA,NA,NA,2020-04-01
NCT04483830,https://clinicaltrials.gov/show/NCT04483830,Sulodexide in the Treatment of Early Stages of COVID-19,Covid19,Drug: Sulodexide;Drug: Placebo,Suloexide in the Treatment of Early Stages of COVID-19,CT.gov,2020-07-22,2020-06-05,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).,Phase 2/Phase 3,243,Clinedem,Mexico,FALSE,Yes,22/07/2020,"June 5, 2020",21 September 2020,SulES-COVID,20200722,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,40 Years,80 Years,All,NA,"Alejandro j Gonzalez-Ochoa, md",NA,NA,NA,Clinedem,"<br>        Inclusion Criteria:<br><br>          -  3 days or less with clinical COVID-19 symptoms (fever, cough, sour throat, headache,<br>             body ache, anosmia, diarrhoea, vomiting).<br><br>          -  sign inform consent.<br><br>          -  >50% risk developing a severe clinical presentation of COVID-19 according to risk<br>             calculator<br><br>        Exclusion Criteria:<br><br>          -  COVID-19 negative test<br><br>          -  known pregnancy<br><br>          -  chronic use of steroid medication<br><br>          -  deep vein thrombosis in the last 6 months<br><br>          -  extended anticoagulation in the last 3 months.<br><br>          -  known allergy to sulodexide.<br><br>          -  severe symptoms that warrant hospital care at initial screening<br>",NA,hospital care;days of hospital care;days of need suplemental oxigen;serum level of d-dimmer;serum level of creatinine,NA,NA,NA,NA,NA,2020-07-22
NCT04436458,https://clinicaltrials.gov/show/NCT04436458,"Phase 2, Multicentre, Randomized, Double Blind, 2 Arms Placebo-controlled Study in Adults With Moderate COVID-19 With Gastrointestinal Signs and Symptoms",COVID,Drug: Niclosamide Oral Tablet;Drug: Placebo,Niclosamide In Moderate COVID-19,CT.gov,2020-06-16,2020-12-01,TRUE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,100,"First Wave Bio, Inc.",NA,FALSE,Yes,16/06/2020,December 2020,21 September 2020,NA,20200616,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,NA,"Tony Opipari, M.D.",NA,tony@firstwavebio.com,734-546-0228,NA,"<br>        Inclusion Criteria:<br><br>          -  Patients hospitalized for treatment of COVID-19 with or without pneumonia, who are<br>             expected to remain in hospital at least seven days after the randomization and who<br>             accept continuing to be assessed for the study procedures (home or outpatient unit) up<br>             to 6 weeks in case of discharge.<br><br>          -  Patients who prior to developing COVID-19 usually have normal bowel habits defined as<br>             at least 3 stools per week and no more than 3 stools per day.<br><br>          -  SARS-CoV-2 infection confirmed by RT-PCR in rectal swab (or stool test) =2 days before<br>             randomization by local or central lab.<br><br>          -  Diarrhea defined as at least 3 watery stools in the last 24 hours prior to enrolment<br><br>        Exclusion Criteria:<br><br>          -  At the time of randomization patients requiring ICU admission or patients with severe<br>             respiratory insufficiency requiring mechanical ventilation or with rapid worsening of<br>             respiratory function leading to expectation for mechanical ventilation or ICU<br>             admission.<br><br>          -  Evidence of rapid clinical deterioration or existence of any life-threatening<br>             co-morbidity or any other medical condition which, in the opinion of the investigator,<br>             makes the patient unsuitable for inclusion.<br>",NA,"The primary endpoint is the rate of faecal SARS-CoV-2 virus clearance (rectal swab or stool sample) assessed by RT-PCR in the niclosamide group, compared to the placebo group",NA,NA,NA,NA,NA,2020-06-16
NCT04535856,https://clinicaltrials.gov/show/NCT04535856,"Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled",Covid19;Corona Virus Infection;SAR,Drug: allogeneic mesenchymal stem cell;Other: Placebo,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,CT.gov,2020-08-28,2020-10-26,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 1,9,Ina-Respond,Indonesia,FALSE,Yes,28/08/2020,"October 26, 2020",2 November 2020,DW-MSC,20200828,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,19 Years,N/A,All,NA,"Dr. Muhammad Karyana, MPH",NA,m.karyana@ina-respond.net,+62 21 42879189,NA,"<br>        Inclusion Criteria:<br><br>          1. Age of 19 years or older at the time of screening<br><br>          2. Those who have been confirmed COVID-19 infection through PCR test<br><br>          3. Patients with mild or moderate COVID-19 who meet National EWS (0~6)<br><br>          4. Those who have given written consent and voluntarily decided to participate before the<br>             screening procedure after understanding the detailed description of the clinical<br>             trial.<br><br>          5. Those who are suitable as subjects for this clinical study when judged by physical<br>             examination, clinical laboratory test, and other medical examination as stated in the<br>             flowchart of protocol.<br><br>        Exclusion Criteria:<br><br>          1. Those who have history of hypersensitivity to the components of the investigational<br>             product or the reference product<br><br>          2. Those with viral or bacterial pneumonia other than expected indications<br><br>          3. Patients receiving organ transplants within 6 months of screening<br><br>          4. Patients with a history of pulmonary embolism<br><br>          5. Patients who have indications of investigational products as an underlying disease<br>             (ex. HIV patients in the clinical study of antiretroviral drugs)<br><br>          6. Patients who are pregnant or lactating<br><br>          7. Those who are determined by the investigator to be unsuitable for participation in the<br>             clinical trial due to other reasons including the results of the clinical laboratory<br>             test.<br><br>          8. Patients participating in other clinical studies<br>",NA,Incidence of TEAE* in Treatment group,NA,NA,NA,NA,NA,2020-08-28
NCT04394377,https://clinicaltrials.gov/show/NCT04394377,Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial,Coronavirus Infection,Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed;Drug: Group 2: control group with enoxaparin 40mg/d,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,CT.gov,2020-05-08,2020-06-21,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).,Phase 4,600,Brazilian Clinical Research Institute,Brazil,FALSE,Yes,08/05/2020,"June 21, 2020",19 October 2020,ACTION,20200508,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,;,"Renato D. Lopes, MD, PhD;Renato D. Lopes, MD, PhD",NA,;renato.lopes@duke.edu,;55 11 5904 7339,BCRI;,"<br>        Inclusion Criteria:<br><br>          -  Patients with confirmed diagnosis of COVID-19 admitted to hospital;<br><br>          -  Onset of symptoms leading to hospitalization <14 days;<br><br>          -  Patients = 18 year old;<br><br>          -  D-dimer = 3 x the upper limit of normal;<br><br>          -  Agreement to participate by providing the informed consent form (ICF).<br><br>        Exclusion Criteria:<br><br>          -  Patients with indication for full anticoagulation during inclusion (for example,<br>             diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve<br>             prosthesis);<br><br>          -  Platelets < 50,000 /mm3<br><br>          -  Need for ASA therapy > 100 mg;<br><br>          -  Need for P2Y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel);<br><br>          -  Chronic use of non-hormonal anti-inflammatory drugs;<br><br>          -  Sustained uncontrolled systolic blood pressure (BP) of =180 mmHg or diastolic BP of<br>             =100 mmHg;<br><br>          -  INR > 1,5;<br><br>          -  Patients contraindicated to full anticoagulation (active bleeding, liver failure,<br>             blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator);<br><br>          -  Criteria for disseminated intravascular coagulation (DIC);<br><br>          -  A history of hemorrhagic stroke or any intracranial bleeding at any time in the past<br>             or current intracranial neoplasm (benign or malignant), cerebral metastases,<br>             arteriovenous (AV) malformation, or aneurysm;<br><br>          -  Active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission<br>             or requiring active chemotherapy or adjunctive therapies such as immunotherapy or<br>             radiotherapy;<br><br>          -  Hypersensitivity to rivaroxaban;<br><br>          -  Use of strong inhibitors of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp)<br>             (e.g. protease inhibitors, ketoconazole, Itraconazole) and/or use of P-gp and strong<br>             CYP3A4 inducers (such as but not limited to rifampin/rifampicin, rifabutin,<br>             rifapentine, phenytoin, phenobarbital, carbamazepine, or St. John's Wort);<br><br>          -  Known HIV infection;<br><br>          -  Creatinine clearance < 30 ml/min according to the Cockcroft-Gault Formula;<br><br>          -  Pregnancy or breastfeeding.<br>",NA,"Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days.",NA,NA,NA,NA,NA,2020-05-08
NCT04494399,https://clinicaltrials.gov/show/NCT04494399,"An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection",Covid19,Drug: Interferon beta-1b;Drug: Ribavirin,IFN Beta-1b and Ribavirin for Covid-19,CT.gov,2020-07-28,2020-07-29,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,96,The University of Hong Kong,Hong Kong,FALSE,Yes,28/07/2020,"July 29, 2020",10 August 2020,NA,20200728,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ;,"Ivan FN Hung, MD FRCP;Ivan FN Hung, MD FRCP;Ivan FN Hung, MD FRCP",NA,;ivanhung@hku.hk;ivanhung@hku.hk,;22554049;22554049,The University of Hong Kong;,"<br>        Inclusion Criteria:<br><br>          1. Recruited subjects include all adult patients =18 years hospitalized for virologic<br>             confirmed SARS-CoV-2 infection.<br><br>          2. All subjects give written informed consent. For patients who are critically ill,<br>             requiring ICU, ventilation or confused, informed consent will be obtained from spouse,<br>             next-of-kin or legal guardians.<br><br>          3. Subjects must be available to complete the study and comply with study procedures.<br>             Willingness to allow for serum samples to be stored beyond the study period, for<br>             potential additional future testing to better characterize immune response.<br><br>        Exclusion Criteria:<br><br>          1. Inability to comprehend and to follow all required study procedures.<br><br>          2. Allergy or severe reactions to the study drugs<br><br>          3. Patients taking medication that will potentially interact with l interferon beta-1b or<br>             ribavirin<br><br>          4. Pregnant or lactation women<br><br>          5. Patients with known history of severe depression<br><br>          6. Received an experimental agent (vaccine, drug, biologic, device, blood product, or<br>             medication) within 1 month prior to recruitment in this study or expect to receive an<br>             experimental agent during this study.<br><br>          7. To participate in an unrelated trial during the current clinical trial. Nevertheless,<br>             the patients have the right to withdraw from the current clinical trial to join<br>             another clinical trial.<br><br>          8. Have a history of alcohol or drug abuse in the last 5 years.<br><br>          9. Have any condition that the investigator believes may interfere with successful<br>             completion of the study.<br>",NA,Clinical symptoms alleviation,NA,NA,NA,NA,NA,2020-07-28
NCT04287686,https://clinicaltrials.gov/show/NCT04287686,"A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19",COVID-19,Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2),Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,CT.gov,2020-02-21,2020-02-01,TRUE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,N/A,0,The First Affiliated Hospital of Guangzhou Medical University,China,FALSE,Yes,21/02/2020,February 2020,30 March 2020,NA,20200221,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,80 Years,All,NA,"Yimin Li, PhD, MD",NA,NA,NA,The First Affiliated Hospital of Guangzhou Medical University,"<br>        Inclusion Criteria:<br><br>          1. Laboratory diagnosis:<br><br>               -  Respiratory specimen is positive for SARS-CoV-2 nucleic acid by RT-PCR; OR,<br><br>               -  The viral gene sequencing of the respiratory specimen is highly homologous to<br>                  known novel coronavirus.<br><br>          2. Fever:<br><br>             Axillary temperature >37.3?<br><br>          3. Respiratory variables (meets one of the following criteria):<br><br>               -  Respiratory rate: RR =25 breaths/min<br><br>               -  Oxygen saturation =93% at rest on room air<br><br>               -  PaO2/FiO2 =300 mmHg(1 mmHg=0.133 KPa)<br><br>               -  Pulmonary imaging showed that the lesions progressed more than 50% within 24-48<br>                  hours, and the patients were managed as severe<br><br>          4. HBsAg negative, or HBV DNA =10^4 copy/ml if HBsAg positive; anti-HCV negative; HIV<br>             negative two weeks prior to signed Informed Consent Form (ICF)<br><br>          5. Appropriate ethics approval and<br><br>          6. ICF<br><br>        Exclusion Criteria:<br><br>          -  Age <18 years; Age >80 years<br><br>          -  Pregnant or breast feeding woman or with positive pregnancy test result<br><br>          -  P/F <100 mmHg<br><br>          -  Moribund condition (death likely in days) or not expected to survive for >7 days<br><br>          -  Refusal by attending MD<br><br>          -  Not hemodynamically stable in the preceding 4 hours (MAP =65 mmHg, or SAP <90 mmHg,<br>             DAP <60 mmHg, vasoactive agents are required)<br><br>          -  Patient on invasive mechanical ventilation or ECMO<br><br>          -  Patient in other therapeutic clinical trial within 30 days before ICF<br><br>          -  Receive any other ACE inhibitors (ACEI), angiotensin-receptor blockers (ARB) treatment<br>             within 7 days before ICF<br><br>          -  Chronic immunosuppression: current autoimmune diseases or patients who received<br>             immunotherapy within 30 days before ICF<br><br>          -  Hematologic malignancy (lymphoma, leukemia, multiple myeloma)<br><br>          -  Other patient characteristics (not thought to be related to underlying COVID-19) that<br>             portend a very poor prognosis (e.g, severe liver failure, and ect)<br><br>          -  Known allergy to study drug or its ingredients related to renin-angiotensin system<br>             (RAS), or frequent and/or severe allergic reactions with multiple medications<br><br>          -  Other uncontrolled diseases, as judged by investigators<br><br>          -  Body weight =85 kg<br>",NA,Time course of body temperature (fever);Viral load over time,NA,NA,NA,NA,NA,2020-02-21
NCT04409262,https://clinicaltrials.gov/show/NCT04409262,"A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia",COVID-19 Pneumonia,Drug: Remdesivir;Drug: Tocilizumab;Drug: Placebo,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,CT.gov,2020-05-28,2020-06-16,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 3,500,Hoffmann-La Roche,United States;Brazil;France;Russian Federation;Spain;Brazil;France;Russian Federation;Spain;United States,FALSE,Yes,28/05/2020,"June 16, 2020",30 November 2020,REMDACTA,20200528,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,12 Years,N/A,All,;,Clinical Trials;Reference Study ID #: WA42511 www.roche.com/about_roche/roche_worldwide.htm,NA,;global-roche-genentech-trials@gene.com,;888-662-6728,Hoffmann-La Roche;,"<br>        Inclusion Criteria<br><br>          -  Hospitalized with COVID-19 pneumonia confirmed per a positive polymerase chain<br>             reaction (PCR) of any specimen (e.g., respiratory, blood, urine, stool, other bodily<br>             fluid) and evidenced by chest X-ray or CT scan<br><br>          -  Requiring more than 6 L/min supplemental oxygen to maintain SpO2 > 93%<br><br>          -  Agrees to not participate in another clinical trial for the treatment of COVID-19<br>             while participating in this study<br><br>        Exclusion Criteria<br><br>          -  Known severe allergic reactions to tocilizumab or other monoclonal antibodies<br><br>          -  Known hypersensitivity to remdesivir, the metabolites, or formulation excipients<br><br>          -  Active tuberculosis (TB) infection<br><br>          -  Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)<br><br>          -  In the opinion of the investigator, progression to death is imminent and inevitable<br>             within the next 24 hours, irrespective of the provision of treatments<br><br>          -  Treatment with immunosuppressive or immunomodulatory therapy (including tocilizumab)<br>             within the past 3 months<br><br>          -  Concurrent treatment with other agents with actual or possible direct-acting antiviral<br>             activity against SARS-CoV-2 within 24 hours prior to study drug dosing. In addition,<br>             participants with prior or current treatment with > 2 doses of remdesivir for COVID-19<br>             are excluded<br><br>          -  Participating in other drug clinical trials<br><br>          -  Estimated glomerular filtration rate (eGFR) < 30 mL/min (including patients receiving<br>             hemodialysis or hemofiltration)<br><br>          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 x upper limit<br>             of normal (ULN) detected within 24 hours of screening (according to local laboratory<br>             reference ranges)<br><br>          -  Absolute neutrophil count (ANC) < 1000/uL at screening<br><br>          -  Platelet count < 50,000/uL at screening<br><br>          -  Body weight < 40 kg<br><br>          -  Treatment with an investigational drug within 5 half-lives or 30 days (whichever is<br>             longer) of randomization<br>",NA,"Time from Randomization to Hospital Discharge (or ""ready for discharge"" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or </= 2 liters (L) of supplemental oxygen)",NA,NA,NA,NA,NA,2020-05-28
NCT04466280,https://clinicaltrials.gov/show/NCT04466280,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19 Disease in Healthcare Providers at Baqiyatallah Hospital in Tehran",COVID-19,Drug: Hydroxychloroquine;Drug: Mucodentol;Device: Personal protective equipment,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19",CT.gov,2020-07-09,2020-07-15,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Investigator, Outcomes Assessor).",N/A,180,Baqiyatallah Medical Sciences University,"Iran, Islamic Republic of",FALSE,Yes,09/07/2020,"July 15, 2020",20 July 2020,NA,20200709,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,;,Mohammad Sadegh Bagheri Baghdasht;Mohammad Sadegh Bagheri Baghdasht,NA,sadegh.bagheri@gmail.com;sadegh.bagheri@gmail.com,0098 9356318204;+989356318204,NA,"<br>        Inclusion Criteria:<br><br>          -  Negative PCR testing through throat swabs<br><br>          -  Signing Conscious Consent<br><br>        Exclusion Criteria:<br><br>          -  History of ocular complications and visual disturbances<br><br>          -  Sensitivity to plant compounds in the product<br>",NA,PCR test,NA,NA,NA,NA,NA,2020-07-09
NCT04494724,https://clinicaltrials.gov/show/NCT04494724,A Phase 2 Trial to Evaluate the Safety and Tolerability of Clazakizumab® [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 Infection,COVID-19 Infection,Drug: Clazakizumab;Drug: Placebo,Clazakizumab vs. Placebo - COVID-19 Infection,CT.gov,2020-07-21,2020-07-13,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,60,The Methodist Hospital System,United States,FALSE,Yes,21/07/2020,"July 13, 2020",10 August 2020,NA,20200721,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ;,"Howard Huang, MD;Isioma Agboli, MD;Isioma Agboli, MD",NA,;iagboli@houstonmethodist.org;iagboli@houstonmethodist.org,;713-441-6311;713-441-6311,The Methodist Hospital System;,"<br>        Inclusion Criteria:<br><br>          1. Age >18 at the time of screening.<br><br>          2. Participant or legally authorized representative (LAR) must be able to understand and<br>             provide informed consent.<br><br>          3. Hospitalized with coronavirus disease (COVID-19) confirmed by polymerase chain<br>             reaction (PCR) assay from any specimen (eg, respiratory, blood, urine, stool, other<br>             bodily fluid) within the prior 72 hours.<br><br>          4. C-reactive protein (CRP) > 3.5 mg/dL<br><br>          5. Evidence of pulmonary involvement with at least 2 of the following:<br><br>               1. oxygen saturation at rest in ambient air with peripheral capillary oxygen<br>                  saturation (SpO2) = 94%<br><br>               2. tachypnea with resting respiration rate > 25 breaths/minute<br><br>               3. Partial pressure of oxygen (PaO2)/initial fraction of inspired oxygen (FiO2) =<br>                  300 mmHg<br><br>               4. Chest imaging (radiograph, CT, or ultrasound) with abnormalities consistent<br>                  COVID-19 pneumonia<br><br>        Exclusion Criteria:<br><br>          1. Previous hypersensitivity or allergic reactions to clazakizumab<br><br>          2. Lactating or pregnant females<br><br>          3. Patients with latent tuberculosis (TB) and who are not receiving treatment<br><br>          4. Patients with active TB<br><br>          5. Patients with known active inflammatory bowel disease, untreated diverticulitis, or<br>             gastrointestinal perforation<br><br>          6. Requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO)<br><br>          7. A significantly abnormal general serum screening lab result defined as a white blood<br>             cell (WBC) count < 3.0 X 10^3/mL, a hemoglobin (Hgb) < 8.0 g/dL, a platelet count < 50<br>             X 10^3/mL, an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5<br>             times upper limit normal<br><br>          8. Participation in another clinical trial investigating COVID-19-aimed agents<br><br>          9. Presence of any medical or psychosocial condition, which the investigator believes,<br>             would hinder adherence to the study requirements.<br>",NA,Primary Endpoint,NA,NA,NA,NA,NA,2020-07-21
NCT04282902,https://clinicaltrials.gov/show/NCT04282902,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Novel Coronavirus Pneumonia;Pneumonia;Pirfenidone,Drug: pirfenidone,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,CT.gov,2020-02-10,2020-02-04,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 3,294,Huilan Zhang,China,FALSE,Yes,10/02/2020,"February 4, 2020",9 March 2020,NA,20200210,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,;,"Huilan Zhang, PD;Huilan Zhang, PD",NA,huilanz_76@163.com;,15391532171;,NA,"<br>        Inclusion Criteria:<br><br>        (1) Age = 18 years. (2) Clinically diagnosed patients with new type of coronavirus<br>        pneumonia include: on the basis of meeting the criteria for suspected cases, one of the<br>        following pathogenic evidence: ? real-time fluorescent RT-PCR of respiratory specimens or<br>        blood specimens for detection of new coronavirus nucleic acid; Respiratory or blood<br>        specimens are genetically sequenced and highly homologous to known new coronaviruses. (3)<br>        The time interval between the suspected neocoronary pneumonia pneumonia case and the random<br>        enrollment is determined within 4 days to 7 days according to the history symptoms and<br>        chest CT imaging. Cough, diarrhea, or other related symptoms can be used. The imaging<br>        changes are mainly based on chest CT.<br><br>        Exclusion Criteria:<br><br>        (1) AST and ALT> 1.5 x ULN at visit 1; (2) bilirubin> 1.5 x ULN at visit 1; (3) creatinine<br>        clearance rate calculated by Cockcroft-Gault formula at visit 1 <30 mL / min; (4) patients<br>        with potential chronic liver disease (Child Pugh A, B or C liver injury; (5) previous<br>        treatment with nidanib or pirfenidone; (6) screening visits (interviews 1) Received other<br>        research drug treatment within 1 month or 6 half-lives (whichever is greater); (7) IPF<br>        diagnosis based on ATS / ERS / JRS / ALAT 2011 guidelines (P11-07084); (8 ) Significant<br>        pulmonary hypertension (PAH) defined by any of the following standards: ? Clinical /<br>        echocardiographic evidence of previously significant right heart failure; ? Medical history<br>        including right heart catheter showing a cardiac index = 2l / min / m2; ? Prostaglandol /<br>        qu Parenteral administration of prostacyclin in the treatment of PAH; (9) other clinically<br>        significant lung abnormalities considered by the investigator; (10) major extrapulmonary<br>        physiological limitations (such as chest wall deformity, large amount of pleural effusion);<br>        (11) Cardiovascular diseases, any of the following diseases: ? Severe hypertension within 6<br>        months of Visit 1, uncontrollable after treatment (=160 / 100 mmHg); ? myocardial<br>        infarction within 6 months of visit 1; ? unstable angina within 6 months of visit 1; (12)<br>        history of severe central nervous system (CNS) events; (13) known trials Drug allergies;<br>        (14) Other diseases that may interfere with the testing process or as judged by the<br>        investigator may interfere with the trial participation or may put the patient at risk when<br>        participating in the trial; (15) Women who are pregnant, breastfeeding, or planning<br>        pregnancy in this trial (16) Patients are unable to understand or follow the trial<br>        procedures, including completing the questionnaires themselves without assistance.<br>",NA,chest CT;Finger pulse oxygen;blood gas;K-BILD,NA,NA,NA,NA,NA,2020-02-10
NCT04442048,https://clinicaltrials.gov/show/NCT04442048,"COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure",Cancer;Covid-19,Biological: IMM-101;Other: Observation,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,CT.gov,2020-06-19,2020-06-25,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 3,1500,Canadian Cancer Trials Group,Canada,FALSE,Yes,19/06/2020,"June 25, 2020",24 November 2020,COV-IMMUNO,20200619,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,;,Rebecca A Auer;Chris O'Callaghan,NA,;cocallaghan@ctg.queensu.ca,;613-533-6430,Ottawa Hospital Research Institute;,"<br>        Inclusion Criteria:<br><br>          -  Patient must be undergoing (or be planned to undergo) active treatment for one or more<br>             solid malignancy, lymphoma or myeloma, requiring them to present to the hospital or<br>             cancer clinic at least twice/month for assessments and/or treatments, anticipated for<br>             at least 3 months.<br><br>          -  Patients must have one or more of the following risk factors [CDC 2019] for a severe<br>             COVID-19 infection:<br><br>               -  Age > 65 years old<br><br>               -  Hypertension (on medications);<br><br>               -  Type 1 or 2 Diabetes (on medication)<br><br>               -  A relevant chronic condition as per the investigator based on the medical record,<br>                  including:<br><br>                    -  heart (e.g. heart failure, coronary artery disease, congenital heart<br>                       disease, cardiomyopathies, and pulmonary hypertension)<br><br>                    -  lung (e.g. chronic obstructive pulmonary disease (COPD including emphysema<br>                       and chronic bronchitis), moderate to severe asthma, idiopathic pulmonary<br>                       fibrosis and cystic fibrosis)<br><br>                    -  liver cirrhosis<br><br>                    -  serious kidney disease requiring dialysis<br><br>               -  Receiving systemic therapy (such as cytotoxic chemotherapy, immunotherapy or<br>                  targeted agents excluding single-agent hormonal therapy)<br><br>               -  Body Mass Index > 40<br><br>               -  Living in a nursing home or long term care facility<br><br>          -  Patient must have a life expectancy of >6 months as assessed by the investigator<br><br>          -  Patient must have an ECOG Performance Status = 2<br><br>          -  Patient has adequate organ function appropriate for the therapy the patient is planned<br>             to receive in the opinion of the investigator and based on local assessment and<br>             practices.<br><br>          -  Patient is aged = 18 years<br><br>          -  Patient has agreed to receive pneumococcal vaccination and a seasonal influenza<br>             vaccination in accordance with Canadian Guidelines.<br><br>          -  Patient is able (i.e. sufficiently fluent) and willing to complete the health utility<br>             questionnaires in either English or French.<br><br>          -  Patient consent must be appropriately obtained in accordance with applicable local and<br>             regulatory requirements. Each patient must sign a consent form prior to enrollment in<br>             the trial to document their willingness to participate.<br><br>          -  Patient must be willing to provide identifying information including provincial health<br>             insurance number to facilitate data linkage and follow up.<br><br>          -  Patients must be accessible for treatment and follow-up. Investigators must assure<br>             themselves the patients enrolled on this trial will be available for complete<br>             documentation of the treatment, adverse events, and follow-up.<br><br>          -  Women/men of childbearing potential must have agreed to use a highly effective<br>             contraceptive method throughout the treatment period and for at least 3 months after<br>             discontinuation of treatment.<br><br>        Exclusion Criteria:<br><br>          -  Patient previously received treatment with IMM-101.<br><br>          -  Patient cannot have either at present or in the past, a positive test for COVID-19<br>             infection. If a patient has been tested for COVID-19, result must be confirmed as<br>             negative prior to enrollment.<br><br>          -  Patient cannot have experienced ""flu-like symptoms"" within 14 days prior to<br>             enrollment, including fever, extreme fatigue, new or worsening cough, myalgias, new or<br>             worsening dyspnea, and/or sputum production.<br><br>          -  Patient is receiving concomitant treatment with another investigational product or has<br>             received such treatment within the 3 weeks prior to enrollment.<br><br>          -  Patient has any co-existing active infection that, in the opinion of the Investigator,<br>             may increase the risk associated with study participation or study drug<br>             administration, impair the ability of the subject to receive protocol therapy,<br>             interfere with the patient's participation for the full duration of the study, or is<br>             not in the best interest of the patient to participate.<br><br>          -  Patient has previously experienced an allergic reaction to any mycobacterial product,<br>             including the BCG vaccine.<br><br>          -  Patients with superficial bladder cancer or any other condition currently receiving or<br>             planned to be treated with BCG.<br><br>          -  Patient has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)<br>             or a known history of or is known to have a positive test for Hepatitis B (HBsAg<br>             reactive) or Hepatitis C (HCV RNA [qualitative]).<br><br>          -  Patients with prior or concurrent leukemia.<br><br>          -  Patient has had a prior bone marrow transplant.<br><br>          -  Patient is pregnant or breast-feeding<br><br>          -  Patient has documented history of clinically severe autoimmune disease or a syndrome<br>             that requires systemic steroids or immunosuppressive agents. This includes patient<br>             requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone<br>             equivalent, or depot corticosteroids in the 6 weeks before enrollment) or<br>             immunosuppressant drugs (such as azathioprine, tacrolimus, cyclosporine, etc.) within<br>             the 14 days prior to enrollment. Inhaled or topical steroids, and adrenal replacement<br>             steroid doses = 10 mg daily prednisone equivalent, are permitted in the absence of<br>             active autoimmune disease. Steroids used for premedication prior to chemotherapy or as<br>             part of a chemotherapy regimen are allowed.<br>",NA,"The rate of ""flu-like illness"" which includes:",NA,NA,NA,NA,NA,2020-06-19
NCT04347239,https://clinicaltrials.gov/show/NCT04347239,"A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)",Coronavirus Disease 2019,Drug: Placebos;Drug: Leronlimab (700mg),Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),CT.gov,2020-04-13,2020-04-15,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,390,"CytoDyn, Inc.",United States,TRUE,Yes,13/04/2020,"April 15, 2020",24 November 2020,NA,20200413,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,Yes,18 Years,N/A,All,NA,"Kush Dhody, MBBS, MS, CCRA",NA,kushd@amarexcro.com,301-956-2536,NA,"<br>        Inclusion Criteria:<br><br>          1. Male or female adult = 18 years of age at time of screening.<br><br>          2. Subjects hospitalized with severe or critical illness caused by coronavirus 2019<br>             infection as defined below:<br><br>             A. Severe Illness:<br><br>             - Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing within 5 days<br>             of screening<br><br>             AND<br><br>             Symptoms of severe systemic illness/infection with COVID-19:<br><br>             - At least 1 of the following: fever, cough, sore throat, malaise, headache, muscle<br>             pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe<br>             lower respiratory symptoms including dyspnea at rest or respiratory distress<br><br>             AND<br><br>             Clinical signs indicative of severe systemic illness/infection with COVID-19, with at<br>             least 1 of the following:<br><br>             - RR = 30, HR = 125, SaO2 <93% on room air or requires > 2L oxygen by NC in order<br>             maintain SaO2 =93%, PaO2/FiO2 <300<br><br>             AND<br><br>             - None of the following: Respiratory failure (defined by endotracheal intubation and<br>             mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive<br>             positive pressure ventilation, or clinical diagnosis of respiratory failure in setting<br>             of resource limitations), Septic shock (defined by SBP < 90 mm Hg, or Diastolic BP <<br>             60 mm Hg), Multiple organ dysfunction/failure<br><br>             B. Critical Illness:<br><br>             - Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing within 5 days<br>             of screening<br><br>             AND<br><br>             Evidence of critical illness, defined by at least 1 of the following:<br><br>             - Respiratory failure defined based on resource utilization requiring at least 1 of<br>             the following: Endotracheal intubation and mechanical ventilation, oxygen delivered by<br>             high-flow nasal cannula, noninvasive positive pressure ventilation, ECMO, or clinical<br>             diagnosis of respiratory failure (in setting of resource limitation)<br><br>             OR<br><br>             - Shock (defined by SBP < 90 mm Hg, or Diastolic BP < 60 mm Hg or requiring<br>             vasopressors)<br><br>             OR<br><br>             -Multiple organ dysfunction/failure<br><br>          3. Subject, if intubated, positive endexpiratory pressure (PEEP) <15 cmH2O with PaO2/FiO2<br>             >150 mmHg.<br><br>          4. Electrocardiogram (ECG) with no clinically significant findings as assessed by the<br>             Investigator<br><br>          5. Subject (or legally authorized representative) provides written informed consent prior<br>             to initiation of any study procedures.<br><br>          6. Understands and agrees to comply with planned study procedures.<br><br>          7. Women of childbearing potential and their partner must agree to use at least one<br>             highly effective method of contraception (e.g., hormonal contraceptives [implants,<br>             injectables, combination oral contraceptives, transdermal patches, or contraceptive<br>             rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the<br>             duration of the study.<br><br>        Exclusion Criteria:<br><br>          1. Subjects with do-not-resuscitate (DNR) and/or do-not-intubate (DNI) orders or expected<br>             to be made DNR/DNI in setting of resource limitations or family wishes.<br><br>          2. Not a candidate for dialysis or continuation of care (or full medical support) in<br>             setting of resource limitations.<br><br>          3. Subject on continuous vasopressors (at the dose of norepinephrine >20µg/min and/or<br>             vasopressin >0.04 units/kg/min) for >48 hours at time of screening.<br><br>          4. Subjects who have a history of allergic reactions attributed to compounds of similar<br>             chemical or biologic composition to leronlimab (PRO 140) are not eligible.<br><br>          5. Inability to provide informed consent or to comply with test requirements<br><br>          6. Consideration by the investigator, for safety reasons, that the subject is an<br>             unsuitable candidate to receive study treatment<br><br>          7. Pregnancy or breast feeding<br><br>          8. Subject participating in another study with for an investigational treatment for<br>             COVID-19.<br><br>        Note: Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without<br>        azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory<br>        treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and<br>        anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included<br>        and may continue to receive these agents as part of standard-of-care.<br>",NA,All-cause mortality at Day 28,NA,NA,NA,parent,NA,2020-04-13
NCT04419623,https://clinicaltrials.gov/show/NCT04419623,"A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer",COVID-19;Sars-CoV2;Cancer;Solid Tumor;Carcinoma;Blood Cancer,Drug: Part 1 - TL-895;Drug: Part 2 - TL-895;Drug: Part 2 - Placebo,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,CT.gov,2020-06-03,2020-07-09,FALSE,Interventional,"Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 1/Phase 2,146,"Telios Pharma, Inc.",United States,TRUE,Yes,03/06/2020,"July 9, 2020",5 October 2020,NA,20200603,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,Yes,18 Years,N/A,All,NA,John Mei,NA,jmei@teliospharma.com,650-542-0136,NA,"<br>        Inclusion Criteria:<br><br>          -  Known diagnosis of active cancer that is not considered cured or disease free.<br><br>          -  Confirmed COVID-19 infection as per World Health Organization (WHO) criteria with<br>             suspected pneumonia requiring hospitalization and oxygen saturation < 94% on room air<br>             or requires supplemental oxygen.<br><br>          -  Adequate hematological, hepatic and renal function as would be medically expected of a<br>             cancer patient population.<br><br>          -  Able to swallow and absorb oral medications.<br><br>        Exclusion Criteria:<br><br>          -  Current active treatment with medications contraindicated for receipt of<br>             investigational product.<br><br>          -  Require chemotherapy or urgent systemic therapy for active cancer that cannot be<br>             withheld.<br><br>          -  No remaining available therapies for advanced or metastatic malignancies.<br><br>          -  Participation in another clinical study with therapeutic intent for COVID-19, except<br>             where patients are receiving hydroxychloroquine or chloroquine and/or azithromycin<br>             and/or remdesivir.<br><br>          -  Require artificial ventilation at screening.<br><br>          -  Life expectancy less than 6 months.<br><br>          -  Advanced healthcare directive that includes do not intubate (DNI) or do not<br>             resuscitate (DNR) orders<br><br>          -  Medical conditions that make it unsafe to receive investigational product (for<br>             example, heart attack in the last 6 mos, unstable angina, uncontrolled arrhythmia,<br>             heart failure class 3/4, QTC interval > 480 msec; known bleeding disorders, stroke or<br>             intracranial hemorrhage in the last 6 mos; active HBV, HCV or history of HIV; GI<br>             malabsorption syndrome, small bowel resection, poorly controlled IBS;<br>             untreated/actively progressing known CNS lesions).<br><br>          -  Receipt of radiation therapy to the lung or mediastinum for treatment of COVID-19<br>",NA,Part 1 - Recommended dose of TL-895;Part 2 - Change in the need for artificial ventilation or death,NA,NA,NA,parent,NA,2020-06-03
NCT04372186,https://clinicaltrials.gov/show/NCT04372186,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia",COVID-19 Pneumonia,Drug: Placebo;Drug: Tocilizumab,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,CT.gov,2020-04-29,2020-05-14,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 3,379,"Genentech, Inc.",United States;Brazil;Kenya;Mexico;Peru;South Africa;Brazil;Kenya;Mexico;Peru;South Africa;United States,TRUE,Yes,29/04/2020,"May 14, 2020",16 November 2020,EMPACTA,20200429,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,Yes,18 Years,N/A,All,NA,Clinical Trials,NA,NA,NA,Hoffmann-La Roche,"<br>        Inclusion Criteria<br><br>          -  Hospitalized<br><br>          -  COVID-19 pneumonia confirmed by a positive polymerase chain reaction (PCR) of any<br>             specimen and radiographic imaging<br><br>          -  SpO2 < 94% while on ambient air<br><br>        Exclusion Criteria<br><br>          -  Known severe allergic reactions to TCZ or other monoclonal antibodies<br><br>          -  Require continuous positive airway pressure (CPAP), bilevel positive airway pressure<br>             (BIPAP), or invasive mechanical ventilation<br><br>          -  Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)<br><br>          -  In the opinion of the investigator, progression to death is imminent and inevitable<br>             within the next 24 hours, irrespective of the provision of treatments<br><br>          -  Immunocompromised (besides well-controlled HIV) or on immunosuppressive therapy<br>             (except for steroids for COVID), advanced cancer<br><br>          -  Have received oral anti-rejection or immunomodulatory drugs (including TCZ) within the<br>             past 3 months<br><br>          -  Participating in another interleukin (IL)-6 antagonist clinical trial or other drug<br>             clinical trials (participation in COVID-19 anti-viral trials may be permitted if<br>             approved by Medical Monitor)<br><br>          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 10 x upper limit<br>             of normal (ULN) detected within 24 hours at screening (according to local laboratory<br>             reference ranges)<br><br>          -  Absolute neutrophil count (ANC) < 1000/uL at screening (according to local laboratory<br>             reference ranges)<br><br>          -  Platelet count < 50,000/uL at screening (according to local laboratory reference<br>             ranges)<br><br>          -  Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination<br><br>          -  Treatment with an investigational drug within 5 half lives or 30 days (whichever is<br>             longer) of randomization (investigational COVID-19 antivirals may be permitted if<br>             approved by Medical Monitor)<br><br>          -  Any serious medical condition or abnormality of clinical laboratory tests that, in the<br>             investigator's judgment, precludes the patient's safe participation in and completion<br>             of the study<br><br>          -  Any history of Diverticulitis or GI perforation<br><br>          -  Use of systemic corticosteroids unless on a stable chronic dose<br>",NA,Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28,NA,NA,NA,parent,NA,2020-04-29
NCT04498936,https://clinicaltrials.gov/show/NCT04498936,"Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial",COVID,Drug: Sofosbuvir and Ledipasvir;Drug: Nitazoxanide,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,CT.gov,2020-04-14,2020-07-15,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 4,240,Assiut University,Egypt,FALSE,Yes,14/04/2020,"July 15, 2020",24 November 2020,NA,20200414,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,12 Years,65 Years,All,; ;,"Mohammed A Medhat, PhD;Mohamed El Kassas, PhD;Haidi K Ramadan, PhD",NA,;;,;;,Assiut University;Helwan University;Assiut University,"<br>        This study is an open-label, randomized, controlled trial. A total of 216 patients who are<br>        recruited in 2 quarantine hospitals (15th of May hospital, Cairo, and Al Rajhi hospital,<br>        Assiut), will be randomly assigned in a 1:1:1 ratio (72 patient in each treatment arm), to<br>        receive either the fixed combination of Sofosbuvir/Ledipasvir (400 mg and 90 mg, orally)<br>        once daily for 14 days, plus the standard care treatment regimen (SCT) for COVID-19<br>        patients according to the Egyptian Ministry of Health (MOH) protocol (Group 1), or<br>        nitazoxanide (500 mg, orally) four times per day for 14 days, plus STC (Group 2), or SCT<br>        alone (Group 3). All treatment groups will be followed up by laboratory investigations and<br>        PCR for SARS-CoV-2 virus at the time of enrollment, days 5, 8, 11, and 14. Supportive care<br>        comprised, as necessary, supplemental oxygen, noninvasive and invasive ventilation,<br>        antibiotic agents, vasopressor support, renal-replacement therapy, and extracorporeal<br>        membrane oxygenation (ECMO). To ensure a balanced distribution of case severities in all<br>        study groups, randomization will be stratified based on the case severity index issued by<br>        WHO<br>        (https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf)<br>        .<br><br>        Written informed consent will be obtained from all patients or the patient's legal<br>        representative if the patient is too unwell to provide consent. The trial will be conducted<br>        in accordance with the principles of the Declaration of Helsinki and the Good Clinical<br>        Practice guidelines of the International Conference on Harmonisation. The authors are<br>        responsible for designing the trial and for compiling and analyzing the data. The authors<br>        vouch for data completeness and accuracy and adherence to the trial protocol.<br><br>        Inclusion Criteria:<br><br>          -  This study will include patients with confirmed COVID-19 infection and admitted to<br>             COVID-19 quarantine hospitals. Included patients should be > 12 years old, with<br>             creatinine clearance > 30 mL/ml, and without any malignancy. Patients with COVID-19<br>             infection are classified clinically into mild, moderate, severe, and critical cases<br>             according to the management guide for COVID-19 published by the Egyptian Ministry of<br>             Health and Population. Mild cases are defined as patients in whom clinical symptoms<br>             are mild, and no pneumonia manifestations can be found in imaging. Moderate cases are<br>             defined as patients having symptoms such as fever and respiratory tract symptoms, etc.<br>             and pneumonia manifestations can be seen in imaging. Severe cases are patients who<br>             meet any of the following criteria; (a) respiratory rate > 30 breaths/min, (b) oxygen<br>             saturations< 93% at a rest state, (c) arterial partial pressure of oxygen (PaO2)/<br>             Fraction of inspired oxygen (FiO2)<300 mm Hg, or (d) patients with more than 50%<br>             lesions progression within 24 to 48 hours in lung imaging should be treated as severe<br>             cases. Finally, critical patients are those who are meeting any of the following<br>             criteria; (a) occurrence of respiratory failure requiring mechanical ventilation, or<br>             (b) the presence of shock; other organ failures that require monitoring and treatment<br>             in the ICU. All patients with an established diagnosis of COVID-19 in Egyptian<br>             quarantine hospitals at any clinical stage will be included in this study.<br><br>        Exclusion Criteria:<br><br>          -  Patients < 12 years old.<br><br>          -  Pregnant females.<br><br>          -  Patients with renal impairment with creatinine clearance < 30 mL/min.<br><br>          -  Patients with malignancies particularly Hepatocellular Carcinoma (HCC).<br><br>          -  Patients using Favipiravir or Lopinavir-Ritonavir, as the co-administration of these<br>             drugs with Sofosbuvir/Ledipasvir has not been studied.<br><br>          -  Patients with decompensated liver cirrhosis (Child-Pugh score B and C).<br>",NA,Change of PCR from positive to negative;Clinical improvement,NA,NA,NA,NA,NA,2020-04-14
NCT04380519,https://clinicaltrials.gov/show/NCT04380519,"An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)",COVID-19,Biological: RPH-104 80 mg;Drug: Olokizumab 64 mg;Drug: Placebo,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),CT.gov,2020-05-06,2020-04-23,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 2/Phase 3,372,"R-Pharm International, LLC",Russian Federation,FALSE,Yes,06/05/2020,"April 23, 2020",12 October 2020,NA,20200506,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,100 Years,All,NA,Mikhail Samsonov,NA,NA,NA,"Chief Medical Officer, R-Pharm","<br>        Inclusion criteria:<br><br>          -  1. Signed and dated patient's Informed consent for participation in this study, or<br>             record of a medical board decision justifying patient's participation in case of<br>             patient is unable to state his/her will.<br><br>          -  2. Having either of the following COVID-associated respiratory syndromes:<br><br>               -  pneumonia with oxygenation parameters SpO2 =93% (on room air) or respiratory rate<br>                  greater than 30/min;<br><br>               -  ARDS ( PaO2/FiO2 = 300 mmHg or SpO2/FiO2 = 315 if PaO2 is not available).<br><br>          -  3. COVID-19 diagnosis based on:<br><br>               -  laboratory-confirmed SARS-CoV-2 infection as determined by Polymerase Chain<br>                  Reaction method (PCR).<br><br>        OR<br><br>        • Bilateral changes in the lungs typical for COVID-19, based on chest computed tomography<br>        results.<br><br>        Exclusion criteria:<br><br>          -  1. Hypersensitivity to the study drugs (RPH-104 and/or OKZ), and/or its components.<br><br>          -  2. Presence of any of the following laboratory abnormalities:<br><br>               -  absolute neutrophil counts < 0.5 x 10^9 L<br><br>               -  white blood cell count < 2 x 10^9 L<br><br>               -  platelet count <50 x 10^9 L<br><br>               -  Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) = 3.0 x<br>                  Upper Limit of Normal (ULN)<br><br>          -  3. Severe renal failure: creatinine clearance < 30 mL/min<br><br>          -  4. Septic shock (to maintain mean arterial pressure = 65 mm Hg and lactate = 2 mmol/L<br>             in the absence of hypovolemia, vasopressors are necessary)<br><br>          -  5. Progression of disease up to the death in the following 24 hours regardless of<br>             treatment, as per Investigator's opinion<br><br>          -  6. History of perforation of gastrointestinal tract, history of diverticulitis<br><br>          -  7. Plasma infusion from convalescent COVID-19 donors within 4 weeks prior to patient<br>             inclusion and/or planned infusion during the study<br><br>          -  8.Recent (less then 5 half-lives) administration of tocilizumab or sarilumab;<br><br>          -  9. Recent (less then 5 half-lives) or planned during the current study period use of<br>             the following drugs:<br><br>               -  immunosuppressive biologics over than OKZ or RPH-104, including but not limited,<br>                  Interleukin-1 (IL-1) inhibitors (rilonacept, anakinra, canakinumab) , IL-6<br>                  inhibitors (except tocilizumab and sarilumab), IL-17A inhibitors<br>                  (secukinumab),tumor necrosis factor a (TNFa) inhibitors (adalimumab, infliximab,<br>                  etanercept), anti-B-cell therapy and others<br><br>               -  other immunosuppressors except methotrexate dosed up to 25 mg per week, including<br>                  but not limited:<br><br>                    1. high-dose glucocorticoids ( > 1mg/kg of prednisolone equivalent), oral and<br>                       parental;<br><br>                    2. JAK inhibitors, cyclophosphamide, and others<br><br>          -  10. Concurrent participation in another clinical trial.<br><br>          -  11. Pregnancy or lactation<br><br>          -  12. History of active tuberculosis, active tuberculosis suspected by Investigator<br>",NA,"Proportion of patients, responded to the study therapy, in each of the treatment groups",NA,NA,NA,NA,NA,2020-05-06
NCT04575597,https://clinicaltrials.gov/show/NCT04575597,"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.",Coronavirus Disease (COVID-19),Drug: Molnupiravir;Drug: Placebo,Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002),CT.gov,2020-09-30,2020-10-19,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 2/Phase 3,1450,Merck Sharp & Dohme Corp.,United States;Chile;Colombia;Israel;Russian Federation;Spain;United Kingdom;Chile;Colombia;Israel;Russian Federation;Spain;United Kingdom;United States,FALSE,Yes,30/09/2020,"October 19, 2020",30 November 2020,NA,20200930,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,;,Medical Director;Toll Free Number,NA,;Trialsites@merck.com,;1-888-577-8839,Merck Sharp & Dohme Corp.;,"<br>        Inclusion Criteria:<br><br>          -  Has documentation of polymerase chain reaction (PCR)-confirmed severe acute<br>             respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with sample collection =7<br>             days prior to randomization. PCR is the preferred method; however other diagnostic<br>             methods are allowed if authorized by use in the country.<br><br>          -  Has initial onset of signs/symptoms attributable to COVID-19 for =7 days prior to<br>             randomization and at least 1 sign/symptom attributable to COVID-19 on the day of<br>             randomization<br><br>          -  Has mild or moderate COVID-19. Participants with mild COVID-19 must have at least 1<br>             characteristic or underlying medical condition associated with an increased risk of<br>             severe illness from COVID-19<br><br>          -  Has oxygenation saturation of >93% (on room air OR on supplemental oxygen prior to<br>             randomization which has not increased since onset of COVID-19 signs/symptoms) obtained<br>             at rest by study staff at randomization.<br><br>          -  Is willing and able to take oral medication<br><br>          -  Males agree to the following during the intervention period and for at least 90 days<br>             after the last dose of study intervention: Refrain from donating sperm; and either<br>             abstain from heterosexual intercourse as their preferred and usual lifestyle<br>             (abstinent on a long term and persistent basis) and agree to remain abstinent; or must<br>             agree to use contraception<br><br>          -  Females are not pregnant or breastfeeding, and at least one of the following<br>             conditions applies: Is not a woman of child bearing potential (WOCBP); or is a WOCBP<br>             and using a contraceptive method that is highly effective (a low user dependency<br>             method OR a user dependent method in combination with barrier method), or be abstinent<br>             from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a<br>             long-term and persistent basis) during the intervention period and for at least 7<br>             months after the last dose of study intervention; a WOCBP must have a negative highly<br>             sensitive pregnancy test (urine or serum test is required) within 24 hours before the<br>             first dose of study intervention.<br><br>        Exclusion Criteria:<br><br>          -  Is currently hospitalized or is expected to need hospitalization for COVID-19 within<br>             48 hours of randomization<br><br>          -  Is on dialysis or has reduced estimated glomerular filtration rate (eGFR) <30<br>             mL/min/1.73m^2 by the Modification of Diet in Renal Disease (MDRD) equation<br><br>          -  Has any of the following conditions: human immunodeficiency virus (HIV) with a recent<br>             viral load >50 copies/mL or cluster of differentiation 4 (CD4) <200 cell/mm^3;<br>             chemotherapy required within 6 weeks before randomization; a neutrophilic granulocyte<br>             absolute count <500/mm^3; autologous or allogeneic hematopoietic stem cell transplant<br>             recipient<br><br>          -  Has an active diagnosis of hepatitis due to any cause<br><br>          -  Has a history of acute pancreatitis within 3 months prior to randomization or a<br>             history of chronic pancreatitis<br><br>          -  Is taking or is anticipated to require any prohibited therapies<br><br>          -  Is unwilling to abstain from participating in another interventional clinical study<br>             through Day 29 with an investigational compound or device, including those for<br>             COVID-19 therapeutics<br><br>          -  Has a baseline heart rate of < 50 beats per minute at rest<br><br>          -  Has a platelet count <100,000/µL or received a platelet transfusion in the 5 days<br>             prior to randomization.<br><br>          -  Has hypersensitivity or other contraindication to any of the components of the study<br>             interventions as determined by the investigator<br><br>          -  Has any condition for which, in the opinion of the investigator, participation would<br>             not be in the best interest of the participant or that could prevent, limit, or<br>             confound the protocol-specified assessments including but not limited to: participants<br>             who are not expected to survive longer than 48 hours after randomization, participants<br>             who are expected to require mechanical ventilation within 48 hours after<br>             randomization, or participants with a recent history of mechanical ventilation not<br>             associated with COVID-19, or participants with conditions that could limit<br>             gastrointestinal absorption of capsule contents.<br>",NA,Percentage of participants who are hospitalized and/or die;Percentage of participants with an adverse event (AE);Percentage of participants who discontinued study intervention due to an AE,NA,NA,NA,NA,NA,2020-09-30
NCT04423861,https://clinicaltrials.gov/show/NCT04423861,"A Phase III, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Efficacy and Safety of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Non-critical Condition",covid19,Drug: Nitazoxanide;Drug: Placebo,Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19,CT.gov,2020-06-08,2020-12-01,TRUE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 3,380,Azidus Brasil,NA,FALSE,Yes,08/06/2020,December 2020,30 November 2020,NA,20200608,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,NA,"Florentino de Araujo Cardoso Filho, MD, PhD",NA,florentino.cardoso@hospitalcare.com.br,+55 19 991232882,NA,"<br>        Inclusion Criteria:<br><br>          1. Informed consent from patient or legal representative.<br><br>          2. Male or female, aged = 18 years;<br><br>          3. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase<br><br>          4. chain reaction (RT-PCR) from any diagnostic sampling source;<br><br>          5. Hospitalized for up to 48h with signs of respiratory failure with or without<br>             non-invasive ventilation and i. Oxygen saturation <98%;<br><br>        7. Negative result for pregnancy test (if applicable).<br><br>        Exclusion Criteria:<br><br>          1. Participating in another RCT in the past 12 months;<br><br>          2. Known allergy to nitazoxanide<br><br>          3. Severely reduced LV function;<br><br>          4. Severely reduced renal function;<br><br>          5. Pregnancy or breast feeding;<br><br>          6. Diagnosis of any other active infection (viral, bacterial, fungal or caused by another<br>             pathogen, except the one studied in the trial);<br><br>          7. History of HIV 1 and/or 2 (Anti-HIV-1,2) and/or HTLV I and II positive;<br><br>          8. Ongoing antineoplastic treatment with chemotherapy or radiation therapy;<br><br>          9. Diagnose of severe autoimmune diseases in immunosuppression;<br><br>         10. Transplanted patients;<br><br>         11. Any other clinical condition which, in the opinion of the principal investigator,<br>             would not allow safe completion of the protocol and safe administration of the<br>             investigational products<br>",NA,Need of mechanical ventilation,NA,NA,NA,NA,NA,2020-06-08
NCT04455815,https://clinicaltrials.gov/show/NCT04455815,"A Randomised Phase II/III Trial in a Community Setting, Assessing Use of Camostat in Reducing the Clinical Progression of COVID-19 by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion",COVID-19 Infection,Drug: Camostat,A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home,CT.gov,2020-06-25,2020-09-25,FALSE,Interventional,Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2/Phase 3,389,Cancer Research UK,United Kingdom,FALSE,Yes,25/06/2020,"September 25, 2020",12 October 2020,NA,20200625,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,50 Years,N/A,All,NA,"Kevin Dhaliwal, Professor",NA,Kev.Dhaliwal@ed.ac.uk,01312429180,NA,"<br>        Inclusion Criteria:<br><br>          -  Patient willing and able to give informed consent<br><br>          -  Adults, 50 years of age and above<br><br>          -  Typical symptoms of COVID-19 infection (i.e. fever > 37.8 °C, and/or persistent dry<br>             cough and/or shortness of breath)<br><br>          -  Evidence of current COVID-19 infection from a validated assay<br><br>        Exclusion Criteria:<br><br>          -  Significant electrolyte disturbance (e.g. hyperkalaemia, potassium >5.0 mmol/L )<br><br>          -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) and/or Alkaline<br>             Phosphatase (ALP) > 2.5 x ULN<br><br>          -  Any condition that, in the Investigator's opinion, will prevent adequate compliance<br>             with trial therapy e.g. mild cognitive impairment (unable to follow instructions for<br>             self-assessment readings as assessed by the Investigator)<br><br>          -  Patients on long term supplementary oxygen requirement (patients for whom hospital<br>             admission would not be considered e.g. care plan in the community is in place, are not<br>             excluded)<br><br>          -  Known hypersensitivity to camostat<br><br>          -  Platelet count <100 x 109/L<br><br>          -  Co-enrolment with a Clinical Trial of an Investigational Medicinal Product (CTIMP)<br>             will not be permitted. Co-enrolment with a clinical investigation of a Medical Device<br>             or a non-interventional clinical study will be considered on a study-by-study basis<br>             and in discussion with the relevant Chief Investigators and Sponsors and industrial<br>             collaborators.<br><br>          -  Co-enrolment involving non-interventional research (including questionnaire or tissue<br>             only studies) will be allowed provided this is not expected to affect the outcomes of<br>             both studies or place undue burden upon participants and their families.<br><br>          -  Female patients who are able to become pregnant (or are already pregnant or<br>             lactating). However, those patients who are of child bearing potential and have a<br>             negative serum or urine pregnancy test before enrolment and agree to use two forms of<br>             contraception (one effective form plus a barrier method [oral, injected or implanted<br>             hormonal contraception and condom; intra-uterine device and condom; diaphragm with<br>             spermicidal gel and condom]) or agree to sexual abstinence*, effective from the first<br>             administration of camostat, throughout the trial and for 28 days afterwards are<br>             considered eligible.<br><br>        (*Abstinence is only considered to be an acceptable method of contraception when this is in<br>        line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g.,<br>        calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not<br>        acceptable methods of contraception.) 10. Male patients with partners of child-bearing<br>        potential (unless they agree to take measures not to father children by using a barrier<br>        method of contraception [condom plus spermicide] or to sexual abstinence* effective from<br>        the first administration of camostat, throughout the trial and for 28 days afterwards. Men<br>        with partners of child-bearing potential must also be willing to ensure that their partner<br>        uses an effective method of contraception for the same duration for example, hormonal<br>        contraception, intrauterine device, diaphragm with spermicidal gel or sexual abstinence).<br>        Men with pregnant or lactating partners must be advised to use barrier method contraception<br>        (for example, condom plus spermicidal gel) to prevent exposure of the foetus or neonate.<br><br>        (*Abstinence is only considered to be an acceptable method of contraception when this is in<br>        line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g.,<br>        calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not<br>        acceptable methods of contraception.)<br><br>          -  Significant cardiovascular disease (as assessed via the participant's medical record<br>             and history) as defined by:<br><br>               1. History of congestive heart failure requiring therapy (New York Heart Association<br>                  [NYHA] III or IV)<br><br>               2. History of unstable angina pectoris or myocardial infarction up to 6 months prior<br>                  to trial entry<br><br>               3. Presence of severe valvular heart disease<br><br>               4. Presence of a ventricular arrhythmia requiring treatment<br><br>          -  Known allergic reactions to components of camostat e.g., lactose intolerance<br>",NA,Number of participants who require hospital admission and require supplemental oxygen.,NA,NA,NA,NA,NA,2020-06-25
NCT04487886,https://clinicaltrials.gov/show/NCT04487886,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection,COVID-19,Drug: Duvelisib;Drug: Placebo,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),CT.gov,2020-07-23,2020-08-01,TRUE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",Phase 2,80,Emory University,United States,FALSE,Yes,23/07/2020,August 2020,3 August 2020,DAMPEN-CI,20200723,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,;,"Edmund Waller, MD, PhD;Edmund Waller, MD, PhD",NA,;ewaller@emory.edu,;404-778-1900,Emory University;,"<br>        Inclusion Criteria:<br><br>          -  Hospitalized in participating facility.<br><br>          -  Documentation of pneumonia with radiographic evidence of infiltrates by imaging (e.g.,<br>             chest x-ray or CT scan).<br><br>          -  Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction<br>             (PCR) or other authorized or approved assay in any specimen collected within 72 hours<br>             prior to enrollment. Note - An exception must be requested to the Sponsor if =72 hours<br>             since positive test.<br><br>          -  Symptoms suggestive of severe systemic illness with COVID-19, such as respiratory rate<br>             > 30 breaths per minute, heart rate >125 beats per minute, oxygen saturation (O2 sat)<br>             in the blood of <93% on room air at sea level or the ratio of arterial oxygen partial<br>             pressure to fractional inspired oxygen (PaO2/FiO2)< 300<br><br>          -  18 years of age or older<br><br>          -  Patients with hematological parameters at screening consistent with < grade 2 NCI<br>             CTCAE v5.0 toxicity: hemoglobin >8 g/dL, platelet count >50,000 K/mcl, an absolute<br>             neutrophil count (ANC) >1,000/mm3, and an absolute lymphocyte count (ALC) >500/mm3.<br><br>          -  Patients with laboratory measurements of liver function at screening consistent with <<br>             grade 2 NCI CTCAE v5.0 toxicity: alanine aminotransferase (ALT) < 5 times the upper<br>             limit of normal (ULN); aspartate aminotransferase (AST) < 5 times ULN; and bilirubin <<br>             3 times ULN.<br><br>          -  The effects of duvelisib on the developing human fetus are unknown. For this reason,<br>             women of child-bearing potential (WOCBP) must have a negative serum or urine<br>             pr5egnancy test prior to starting therapy. WOCBP and men must agree to use adequate<br>             contraception (hormonal or barrier method of birth control; abstinence) from<br>             enrollment into this study until at least 60 days after the first dose of duvelisib. A<br>             woman of childbearing potential (WOCBP) is a sexually mature woman who: 1) has not<br>             undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally<br>             postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in<br>             the preceding 24 consecutive months. Should a woman become pregnant or suspect she is<br>             pregnant while she or her partner is participating in this study, she should inform<br>             her treating physician immediately. Men treated or enrolled on this protocol must also<br>             agree to use adequate contraception prior to the study, for the duration of study<br>             participation, and 2 months after completion of duvelisib administration. WOCBP must<br>             have a negative pregnancy test within 24 hours of the first dose of duvelisib.<br><br>          -  The patient must be willing to comply with fertility requirements as below:<br><br>               -  Total abstinence (when this is in line with the usual practice and lifestyle of<br>                  the patient) will be accepted. Periodic abstinence (i.e., calendar, ovulation,<br>                  post-ovulation methods) and withdrawals are not acceptable forms<br><br>               -  If a female participant is of reproductive potential, the participant (and her<br>                  partner) must agree to use of one of the following combinations of birth control<br>                  during the study and for 2 months after the last dose of study drug (or tubal<br>                  ligation as a single method):<br><br>                    -  Use of a double-barrier method of contraception: condoms (male or female)<br>                       and a diaphragm or cervical cap with spermicide;<br><br>                    -  Use of an IUD and a barrier method: condoms (male or female, with or without<br>                       spermicide) or a diaphragm or cervical cap with spermicide;<br><br>                    -  Tubal ligation.<br><br>               -  Women who are post-menopausal, defined as age greater than 45 and no menses for<br>                  at least 24 consecutive months, or who have had a hysterectomy, are considered<br>                  not of reproductive potential.<br><br>               -  Males must agree to using contraception during the study and for 2 months after<br>                  the last dose of study drug or have undergone a male sterilization procedure (at<br>                  least 6 months prior to screening.<br><br>               -  Use of oral (estrogen and progesterone), injected or implanted hormonal methods<br>                  of contraception, or placement of an intrauterine device (IUD) or intrauterine<br>                  system (IUS) or other forms of contraception that comparable efficacy (failure<br>                  rate <1%). In case of oral contraception, the woman should be stable on the same<br>                  pill for a minimum of 3 months prior to enrollment on the study.<br><br>          -  Patients must agree not to donate blood, sperm/ova or any other organs while taking<br>             protocol therapy and for at least 2 weeks after stopping treatment.<br><br>          -  Willingness and ability of the patient to comply with scheduled visits, drug<br>             administration plan, protocol specified laboratory tests, other study procedures and<br>             study restrictions<br><br>          -  Evidence of personally signed informed consent indicating that the subject is aware of<br>             the life-threatening nature of the disease and has been informed on the procedures to<br>             be followed, the experimental nature of the therapy, alternative, potential risks and<br>             discomforts, potential benefits and other pertinent aspects of study participation.<br><br>        Exclusion Criteria:<br><br>          -  Patients requiring mechanical ventilation (intubation or Bi-PAP) at the time<br>             randomization.<br><br>          -  Patients receiving any investigational drugs other than drugs or therapies to treat<br>             COVID-19, with the exception of investigational immune-modulatory drugs as per section<br>             5.4.<br><br>          -  Pregnant women are excluded from this study because duvelisib is agent with the<br>             potential for teratogenic or abortifacient effects. Because there is an unknown but<br>             potential risk for adverse events in nursing infants secondary to treatment of the<br>             mother with duvelisib, breastfeeding should be discontinued before starting study drug<br>             and breastfeeding should not be resumed until at least 1 month after last dose of<br>             study drug.<br><br>          -  Clinical suspicion that the etiology of acute illness (acute decompensation) is<br>             primarily due to a condition other than COVID-19<br><br>          -  Known contraindication to duvelisib<br><br>          -  Patients with hepatic cirrhosis as defined by symptomatic liver dysfunction; liver<br>             fibrosis by biopsy; ALT > 5 times ULN, AST> 5 times ULN, or bilirubin > 3 times ULN.<br><br>          -  Patients with autoimmune diseases or patients on chronic immunosuppressive medications<br>             at the time of hospital admission or screening.<br>",NA,Number of Participants Requiring Mechanical Ventilation or Dying,NA,NA,NA,NA,NA,2020-07-23
NCT04334148,https://clinicaltrials.gov/show/NCT04334148,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial),COVID-19,Drug: Hydroxychloroquine;Drug: Placebo oral tablet,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine,CT.gov,2020-04-02,2020-04-22,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).",Phase 3,1363,Adrian Hernandez,United States,FALSE,Yes,02/04/2020,"April 22, 2020",24 November 2020,HERO-HCQ,20200402,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,NA,"Adrian Hernandez, MD",NA,NA,NA,Duke University,"<br>        Inclusion:<br><br>          -  Completed Informed Consent<br><br>          -  Age = 18 years old<br><br>          -  Currently working in any environment in which there is a risk of exposure to patients<br>             with COVID-19 infections (""healthcare worker"")<br><br>        Exclusion Criteria:<br><br>          -  Prior diagnosis of COVID-19 infection<br><br>          -  Participation in another COVID-19 prophylaxis trial within 30 days of consent<br><br>          -  Respiratory illness with new-onset fever (Temperature > 100°F) or ongoing cough or<br>             dyspnea within 14 days<br><br>          -  Known allergy to HCQ or chloroquine<br><br>          -  Congenital prolonged QT syndrome<br><br>          -  Current or planned use of QT prolonging drugs (e.g. procainamide, disopyramide,<br>             mexiletine, flecainide, propafenone, amiodarone, sotalol, cimetidine, dronedarone,<br>             dofetilide, levofloxacin, ciprofloxacin, moxifloxacin) and other contraindicated<br>             medications<br><br>          -  End stage renal disease<br><br>          -  Pre-existing retinopathy<br><br>          -  Current or planned use of Hydroxychloroquine (study drug) for any indication<br><br>        Current or planned use of the following for treatment or prevention of COVID-19 infection:<br><br>          -  Chloroquine<br><br>          -  Azithromycin<br><br>               -  Known cirrhosis or severe liver disease<br><br>               -  History of severe skin reactions such as Steven-Johnson syndrome, toxic epidermal<br>                  necrolysis<br><br>               -  History of psoriasis or porphyria<br><br>               -  Ventricular arrhythmias requiring medical treatment<br><br>               -  Severe coronary artery disease or heart failure/cardiomyopathy with ongoing<br>                  symptoms<br><br>               -  Current or planned use of use of anti-seizure drugs<br><br>               -  History of Glucose-6-phosphate dehydrogenase deficiency<br>",NA,Number of participants with clinical infection with COVID-19 infection,NA,NA,NA,NA,NA,2020-04-02
NCT04491994,https://clinicaltrials.gov/show/NCT04491994,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial,Covid19;Progression,Drug: HCQ,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,CT.gov,2020-07-28,2020-04-10,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 3,540,UNICEF,Pakistan,FALSE,Yes,28/07/2020,"April 10, 2020",31 August 2020,COVID-19,20200728,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,80 Years,All,NA,"Imran m Fazal, FCPS",NA,NA,NA,Pak Emirates Military Hospital (PEMH) Rawalpindi,"<br>        Inclusion Criteria:<br><br>          -  Mild Corona virus disease (COVID-19)<br><br>          -  PCR confirmed infection<br><br>          -  Hospital admitted patients<br><br>        Exclusion Criteria:<br><br>          -  Moderate, severe and critical COVID-19<br><br>          -  day 0 CRP greater than 6mg/dl, ALC < 1000 or evidence of infiltrates on X-ray chest<br><br>          -  comorbidity with life expectancy less than 6 months<br><br>          -  Contraindications to HCQ therapy<br>",NA,Number of Participants With Progression,21/08/2020,NA,https://clinicaltrials.gov/ct2/show/results/NCT04491994,NA,Yes,2020-07-28
NCT04565249,https://clinicaltrials.gov/show/NCT04565249,"A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)",Acute Respiratory Distress Syndrome;SARS-CoV-2,Drug: PLN-74809;Drug: Placebo,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19",CT.gov,2020-09-15,2020-10-22,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,36,"Pliant Therapeutics, Inc.",United States,FALSE,Yes,15/09/2020,"October 22, 2020",9 November 2020,NA,20200915,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ;,"Pliant Therapeutics;Pliant Therapeutics Medical Monitor;Rania Rahman, MD",NA,;clintrials@pliantrx.com;,;clintrials@pliantrx.com;,"Pliant Therapeutics, Inc.;","<br>        Inclusion Criteria:<br><br>          -  Diagnosis of ARDS (Berlin Criteria)<br><br>          -  Hospitalized with at least severe COVID-19 (FDA 2020)<br><br>          -  Receiving support for acute lung injury/respiratory distress via supplemental oxygen<br><br>          -  Serum aspartate aminotransferase (AST) concentration = 120 U/L and serum alanine<br>             aminotransferase (ALT) concentration = 150 U/L<br><br>          -  Serum total bilirubin = 1.8 mg/dL, in the absence of Gilbert's syndrome or hemolysis<br><br>        Exclusion Criteria:<br><br>          -  Greater than 72 hours since time of onset of ARDS.<br><br>          -  Greater than 7 days since start of mechanical ventilation.<br><br>          -  Currently receiving or anticipated to receive extracorporeal life support (ECLS),<br>             extracorporeal membrane oxygenation (ECMO) or high-frequency oscillatory ventilation<br><br>          -  Unwillingness to follow lung protective ventilation strategy (i.e., tidal volume of 6<br>             mL/kg of predicted body weight and prone positioning) and fluid management protocol<br>             (Fluids and Catheters Treatment Trial [FACTT] Conservative or Lite) per local<br>             institutional standards (HFOV).<br>",NA,"Number of participants with treatment-related adverse events and laboratory abnormalities, assessed by CTCAE V5.0",NA,NA,NA,NA,NA,2020-09-15
NCT04390178,https://clinicaltrials.gov/show/NCT04390178,Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease,COVID-19,Biological: SARS-CoV-2 convalescent plasma,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),CT.gov,2020-04-10,2020-04-10,FALSE,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1/Phase 2,10,Joakim Dillner,Sweden,FALSE,Yes,10/04/2020,"April 10, 2020",25 May 2020,NA,20200410,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,80 Years,All,NA,"Johan Ursing, MD, PhD",NA,NA,NA,Danderyd Hospital,"<br>        Inclusion Criteria:<br><br>          -  Age 18 and <81 years<br><br>          -  Active COVID-19 defined as symptoms + SARS CoV-2 identified from upper or lower airway<br>             samples<br><br>          -  Fever =38.5C, admitted to a study hospital, hypoxemia defined as having a peripheral<br>             oxygen saturation below 93% (measured by pulse oximetry) and a breathing rate of >20<br>             breaths per minute without supplemental oxygen treatment<br><br>          -  A negative pregnancy test taken before inclusion and use of an acceptable effective<br>             method of contraception until treatment discontinuation if the participant is a woman<br>             of childbearing potential<br><br>          -  Written informed consent after meeting with a study physician and ability and<br>             willingness to complete follow up.<br><br>        Exclusion Criteria:<br><br>          -  No matching plasma donor (exact matching in both the ABO system and the Rh system is<br>             required)<br><br>          -  Unavailability of plasma<br><br>          -  Significant growth of alternative lower airway pathogen such as Streptococcus<br>             pneumoniae or Haemophilus influenzae in sputum<br><br>          -  Disease duration >8 Days<br><br>          -  Estimated glomerular filtration rate <60 (kidney failure stage III or more)<br><br>          -  Pregnancy (urinary-hcg), breast feeding,<br><br>          -  History of severe allergic reactions<br><br>          -  Inability to give informed consent<br><br>          -  Significantly compromised immunity.*<br><br>               -  Compromised immunity includes but is not limited to treatment with major<br>                  immunosuppressive agents including high dose corticosteroids, anti-tumor necrosis<br>                  factor (TNF) agents, calcineurin inhibitors, mTOR inhibitors, lymphocyte<br>                  depleting biological agents, chemotherapeutic anti neoplastic agents. Also<br>                  patients with advanced HIV/AIDS, severe immunodeficiency such as<br>                  hypoglobulinemia, decompensated liver cirrhosis and bone marrow transplant the<br>                  last year will be excluded.<br>",NA,Disease progression,NA,NA,NA,NA,NA,2020-04-10
NCT04366063,https://clinicaltrials.gov/show/NCT04366063,Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial,Covid-19,Biological: Cell therapy protocol 1;Biological: Cell therapy protocol 2,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,CT.gov,2020-04-20,2020-04-05,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2/Phase 3,60,Royan Institute,"Iran, Islamic Republic of",FALSE,Yes,20/04/2020,"April 5, 2020",11 May 2020,NA,20200420,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,65 Years,All,; ; ;,"Abdol Hossein Shahverdi;Hossein Baharvand, Professor;Masoumeh Nouri;Masoumeh Nouri",NA,;;masoume.nouri2002@gmail.com;masoume.nouri2002@gmail.com,;;00982127635512;,"Royan Institute;Department of Stem Cells Biology and Technology, Cell Science Research Center, Royan Institute for Stem Cells Biology & Technology, Iran;","<br>        Inclusion Criteria:<br><br>          -  Confirmation of 2019-nCoV infection by RT-PCR<br><br>          -  Diagnosis of ARDS according to the Berlin definition of ARDS<br><br>          -  Requiring supplemental oxygen<br><br>          -  Pneumonia that is judged by chest radiograph or CT<br><br>          -  PaO2/oxygen absorption concentration (FiO2) = 300MMHG<br><br>          -  Pulmonary imaging shows that the focused progress > 50% in 24-48 hours<br><br>          -  Mild to Moderate 2019-nCoV pneumonia/ stay in the ICU <48 hours<br><br>          -  SOFA score between 2-3 point<br><br>        Exclusion Criteria:<br><br>          -  Severe allergies or allergies after 1st injection to stem cell preparations and their<br>             components<br><br>          -  Patients with a malignant tumor, other serious systemic diseases, and psychosis<br><br>          -  Co-Infection of HIV, tuberculosis, influenza virus, adenovirus, and other respiratory<br>             infection viruses<br><br>          -  Patients with a previous history of pulmonary embolism<br><br>          -  Be thought by researchers to be inappropriate to participate in this clinical study<br>             (Expected deaths within 48 hours, uncontrolled infections)<br><br>          -  Liver or kidney SOFA score of more than 3 points; combined with other organ failures<br>             (need organ support), Stage 4 severe chronic kidney disease or requiring dialysis<br>             (i.e. estimated glomerular filtration rate (eGFR) < 30)<br><br>          -  Pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar<br>             proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial<br>             pneumonia<br><br>          -  Continuous use of immunosuppressive agents or organ transplants in the past 6 months<br><br>          -  In vitro life support (ECMO, ECCO2R, RRT)<br><br>          -  Pregnant or lactating women<br><br>          -  Uncontrolled underlying disease<br>",NA,Blood oxygen saturation;Adverse events assessment,NA,NA,NA,NA,NA,2020-04-20
NCT04334005,https://clinicaltrials.gov/show/NCT04334005,Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19,Patients Infected With COVID-19,Dietary Supplement: Vitamin D,Vitamin D on Prevention and Treatment of COVID-19,CT.gov,2020-03-29,2020-04-10,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor).",N/A,200,Universidad de Granada,Spain,FALSE,Yes,29/03/2020,"April 10, 2020",20 April 2020,COVITD-19,20200329,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,40 Years,70 Years,All,;,"Manuel J Castillo, MD, PhD;Manuel J Castillo, MD, PhD",NA,;mcgarzon@ugr.es,;+34 649440850,Universidad de Granada;,"<br>        Inclusion Criteria:<br><br>          -  Non-severe symptomatic patients who present cough, fever, nasal congestion,<br>             gastrointestinal symptoms, fatigue, anosmia, ageusia or alternative signs of<br>             respiratory infections.<br><br>        Exclusion Criteria:<br><br>          -  Patients presenting severe respiratory and/or multisystemic symptoms compatible with<br>             advanced COVID-19 and intercurrent acute or severe chronic diseases (i.e. active<br>             cancer).<br>",NA,Composite of cumulative death (i.e. mortality) for all causes and for specific causes.,NA,NA,NA,NA,NA,2020-03-29
NCT04350580,https://clinicaltrials.gov/show/NCT04350580,Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections,Acute Respiratory Distress Syndrome;COVID-19,Drug: Human immunoglobulin;Drug: Placebo,Polyvalent Immunoglobulin in COVID-19 Related ARds,CT.gov,2020-04-08,2020-04-11,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",Phase 3,138,Centre Hospitalier St Anne,France,FALSE,Yes,08/04/2020,"April 11, 2020",28 September 2020,ICAR,20200408,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ;,"Tarek Sharshar, MD, PHD;Aurélien Mazeraud, MD, PHD;Aurélien Mazeraud, MD, PHD",NA,;;a.mazeraud@ghu-paris.fr,;;0145658902,Centre Hospitalier Sainte Anne;Centre Hospitalier Sainte Anne;,"<br>        Inclusion Criteria:<br><br>          -  Any patient in intensive care:<br><br>               1. Receiving invasive mechanical ventilation for less than 36 hours<br><br>               2. ARDS meeting the Berlin criteria<br><br>               3. PCR-proven SARS-CoV-2 infection<br><br>               4. Patient, family or deferred consent (emergency clause)<br><br>               5. Affiliation to a social security scheme (or exemption from affiliation)<br><br>        Exclusion Criteria:<br><br>          -  Allergy to polyvalent immunoglobulins<br><br>          -  Pregnant woman or minor patient<br><br>          -  Known IgA deficiency<br><br>          -  Patient with renal failure on admission defined by a 3 times baseline creatinine or<br>             creatinine >354 micromol/L or a diuresis of less than 0.3 mL/Kg for 24 hours or anuria<br>             for 12 hours<br><br>          -  Participation in another interventional trial<br>",NA,Ventilator-free days,NA,NA,NA,NA,NA,2020-04-08
NCT04360759,https://clinicaltrials.gov/show/NCT04360759,Multi-centre Randomised Controlled Trial of Chloroquine/Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South Africa,Covid-19;HIV,Drug: Chloroquine or hydroxychloroquine,Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19,CT.gov,2020-04-22,2020-05-01,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 3,0,University of Cape Town,South Africa,FALSE,Yes,22/04/2020,"May 1, 2020",24 August 2020,CQOTE,20200422,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,;,"Sean Wasserman, MBChB;Graeme Meintjes, PhD",NA,;,;,"CIDRI-Africa, University of Cape Town;CIDRI-Africa, University of Cape Town","<br>        Inclusion Criteria:<br><br>          -  Tested for Covid-19 at a trial recruitment site as an outpatient;<br><br>          -  Age 18 years or older;<br><br>          -  Not requiring immediate hospitalisation;<br><br>          -  Mild disease, defined as respiratory rate <25/min, pulse rate <120/min, SpO2 >94%;<br><br>          -  HIV-positive by rapid test or documented history;<br><br>          -  Suspected or confirmed Covid-19;<br><br>          -  Signed informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Covid-19 diagnosed > 5 days prior to randomization;<br><br>          -  Active tuberculosis;<br><br>          -  Need for concomitant drugs that are contraindicated with the use of<br>             Chloroquine/hydroxychloroquine;<br><br>          -  QTcF interval > 480 ms;<br><br>          -  Known glomerular filtration rate < 10 ml/min;<br><br>          -  Known with glucose-6-phosphate dehydrogenase deficiency (G6PD);<br><br>          -  Previous adverse drug reaction to investigational product;<br><br>          -  Concurrent involvement in other research or use of chloroquine, hydroxychloroquine or<br>             any other 4-aminoquinolone or another experimental investigational medicinal product<br>             that is likely to interfere with the study medication.<br><br>        Note: Pregnancy and breastfeeding are not exclusions for entry<br>",NA,Event-free survival at 28 days post-randomization between experimental group and standard of care group,NA,NA,NA,NA,NA,2020-04-22
NCT04549376,https://clinicaltrials.gov/show/NCT04549376,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo: an Open Label Randomized Clinical Trial,COVID19,Drug: Povidone-Iodine 0.4% NI;Drug: Povidone-Iodine 0.5% NI;Drug: Povidone-Iodine 0.6% NI;Drug: Povidone-Iodine 0.5% NS;Drug: Povidone-Iodine 0.6% NS;Other: Placebo comparator: DW-NI;Other: Placebo comparator: DW-NS,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,CT.gov,2020-09-11,2020-07-01,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Phase 2,200,"Pi Research Consultancy Center, Bangladesh",Bangladesh,FALSE,Yes,11/09/2020,"July 1, 2020",21 September 2020,VEP-COV,20200911,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,15 Years,90 Years,All,; ;,"Prof Sk Nurul Fattah Rumi, MBBS, MS;Mostafa Kamal Arefin, MBBS,FCPS;Brig. General Dr. AKM Nasir Uddin, MBBS,MPH",NA,;arefin61dmc@gmail.com;dmch@hospi.dghs.gov.bd,;+8801671748866;+8801715016984,Dhaka Medical College;,"<br>        Inclusion Criteria:<br><br>          -  Age: 15-90 years<br><br>          -  Either gender<br><br>          -  Patients diagnosed with COVID-19 disease by RT-PCR<br><br>          -  Have confirmed COVID-19 symptoms and symptom onset within the past 10 days<br><br>          -  Capable of using a nasal spray device and perform nasal irrigation required by the<br>             study<br><br>          -  Willing to participate<br><br>        Exclusion Criteria:<br><br>          -  Patient with known sensitivity to PVP-I aqueous antiseptic solution or any of its<br>             listed excipients<br><br>          -  Previously diagnosed thyroid disease<br><br>          -  Patients with chronic renal failure (stage =3 by estimated Glomerular Filtration rate<br>             (eGFR) Modification of Diet in Renal Disease( MDRD)<br><br>          -  Patients with acute renal failure (KDIGO =stage 2: creatinine =2 X baseline)<br><br>          -  Pregnant and lactating mother<br><br>          -  Current requirement for invasive or non-invasive ventilation or planned within next 6<br>             hours.<br>",NA,Proportion of COVID-19 positive cases following intervention,NA,NA,NA,NA,NA,2020-09-11
NCT04366908,https://clinicaltrials.gov/show/NCT04366908,Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS),SARS-CoV 2;COVID19;SARS (Severe Acute Respiratory Syndrome);Cytokine Release Syndrome;Cytokine Storm,Drug: BAT + Calcifediol;Drug: BAT,Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome,CT.gov,2020-04-25,2020-04-28,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,1008,Maimónides Biomedical Research Institute of Córdoba,NA,FALSE,Yes,25/04/2020,"April 28, 2020",11 May 2020,COVIDIOL,20200425,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,90 Years,All,;,"José López Miranda, MD;José Manuel Quesada Gómez, MD",NA,;md1qugoj@uco.es,;0034671596070,Hospital Universitario Reina Sofía;,"<br>        Inclusion Criteria:<br><br>          -  Age = 18 and < 90 years<br><br>          -  PCR confirmed diagnosis of COVID-19<br><br>          -  Radiological image compatible with inflammatory pleuropulmonary exudate<br><br>          -  Signature of direct or delegated informed consent<br><br>        Exclusion Criteria:<br><br>          -  Being treated with Calcifediol or Cholecalciferol in any of its presentations and<br>             dosages<br><br>          -  Intolerance or allergy to Calcifediol or its components<br><br>          -  Pregnancy<br>",NA,Admission to Intensive Care Unit;Death,NA,NA,NA,NA,NA,2020-04-25
NCT04555148,https://clinicaltrials.gov/show/NCT04555148,"A Prospective, Open-label, Randomized, Multi-center, Phase 2a Study to Evaluation the Dose Response, Efficacy and Safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in Patients With COVID-19",Covid19,Biological: GC5131;Other: Placebo,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),CT.gov,2020-09-16,2020-09-20,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,60,Green Cross Corporation,"Korea, Republic of",FALSE,Yes,16/09/2020,"September 20, 2020",28 September 2020,NA,20200916,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,19 Years,N/A,All,NA,NA,NA,NA,NA,NA,"<br>        Inclusion Criteria:<br><br>          -  The COVID-19 patient who diagnosed by PCR within 3 days prior to randomized And who is<br>             hospitalized with COVID-19 related symptoms<br><br>          -  The subject who has symptoms of COVID-19 within 7 days<br><br>          -  The subject with pneumonia confirmed by imaging diagnosis related to COVID-19 OR a<br>             70-year-old or older OR 60-year-old or older with underlying disease (diabetes or<br>             hypertension or obesity or smoker)<br><br>          -  Willing and able to provide written informed consent prior to performing study<br>             procedures<br><br>        Exclusion Criteria:<br><br>          -  asymptomatic patient<br><br>          -  The subject who requiring mechanical ventilation or ECMO<br><br>          -  The subject who are underlying oxygen therapy before affected by COVID-19<br><br>          -  The subject who have received antiviral drugs for other disease within 4 weeks<br><br>          -  History of allergy to IVIG or plasma products<br><br>          -  The subject who received IVIG or convalescent plasma from a person who recovered from<br>             COVID-19<br><br>          -  IgA deficiency<br><br>          -  Cretinine > 2 X ULN<br><br>          -  The subject with a history of thrombosis or high risk of thromboembolism<br><br>          -  The subject with reduced heart function [NYHA (New York Heart Association) Functional<br>             Class III or IV]; or cerebral cardiovascular disorder or a patient with the medical<br>             history (ischemic disease, cardiovascular disease, cerebrovascular disorder, blood<br>             vessel disorder, etc.)<br>",NA,Ordinal scale outcome,NA,NA,NA,NA,NA,2020-09-16
NCT04563702,https://clinicaltrials.gov/show/NCT04563702,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers",Covid19,Biological: VXA-CoV2-1,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,CT.gov,2020-09-21,2020-09-21,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Phase 1,35,Vaxart,United States,FALSE,Yes,21/09/2020,"September 21, 2020",24 November 2020,NA,20200921,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,54 Years,All,NA,NA,NA,NA,NA,NA,"<br>        Inclusion Criteria:<br><br>          1. Male or female between the ages of 18 to 54 years, inclusive.<br><br>          2. Negative for SARS-CoV-2 infection at the time of screening<br><br>          3. In generally good health, without significant medical illness<br><br>          4. Demonstrates comprehension of the protocol procedures and is able to provide written<br>             informed consent.<br><br>          5. Available for all planned visits and willing to complete all protocol defined<br>             procedures and assessments<br><br>          6. Body mass index between 17 and 30 kg/m2 at screening.<br><br>          7. Female subjects must have a negative pregnancy test at screening and before each<br>             vaccination and fulfill an acceptable method of birth control (per protocol)<br><br>        Exclusion Criteria:<br><br>          1. Known previous exposure to SARS-CoV-2 or receipt of an investigational product for the<br>             prevention or treatment of COVID-19, middle east respiratory syndrome (MERS), or<br>             severe acute respiratory syndrome (SARS).<br><br>          2. Is in a current occupation with high risk of exposure to SARS-CoV-2<br><br>          3. Individuals with the following underlying medical conditions who are at higher risk<br>             (or might be at higher risk) of severe illness from COVID-19 per the CDC's guidance<br><br>          4. Donation or use of blood or blood products within 4 weeks prior to vaccination or<br>             planned donation during the study period.<br><br>          5. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that<br>             could make blood draws problematic.<br><br>          6. Any condition that resulted in the absence or removal of the spleen.<br><br>          7. Positive HIV, HBsAg or HCV tests at the screening visit.<br><br>          8. Stool sample with occult blood at screening.<br><br>          9. Use of antiviral medications, including anti-retrovirals, or any prescriptive<br>             medications for the prevention of COVID-19 within 7 days before vaccination<br><br>         10. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids or medications<br>             known to affect the immune function within 7 to 14 days before vaccination<br><br>         11. Regular use of nonsteroidal anti-inflammatory drugs, sulfonylureas, and angiotensin II<br>             blockers within 7 days before vaccination<br><br>         12. Acute disease within 72 hours prior to vaccination defined as the presence of a<br>             moderate or severe illness<br><br>         13. History of drug, alcohol or chemical abuse within 1 year of screening or positive<br>             urine drug screen for drugs of abuse at screening<br><br>         14. History of hypersensitivity or allergic reaction to any component of the<br>             investigational vaccine<br><br>         15. Administration of any investigational vaccine, drug or device within 8 weeks preceding<br>             vaccination<br><br>         16. Any other condition that in the clinical judgment of the investigator would jeopardize<br>             the safety or rights of a subject participating in the trial, would render the subject<br>             unable to comply with the protocol or would interfere with the evaluation of the study<br>             endpoints.<br>",NA,Frequency of solicited symptoms of reactogenicity;Grade of solicited symptoms of reactogenicity;Frequency of unsolicited adverse events;Grade of unsolicited adverse events;Frequency of serious adverse events (SAEs);Frequency of medically-attended adverse events (MAAEs),NA,NA,NA,NA,NA,2020-09-21
NCT04570449,https://clinicaltrials.gov/show/NCT04570449,Pilot Randomized Controlled Trial: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19),Covid19,Drug: Fluoxetine;Drug: Placebo,Pilot Randomized Controlled Trial: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19),CT.gov,2020-09-29,2020-09-01,TRUE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Early Phase 1,40,Milton S. Hershey Medical Center,United States,FALSE,Yes,29/09/2020,September 2020,12 October 2020,NA,20200929,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,; ;,"Erika Saunders, MD;Erika Saunders, MD;Erika Saunders, MD",NA,;esaunders@pennstatehealth.psu.edu;,;717-531-8516;,Milton S. Hershey Medical Center;,"<br>        Inclusion Criteria:<br><br>          1. English speaking participant<br><br>          2. 18 years of age or older<br><br>          3. able to give informed consent<br><br>          4. Tested positive for active SARS-CoV-2 infection and<br><br>               1. It's been less than 10 days since symptoms first appeared;<br><br>               2. Fever persists for longer than 24 hours without the use of fever reducing<br>                  medications; and<br><br>               3. Experiencing other symptoms of COVID-19 as described by the CDC<br><br>        Exclusion Criteria:<br><br>          1. Prisoner or institutionalized patient<br><br>          2. Unable to give informed consent<br><br>          3. Less than 18 years of age<br><br>          4. Hospitalization<br><br>          5. Active bleeding requiring blood products in past week<br><br>          6. Diagnosed with bipolar disorder and not on mood stabilizing medication<br><br>          7. Known allergy or hypersensitivity to fluoxetine<br><br>          8. Currently taking a monoamine oxidase inhibitor (MAOI)<br><br>          9. Currently taking an selective serotonin reuptake inhibitor (SSRI) or selective<br>             norepinephrine reuptake inhibitor (SNRI)<br><br>         10. Outpatient and currently taking hydroxychloroquine<br><br>         11. Known pregnancy<br><br>         12. Breastfeeding<br><br>         13. Known prolonged QTc, such as congenital prolonged QTc syndromes<br>",NA,Rate of hospitalization;Physical symptoms assessed through daily checklist,NA,NA,NA,NA,NA,2020-09-29
NCT04446377,https://clinicaltrials.gov/show/NCT04446377,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19",COVID-19 Disease,Drug: Apilimod Dimesylate Capsule;Other: Placebo,A Study of LAM-002A for the Prevention of Progression of COVID-19,CT.gov,2020-06-23,2020-07-15,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,142,"AI Therapeutics, Inc.",United States,FALSE,Yes,23/06/2020,"July 15, 2020",16 November 2020,NA,20200623,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,NA,"Peter Young, PhD",NA,pyoung@ai-thera.com,415 860-8370,NA,"<br>        Inclusion Criteria:<br><br>          1. Written documentation of SARS-CoV-2 infection confirmed by a validated test.<br><br>          2. Presence of greater than or equal to =1 of the following COVID-19-related symptoms<br>             indicating mild disease: fever (temperature =100.4), anosmia (loss of taste or smell),<br>             cough, sore throat, gastrointestinal complaints (e.g. nausea, vomiting, or diarrhea),<br>             chills, congestion, or runny nose, headaches, muscle or body aches, fatigue, or<br>             asymptomatic patients who have tested positive for COVID-19 via a validated test<br>             within the past 4 days.<br><br>          3. If symptomatic, symptom onset less than or equal to = 8 days.<br><br>          4. For female participants of childbearing potential, a negative urine (or serum)<br>             pregnancy test.<br><br>          5. For female participants of childbearing potential, willingness to use a<br>             protocol-recommended method of contraception from the start of the screening period<br>             until greater than or equal to =30 days after the final dose of study therapy. Note: A<br>             female subject is considered to be of childbearing potential unless she has had a<br>             hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically<br>             documented ovarian failure (with serum estradiol and follicle-stimulating hormone<br>             [FSH] levels within the institutional laboratory postmenopausal range and a negative<br>             serum or urine beta human chorionic gonadotropin [ßHCG]); or is menopausal (age =50<br>             years with amenorrhea for =6 months).<br><br>          6. For male participants who can father a child and are having intercourse with females<br>             of childbearing potential who are not using adequate contraception, willingness to use<br>             a protocol-recommended method of contraception from the start of study therapy until<br>             =30 days after the final dose of study therapy and to refrain from sperm donation from<br>             the start of study therapy until =90 days after administration of the final dose of<br>             study therapy. Note: A male subject is considered able to father a child unless he has<br>             had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.<br><br>          7. Willingness and ability of the participant to ingest study drug capsules.<br><br>          8. Willingness of the participant to comply with scheduled visits, drug administration<br>             plan, protocol-specified laboratory tests, study procedures, and study restrictions.<br><br>          9. Evidence of a personally signed informed consent indicating that the participant is<br>             aware of the nature of the disease and has been informed of the procedures to be<br>             followed, the experimental nature of the therapy, alternatives, potential risks and<br>             discomforts, potential benefits, and other pertinent aspects of study participation.<br><br>        Exclusion Criteria:<br><br>          1. Respiratory rate greater than or equal to =20 breaths per minute.<br><br>          2. Oxygen saturation by pulse oximetry less than or equal to =93 percent % on room air or<br>             requirement for supplemental oxygen to maintain oxygen saturation greater than >93<br>             percent %.<br><br>          3. Total NEWS score greater than or equal to =6 or presence of a score of 3 on any of the<br>             individual NEWS parameters.<br><br>          4. Radiographic evidence of pulmonary infiltrates (clinical X-ray within 2 days of<br>             referral)<br><br>          5. Hepatic profile showing any of the following:<br><br>               -  Serum alanine aminotransferase (ALT) greater than >5 × upper limit of normal<br>                  (ULN) (CTCAE Grade greater than or equal to =3).<br><br>               -  Serum aspartate aminotransferase (AST) greater than >5 × ULN (CTCAE Grade greater<br>                  than or equal to =3).<br><br>               -  Serum bilirubin greater than >1.5 × ULN (CTCAE Grade greater than or equal to<br>                  =2).<br><br>          6. Renal profile showing an estimated creatinine clearance (eClCR) less than <30<br>             mL/minute (with eClCR to be calculated by the method at the laboratory performing the<br>             serum creatinine test).<br><br>          7. Presence of a cancer with disease manifestations or therapy that could adversely<br>             affect subject safety or longevity, create the potential for drug-drug interactions,<br>             or compromise the interpretation of study results.<br><br>          8. Significant cardiovascular disease (e.g. myocardial infarction, arterial<br>             thromboembolism, cerebrovascular thromboembolism) within 1 month prior to start of<br>             study therapy; unstable angina; symptomatic peripheral vascular disease; CTCAE Grade<br>             greater than or equal to =2 congestive heart failure; or uncontrolled CTCAE Grade<br>             greater than or equal to =3 hypertension (diastolic blood pressure greater than or<br>             equal to =100 mmHg or systolic blood pressure greater than or equal to =160 mmHg)<br>             despite antihypertensive therapy.<br><br>          9. Significant screening ECG abnormalities, including atrial fibrillation/flutter, 2nd<br>             degree atrioventricular (AV) block type II, 3rd-degree AV block, Grade greater than or<br>             equal to =2 bradycardia, or corrected QT (QTc by Fridericia [QTcF]) greater than >480<br>             msec (Grade greater than >1).<br><br>         10. Gastrointestinal disease (e.g. gastric or intestinal bypass surgery, pancreatic enzyme<br>             insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic<br>             diarrheal illness, bowel obstruction) that might interfere with drug absorption or<br>             with interpretation of gastrointestinal AEs.<br><br>         11. Pregnancy or breastfeeding.<br><br>         12. Prior solid organ transplantation.<br><br>         13. Use within 5 days prior to randomization of an approved or investigational therapy<br>             intended to treat COVID-19 (e.g. remdesivir, , anti-interleukin [IL]-6 antibodies,<br>             therapeutic anti-SARS CoV-2 antibodies or post-convalescent plasma, anti- SARS CoV-2<br>             vaccine, Bruton tyrosine kinase [BTK] inhibitor), use within 3 months of chloroquine<br>             or hydroxychloroquine. Note: participants are not precluded from undergoing<br>             evaluations involving observation, noninvasive diagnostic procedures or sampling, or<br>             questionnaires as follow-up to a prior study or as components of a concurrent<br>             noninterventional study.<br><br>         14. Use within 5 days prior to randomization of a strong inhibitor or inducer of<br>             cytochrome P450 (CYP) 3A4 or expected requirement for chronic use of a strong<br>             inhibitor or inducer of CYP3A4 during study therapy.<br><br>         15. Use within 5 days prior to randomization of drug that is a moderate-to-strong<br>             substrate of CYP2C9 (including warfarin, tolbutamide, phenytoin, glimepiride) or<br>             expected requirement for chronic use of such drugs during study therapy.<br><br>         16. Use within 5 days prior to randomization of a drug known to prolong the QT interval<br><br>         17. Ongoing immunosuppressive therapy including systemic or enteric corticosteroids.<br>             (Note: At study entry, participants may be using intraarticular, inhaled, or topical<br>             corticosteroids. Duri",NA,Viral Load Change,NA,NA,NA,NA,NA,2020-06-23
NCT04293887,https://clinicaltrials.gov/show/NCT04293887,"Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon a1ß in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan",COVID-19;Recombinant Human Interferon a1ß,Drug: Recombinant human interferon a1ß,Efficacy and Safety of IFN-a2ß in the Treatment of Novel Coronavirus Patients,CT.gov,2020-02-15,2020-03-01,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Early Phase 1,328,Tongji Hospital,NA,FALSE,Yes,15/02/2020,"March 1, 2020",16 March 2020,NA,20200215,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,NA,"Jianping Zhao, Ph.D.",NA,Zhaojp88@126.com,13507138234,NA,"<br>        Inclusion Criteria:<br><br>          1. Age = 18 years;<br><br>          2. Clinically diagnosed patients with new type of coronavirus pneumonia, including: in<br>             accordance with the criteria for suspected cases, have one of the following etiology<br>             evidence:<br><br>             ? Real-time fluorescence RT-PCR of respiratory specimens or blood specimens for<br>             detection of new coronavirus nucleic acid;<br><br>             ? Sequencing of viral genes in respiratory specimens or blood specimens, highly<br>             homologous to known new coronavirus<br><br>          3. The time interval between the onset of symptoms and random enrollment is within 7<br>             days. The onset of symptoms is mainly based on fever. If there is no fever, cough,<br>             diarrhea or other related symptoms can be used.<br><br>        Exclusion Criteria:<br><br>          1. Any situation where the programme cannot be carried out safely;<br><br>          2. Patients who have used interferon or remedesivir;<br><br>          3. No clinical manifestations and chest imaging findings<br><br>          4. Known allergy or hypersensitivity to interferon (including asthma);<br><br>          5. Disabled in patients with uncontrolled autoimmune diseases;<br><br>          6. Patients with severe heart disease, decompensated liver disease, renal insufficiency<br>             (CrCL <50ml / min), and those with abnormal bone marrow function are prohibited;<br><br>          7. Epilepsy and impaired central nervous system function;<br><br>          8. Pregnancy: Positive pregnancy test for women of childbearing age;<br><br>          9. Breastfeeding women have not stopped breastfeeding;<br><br>         10. The patient may be transferred to a non-participating hospital within 72 hours.<br>",NA,The incidence of side effects;The incidence of side effects;The incidence of side effects,NA,NA,NA,NA,NA,2020-02-15
NCT04343677,https://clinicaltrials.gov/show/NCT04343677,Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study,COVID-19,Drug: Hydroxychloroquine;Dietary Supplement: Placebo,Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study,CT.gov,2020-04-09,2020-04-01,TRUE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).",Phase 2,1450,United States Department of Defense,United States,FALSE,Yes,09/04/2020,April 2020,20 April 2020,NA,20200409,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,; ; ; ; ;,"Angela Phillips, PhD;Scott A Wallace, MD;David S Robinson, MD;John S Baxter, MD, JD;Scott A Wallace, MD;Scott A Wallace, MD",NA,;;;;usaf.pentagon.11-mdg.mbx.flight-med-clinic@mail.mil;usaf.pentagon.11-mdg.mbx.flight-med-clinic@mail.mil,;;;;703-697-3255;703-697-3255,11 MDG;NMRTC Bethesda;11 MDG;11 MDG;,"<br>        Inclusion Criteria:<br><br>        All mission critical personnel enrolled to the DiLorenzo Tricare Health Clinic or Pentagon<br>        Flight Medicine Clinic unable to telework or appropriately socially distance with access to<br>        the Pentagon during the declared public health crisis.<br><br>        Exclusion Criteria:<br><br>        Known recovered COVID-19 patient, G6PD deficient individuals, individuals with significant<br>        QT abnormalities, non-compliant patients, and patients who refuse randomization or consent.<br>",NA,Incidence,NA,NA,NA,NA,NA,2020-04-09
NCT04527081,https://clinicaltrials.gov/show/NCT04527081,"A Randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults",COVID-19,Biological: AG0302-COVID19;Biological: AG0302-COVID19;Biological: AG0302-COVID19,Study of COVID-19 DNA Vaccine (AG0302-COVID19),CT.gov,2020-08-24,2020-08-31,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Phase 1/Phase 2,30,"AnGes, Inc.",Japan,FALSE,Yes,24/08/2020,"August 31, 2020",5 October 2020,NA,20200824,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,20 Years,65 Years,All,NA,"AnGes, Inc. Clinical Development",NA,NA,NA,"AnGes, Inc.","<br>        Inclusion Criteria:<br><br>          1. Subjects who have obtained written consent voluntarily to participate in this clinical<br>             trial<br><br>          2. Subjects whose age at the time of obtaining consent is 20 years to 65 years<br><br>          3. Subjects who are negative for SARS-CoV-2 by PCR test<br><br>          4. Subjects who are negative for both SARS-CoV-2 IgM antibody and SARS-CoV-2 IgG antibody<br>             by antibody test<br><br>        Exclusion Criteria:<br><br>          1. Subjects with symptoms of suspected COVID-19 infection (respiratory symptoms,<br>             headache, malaise, olfactory disorders, taste disorders, etc.)<br><br>          2. Subjects with a history of COVID-19 (hearing from subjects)<br><br>          3. Subjects who have participated in unapproved vaccine clinical trials<br><br>          4. Subjects with axillary temperature of 37.0 degree or higher<br><br>          5. Subjects who have a history of anaphylaxis<br><br>          6. Subjects who have serious renal, liquid, respiratory, liver, kidney, digestive, and<br>             neuropsychiatric history has a current medical history<br><br>          7. Subjects with a history of convulsion or epilepsy<br><br>          8. Subjects with a history of diagnosis of immunodeficiency<br><br>          9. Subjects who have a close relative (within 3rd degree) of congenital immunodeficiency<br><br>         10. Subjects who have a history of bronchial asthma<br><br>         11. Subjects who had a fever of 39.0°C or higher within 2 days after the last vaccination,<br>             and those who suspected allergy such as a systemic rash<br><br>         12. Females who wish to become pregnant from the date of study registration to 12 weeks<br>             after the first inoculation of the investigational drug, and pregnant females who are<br>             breast-feeding. In addition, females who may become pregnant and their male sexual<br>             partners should use appropriate contraceptives (pill), condoms, vasectomy, tubal<br>             ligation, diaphragm, intrauterine devices, spermicides, intrauterine hormone-releasing<br>             system, etc. from the study entry date until 12 weeks after vaccination<br><br>         13. Subjects who have participated in clinical trials of other unapproved drugs and<br>             received the investigational drug within 4 weeks before the start of this clinical<br>             trial (starting from vaccination day)<br><br>         14. Subjects who have been received a live vaccine, inactivated vaccine, or toxoid within<br>             4 weeks before the start of this clinical trial (starting from vaccination day)<br><br>         15. Subjects who have been administered with drugs that affect the immune system<br>             (excluding external preparations) such as immunomodulators (DMARDs, etc.),<br>             immunosuppressants, biologics, etc. within 4 weeks from vaccination<br><br>         16. Subjects who received blood transfusion or gamma globulin therapy within 12 week<br>             before vaccination, or high-dose gamma globulin therapy (200 mg/kg or more) within 24<br>             weeks before vaccination<br><br>         17. Subjects who have a history of overseas travel within 4 weeks before the start of the<br>             clinical trial (starting from vaccination day)<br><br>         18. Subjects who are unable to comply with the clinical trial protocol and follow up (for<br>             mental, family, social or geographical reasons)<br><br>         19. Subjects who are judged to be ineligible for this clinical trial by the investigator<br>",NA,Immunogenicity;Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],NA,NA,NA,NA,NA,2020-08-24
NCT04361214,https://clinicaltrials.gov/show/NCT04361214,Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19,COVID-19,Drug: Leflunomide,Leflunomide in Mild COVID-19 Patients,CT.gov,2020-04-22,2020-05-05,FALSE,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1,20,University of Chicago,United States,FALSE,Yes,22/04/2020,"May 5, 2020",9 November 2020,NA,20200422,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ;,"Michael Millis, MD;Michael Millis, MD;Michael Millis",NA,;mmillis@surgery.bsd.uchicago.edu;mmillis@surgery.bsd.uchicago.edu,;773 702 6319;,University of Chicago;,"<br>        Inclusion Criteria:<br><br>          -  Being tested positive for SARS-Cov-2 in outpatient setting in drive-thru, ED, or<br>             ambulatory clinics at the University of Chicago within 72 hours of enrollment.<br><br>          -  Age >18<br><br>          -  Mild COVID-19, defined as the presence of any symptom consistent with an upper<br>             respiratory tract infection, including dry cough, sore throat, nasal congestion,<br>             fatigue, myalgia, headaches<br><br>        Exclusion Criteria:<br><br>          -  Participation in any other clinical trial of an experimental agent treatment for<br>             COVID-19<br><br>          -  Current hospitalization<br><br>          -  Known hypersensitivity to leflunomide<br><br>          -  Currently taking methotrexate<br><br>          -  Currently taking terliflunomide<br><br>          -  Known chronic kidney disease, stage 4-5, or receiving dialysis<br><br>          -  History of liver disease<br><br>          -  History of interstitial lung disease<br><br>          -  Pregnancy and lactation - pregnancy test required for females<br><br>          -  Inability to monitor body temperature (oral, axillary, tympanic or frontal) at least<br>             twice a day from study enrollment day (Day 1) to the end of the study (Day 14).<br><br>          -  Inability to provide informed consent to the study.<br>",NA,Tolerability of high dose leflunomide as measured by leflunomide dose modifications;Tolerability of high dose leflunomide as measured by discontinuation of leflunomide;Tolerability of high dose leflunomide as measured by Adverse Events,NA,NA,NA,NA,NA,2020-04-22
NCT04447235,https://clinicaltrials.gov/show/NCT04447235,"Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19",Cancer;COVID;Coronavirus Infection,Drug: Placebo;Drug: Ivermectin;Drug: Losartan,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,CT.gov,2020-06-22,2020-07-23,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",Phase 2,176,Instituto do Cancer do Estado de São Paulo,Brazil,FALSE,Yes,22/06/2020,"July 23, 2020",10 August 2020,TITAN,20200622,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ; ;,"Pedro Exman, MD;Maria del Pilar Diz, MD, PhD;Pedro Exman, MD;pedro exman",NA,;;drpedroexman@gmail.com;drpedroexman@gmail.com,;;+5511991764565;+5511991764565,Instituto do Cancer do Estado de São Paulo;Instituto do Cancer do Estado de São Paulo;,"<br>        Inclusion Criteria:<br><br>          -  Age greater than or equal to 18 years of age<br><br>          -  Ability to understand and sign informed consent<br><br>          -  Biopsy-proven diagnosis of previous cancer (solid or hematologic disease)<br><br>          -  Participants must be diagnosed with active malignancy, defined as the presence of<br>             metastatic disease; or patient undergoing curative treatment during cancer treatment,<br>             regardless of the therapeutic modality.<br><br>          -  Confirmed diagnosis of COVID-19 by the presence of a positive PCR test or positive<br>             serological test and / or diagnosis presumed by the presence of flu-like symptoms<br>             associated to suggestive findings on CT scan.<br><br>          -  ECOG performance status 0 to 2<br><br>          -  Patients must have an assessment of adequate organ function within 28 days prior to<br>             enrollment, evidenced by:<br><br>               -  Hemoglobin = 9.0 g / dL<br><br>               -  Leukometry> 2,000 / mm3<br><br>               -  Absolute neutrophil count = 1,500 / mm3<br><br>               -  Platelet count = 100,000 / mm3<br><br>               -  Creatinine clearance = 30 mL / min. Creatinine clearance (CrCl) should be<br>                  calculated according to the Cockcroft-Gault formula.<br><br>               -  Total bilirubin <3 x the upper limit of normal (ULN), except for patients with<br>                  known Gilbert's syndrome.<br><br>               -  Aspartate aminotransaminase (AST) <3.0 x LSN.<br><br>               -  Alanine aminotransaminase (ALT) <3.0 x ULN.<br><br>        Exclusion Criteria:<br><br>          -  Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin<br>             receptor blocker (ARB).<br><br>          -  Patients who presents with severe conditions at the time of diagnosis requiring ICU<br>             admission.<br><br>          -  Prior reaction or intolerance to an ARB or ACE inhibitor.<br><br>          -  Blood pressure less than 110/70 mmHg at presentation<br><br>          -  Potassium greater than 5.0 mEq / L<br><br>          -  Pregnancy or breastfeeding<br><br>          -  Prior reaction to Ivermectin.<br><br>          -  Patient currently enrolled in another research protocol<br>",NA,Incidence of severe complications due COVID-19 infection,NA,NA,NA,NA,NA,2020-06-22
NCT04460651,https://clinicaltrials.gov/show/NCT04460651,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,COVID19,Drug: Icosapent ethyl (IPE);Drug: Placebo,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,CT.gov,2020-07-02,2020-08-14,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",Phase 3,2000,Estudios Clínicos Latino América,Argentina,FALSE,Yes,02/07/2020,"August 14, 2020",30 November 2020,PREPARE-IT,20200702,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ;,"Rafael Diaz, MD;Andres Orlandini, MD;Carolina Chacón, MD",NA,;aorlandinimd@eclainternational.org;cchacon@gmail.com,;+ 54 341 4450210;,ECLA- Estudios Clínicos Latino América;,"<br>        Inclusion Criteria:<br><br>        18 years of age or older and<br><br>          1. Doctors, nurses, ancillary staff , cleaning staff working in Intensive Care Units or<br>             Emergency Departments that care for COVID-19 patients, or<br><br>          2. People performing aerosol-generating procedures on COVID-19 patients (i.e.<br>             anesthesiologist, nurses, dentists, trans-esophageal sonography technicians, etc.) or<br><br>          3. Relatives of COVID-19 index cases who have been in contact (according to the National<br>             Ministry of Health definition in force at the time of the evaluation) or<br><br>          4. Laboratory Staff currently running COVID-19 tests<br><br>        Study authorities will evaluate subjects who fill the pre-screening form and will approve<br>        enrollment into the study upon confirming their risk criteria.<br><br>        Exclusion Criteria:<br><br>          1. Currently presents with symptoms consistent with COVID-19 or influenza-like symptoms<br><br>          2. Previously diagnosed with COVID-19<br><br>          3. Pregnant or breastfeeding women<br><br>          4. Unable to provide informed consent<br><br>          5. Currently taking eicosapentaenoic acid (EPA) or dietary fish oil supplements<br><br>          6. Known hypersensitivity to the study drug<br><br>          7. Administration of a durg with anticoagulant effects (antiplatelet agents are allowed)<br><br>          8. Hemorrhagic Diathesis<br><br>          9. History of recurrent paroxysmal atrial fibrillation (AF) or persistent AF<br>",NA,Percentage of SARS-CoV-2 positive subjects;Highest mean WHO descriptive score of COVID-19 in the active treatment group compared to the placebo group.,NA,NA,NA,NA,NA,2020-07-02
NCT04325061,https://clinicaltrials.gov/show/NCT04325061,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Acute Respiratory Distress Syndrome Caused by COVID-19,Drug: Dexamethasone,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,CT.gov,2020-03-25,2020-04-03,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 4,200,Dr. Negrin University Hospital,Spain,FALSE,Yes,25/03/2020,"April 3, 2020",14 September 2020,DEXA-COVID19,20200325,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,NA,"Jesús Villar, MD",NA,NA,NA,Hospital Universitario Dr. Negrin,"<br>        Inclusion Criteria:<br><br>          -  age 18 years or older;<br><br>          -  positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay for COVID-19<br>             in a respiratory tract sample;<br><br>          -  intubated and mechanically ventilated;<br><br>          -  acute onset of ARDS, as defined by Berlin criteria as moderate-to-severe ARDS,3 which<br>             includes: (i) having pneumonia or worsening respiratory symptoms, (ii) bilateral<br>             pulmonary infiltrates on chest imaging (x-ray or CT scan), (iii) absence of left<br>             atrial hypertension, pulmonary capillary wedge pressure <18 mmHg, or no clinical signs<br>             of left heart failure, and (iv) hypoxemia, as defined by a PaO2/FiO2 ratio of =200<br>             mmHg on positive end-expiratory pressure (PEEP) of =5 cmH2O, regardless of FiO2.<br><br>        Exclusion Criteria:<br><br>          -  Routine treatment with corticosteroids during the previous week irrespective of dose;<br><br>          -  Corticosteroid use within the previous 24 h of more than 20 mg of dexamethasone or<br>             equivalent;<br><br>          -  Patients with a known contraindication to corticosteroids;<br><br>          -  Decision by a physician that involvement in the trial is not in the patient's best<br>             interest;<br><br>          -  Pregnancy and breast-feeding;<br><br>          -  Participation in another therapeutic trial.<br>",NA,60-day mortality,NA,NA,NA,NA,NA,2020-03-25
NCT04343092,https://clinicaltrials.gov/show/NCT04343092,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial),COVID 19,Drug: Ivermectin (IVM),Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,CT.gov,2020-04-05,2020-04-18,FALSE,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1,16,University of Baghdad,Iraq,FALSE,Yes,05/04/2020,"April 18, 2020",16 November 2020,NA,20200405,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,;,"Faiq I Gorial, Professor;Jawad I. Rasheed",NA,;,;,University of Baghdad;Arab Board for Health Specialiazation in Iraq,"<br>        Inclusion Criteria:<br><br>        -1. Patients with age above 18 years and any gender with definite Dx of covid19 and<br>        pneumonia in the ward according to the clinical, laboratory, and imaging criteria.<br><br>        2. Understands and agrees to comply with planned study procedures.<br><br>        Exclusion Criteria:<br><br>          1. Patients with hypersensitivity or severe adverse effects to Ivermectin<br><br>          2. Renal impairment<br><br>          3. Hepatic impairment.<br><br>          4. Pregnancy or a desire to become pregnant (drug considered pregnancy category c)<br><br>          5. Breast feeding.<br><br>          6. Patient with covid 19 positive and mild no pneumonia<br><br>          7. Children under the age of five or those who weigh less than 15 kilograms<br>",NA,Number of Cured Patients,04/11/2020,NA,https://clinicaltrials.gov/ct2/show/results/NCT04343092,NA,Yes,2020-04-05
NCT04246242,https://clinicaltrials.gov/show/NCT04246242,A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV),2019 Novel Coronavirus,"Drug: Conventional treatment group;Drug: arbidol,200mg,tid;Drug: arbidol,400mg,tid",A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV),CT.gov,2020-01-27,2020-01-25,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).,Phase 4,500,Xiangya Hospital of Central South University,NA,FALSE,Yes,27/01/2020,"January 25, 2020",3 February 2020,NA,20200127,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,N/A,N/A,All,NA,"Pinhua Pan, Medical PhD",NA,pinhuapan668@126.com,+86 13574810968,NA,"<br>        Inclusion Criteria:<br><br>        Patients diagnosed with RT-PCR for 2019 Novel Coronavirus (2019-nCoV)<br><br>        Exclusion Criteria:<br><br>        Patients infected with other viruses<br>",NA,mortality,NA,NA,NA,NA,NA,2020-01-27
NCT04519424,https://clinicaltrials.gov/show/NCT04519424,"A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate CSL324 in Coronavirus Disease 2019 (COVID-19)",Coronavirus Disease 2019 (COVID-19),Biological: CSL324;Drug: Placebo,CSL324 in COVID-19,CT.gov,2020-08-18,2020-09-01,TRUE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,0,CSL Behring,United States,FALSE,Yes,18/08/2020,September 2020,26 October 2020,NA,20200818,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,NA,NA,NA,NA,NA,NA,"<br>        Inclusion Criteria:<br><br>          -  Age = 18 years at the time informed consent is obtained<br><br>          -  Positive for SARS-CoV-2 infection determined by a diagnostic test approved by the Food<br>             and Drug Administration (FDA) or allowed under an emergency use authorization<br><br>          -  Chest computed tomography (CT) scan or X ray results confirming interstitial pneumonia<br><br>          -  Meets = 1 of the following criteria (subjects improving while on respiratory support<br>             still qualify):<br><br>               -  Respiratory rate > 30 breaths per minute<br><br>               -  Peripheral (capillary) oxygen saturation (SpO2) = 93% on room air<br><br>               -  Partial pressure of oxygen in arterial blood (PaO2) to fraction of inspired<br>                  oxygen (FiO2) ratio (PaO2 / FiO2) < 300<br><br>               -  SpO2 / FiO2 ratio < 218 (if PaO2 / FiO2 ratio is not available)<br><br>               -  Radiographic lung infiltrates > 50%<br><br>        Exclusion Criteria:<br><br>          -  Currently enrolled, planning to enroll, or participated, within the last 30 days, in a<br>             clinical study requiring administration of an investigational product (ie, not yet<br>             marketed), including expanded access or compassionate use<br><br>               -  Exceptions:<br><br>                    -  Administration of investigational product with emergency use authorization<br>                       granted for treatment of COVID 19 (eg, remdesivir) is permitted<br><br>                    -  Convalescent plasma as part of approved special access programs such as<br>                       expanded access, emergency IND, or compassionate use is permitted<br><br>          -  Pregnant or breastfeeding (female subjects)<br><br>          -  Intubated and requires mechanical ventilation (including ECMO) at time of<br>             randomization<br><br>               -  Exception: use of HFNC oxygen and noninvasive ventilation are permitted<br><br>          -  Endotracheal intubation is imminent, in the opinion of the investigator<br><br>          -  Not expected to survive for more than 48 hours after hospital admission, in the<br>             opinion of the investigator<br><br>          -  Presence of any of the following comorbid conditions before randomization and prior to<br>             SARS-CoV-2 infection:<br><br>               -  New York Heart Association class IV heart failure<br><br>               -  Stage 4 or 5 chronic kidney disease or requires renal replacement therapy<br><br>               -  Biopsy proven cirrhosis, portal hypertension or hepatic encephalopathy<br><br>               -  Stage IV malignancy<br><br>               -  Chronic lung disease requiring home oxygen<br><br>               -  Active tuberculosis<br><br>          -  History or evidence of pulmonary alveolar proteinosis<br><br>          -  Confirmed diagnosis or clinical suspicion of bacterial pneumonia or active<br>             uncontrolled bacterial, fungal, or non SARS-CoV-2 viral infection at Screening<br><br>          -  Absolute neutrophil count (ANC) value < 5 × 109 cells/L at Screening (can be lowered<br>             up to < 1.5 × 109 cells/L after Independent Data Monitoring Committee review of safety<br>             data, if CSL324 induced neutropenia is not assessed as a safety concern)<br><br>          -  Currently receiving a prohibited therapy including G-CSF, granulocyte-macrophage<br>             colony-stimulating factor (GM-CSF), or antibody against interleukin 6 (IL-6) / IL 6<br>             receptor (anti IL-6 / 6R)<br>",NA,Proportion of subjects progressing to endotracheal intubation or death prior to endotracheal intubation,NA,NA,NA,NA,NA,2020-08-18
NCT04333472,https://clinicaltrials.gov/show/NCT04333472,"Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial",COVID-19;Coronavirus Infection,Drug: Piclidenoson;Drug: Placebo,Piclidenoson for Treatment of COVID-19,CT.gov,2020-04-01,2020-10-06,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,40,Can-Fite BioPharma,Israel,FALSE,Yes,01/04/2020,"October 6, 2020",5 October 2020,NA,20200401,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,;,Zivit Harpaz;Zivit Harpaz,NA,;Zivit@canfite.co.il,;+972-3-9241114,Can-Fite BioPharma Ltd;,"<br>        Inclusion Criteria<br><br>          1. 18-85 years of age<br><br>          2. Able and willing to sign informed consent<br><br>          3. Molecular (RT-PCR) diagnosis of SARS-CoV-2 infection<br><br>          4. Moderate illness per NIH COVID-19 Treatment Guidelines:<br><br>               -  Symptoms such as cough, fever, sore throat, malaise, myalgias, headache; and<br><br>               -  Evidence of lower respiratory tract disease by clinical assessment and/or<br>                  imaging; and<br><br>               -  SpO2 >93% on room air at sea level<br><br>          5. Female subjects must have a negative serum pregnancy test (minimum sensitivity 25 IU/L<br>             or equivalent units of human chorionic gonadotropin) within 24 hours prior to the<br>             start of investigational product<br><br>          6. Female subjects of childbearing potential and male subjects with partners of<br>             childbearing potential must agree to use adequate methods of contraception during the<br>             study and through 90 days after the last dose of study medication. Female subjects of<br>             childbearing potential are all those except subjects who are surgically sterile, who<br>             have medically documented ovarian failure, or who are at least 1 year postmenopausal.<br><br>               1. For females: 2 of the following contraceptive methods, with at least 1 being a<br>                  barrier method:<br><br>                    -  Hormonal contraceptives for at least 27 days before dosing<br><br>                    -  Intrauterine device (IUD) in place at least 27 days before dosing<br><br>                    -  Double-barrier methods (use of condom [male partner] with either diaphragm<br>                       with spermicide or cervical cap with spermicide) from screening<br><br>                    -  Surgical sterilization of the partner (vasectomy at least 1 month before<br>                       screening)<br><br>                    -  Female subjects must have a negative urine pregnancy test (minimum<br>                       sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin)<br>                       within 24 hours prior to the start of investigational product.<br><br>               2. For males: Surgical sterilization (vasectomy at least 1 month before screening)<br>                  or double barrier methods.<br><br>        Exclusion Criteria<br><br>          1. Severe illness, including any of the following:<br><br>               -  Respiratory rate >30 breaths/minute; or<br><br>               -  SpO2 =93% on room air at sea level; or<br><br>               -  Ratio of arterial partial pressure of oxygen to fraction of inspired oxygen<br>                  (PaO2/FiO2) <300; or<br><br>               -  Lung infiltrates >50% of pulmonary volume on imaging<br><br>          2. Critical illness, including any of the following:<br><br>               -  Respiratory failure; or<br><br>               -  Septic shock; or<br><br>               -  Multiple organ dysfunction<br><br>          3. Participation in another clinical trial concurrently<br><br>          4. Concurrent treatment with immunomodulators or anti-rejection drugs<br><br>          5. Nursing women, pregnant women, women of childbearing potential who do not want<br>             adequate contraception<br><br>          6. History of any of the following diseases or conditions:<br><br>               -  Advanced or decompensated liver disease (including presence or history of<br>                  bleeding varices, ascites, encephalopathy, or hepato-renal syndrome)<br><br>               -  Inability to swallow tablets, or gastrointestinal disease which could interfere<br>                  with the absorption of piclidenoson<br><br>               -  Any malignancy within 5 years before screening; exceptions are superficial<br>                  dermatologic malignancies (e.g., squamous cell or basal cell skin cancer treated<br>                  with curative intent)<br><br>               -  Cardiomyopathy, significant ischemic cardiac or cerebrovascular disease<br>                  (including history of angina, myocardial infarction, or interventional procedure<br>                  for coronary artery disease), or cardiac rhythm disorder<br><br>               -  QTcF interval on an average of triplicate ECGs >450 milliseconds (msec) for males<br>                  or >470 msec for females (except when QT prolongation is associated with right or<br>                  left bundle branch block, in which case enrollment is allowed)<br><br>               -  Any condition which increases proarrhythmic risk, including hypokalemia,<br>                  hypomagnesemia, congenital Long QT Syndrome<br><br>               -  Ongoing or planned use of a concomitant medication that is on the CredibleMeds<br>                  list of drugs known to cause Torsades de Pointes unless the subject can be<br>                  screened and monitored under the guidelines proposed by Giudicessi (2020)<br><br>               -  Pancreatitis<br><br>               -  Severe or uncontrolled psychiatric disorder, e.g., depression, manic condition,<br>                  psychosis, acute and/or chronic cognitive dysfunction, suicidal behavior, and<br>                  relapse of substance abuse<br><br>               -  Active seizure disorder defined by either an untreated seizure disorder or<br>                  continued seizure activity within the preceding year despite treatment with<br>                  anti-seizure medication<br><br>               -  Bone marrow or solid organ transplantation<br><br>               -  Any serious condition that, in the opinion of the investigator, would preclude<br>                  evaluation of response or make it unlikely that the contemplated course of<br>                  therapy and follow-up could be completed<br><br>          7. Any of the following abnormal laboratory tests:<br><br>               -  Platelet count <90,000 cells/mm3<br><br>               -  Absolute neutrophil count (ANC) <1,500 cells/mm3<br><br>               -  Estimated creatinine clearance (CrCl) <50 mL/min by Cockroft-Gault formulation<br><br>               -  Bilirubin level =2.5 mg/dL unless due to Gilbert's syndrome<br><br>               -  AST or ALT level =3X the upper limit of normal<br><br>               -  Serum albumin level <3.0 g/dL<br><br>               -  International normalized ratio (INR) =1.5 (except subjects maintained on<br>                  anticoagulant medications)<br>",NA,Proportion of subjects alive and free of respiratory failure;Proportion of subjects discharged home alive;Treatment-emergent adverse events (AEs),NA,NA,NA,NA,NA,2020-04-01
NCT04466540,https://clinicaltrials.gov/show/NCT04466540,"Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19",COVID-19,Drug: Hydroxychloroquine;Drug: Placebo,Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),CT.gov,2020-07-03,2020-05-12,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 4,1300,Hospital Alemão Oswaldo Cruz,Brazil,FALSE,Yes,03/07/2020,"May 12, 2020",30 November 2020,COALITION-V,20200703,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,;,"Álvaro Avezum, Ph.D;Dayane Vilanova",NA,;dvilanova@haoc.com.br,;+55(11)3549-0729,International Research Center - Hospital Alemão Oswaldo Cruz;,"<br>        Inclusion Criteria:<br><br>        It will be considered eligible those adults (equal to or greater than 18 years) seeking<br>        medical care with suspected or confirmed COVID-19, with time between symptoms and inclusion<br>        = 07 days, presenting mild symptoms, without indication of hospitalization and at least 1<br>        risk factor for complication:<br><br>          1. > 65 years;<br><br>          2. Hypertension;<br><br>          3. Diabetes mellitus;<br><br>          4. Asthma;<br><br>          5. COPD or other chronic lung diseases;<br><br>          6. Smoking;<br><br>          7. Immunosuppression;<br><br>          8. Obesity (Defined as BMI equal to or greater than 30 Kg/m2).<br><br>        Exclusion Criteria:<br><br>          1. Patients under 18 years old;<br><br>          2. Hospitalization at the first medical care;<br><br>          3. Positive test for influenza at the first medical care;<br><br>          4. Known hypersensitivity to hydroxychloroquine / chloroquine;<br><br>          5. Previous diagnosis of retinopathy or macular degeneration;<br><br>          6. Previous diagnosis of Long QT-syndrome, history of sudden death in close family<br>             members (parents and siblings), decompensated heart failure, unstable coronary artery<br>             disease, use of anti-arrhythmic drugs or other drugs that can increase the<br>             hydroxychloroquine bioavailability or enhance its effect;<br><br>          7. Evidence of known liver disease, reported by the patient;<br><br>          8. Evidence of known chronic kidney disease, reported by the patient;<br><br>          9. Patients with pancreatitis;<br><br>         10. Baseline ECG with QTc interval = 480ms;<br><br>         11. Chronic use of hydroxychloroquine/chloroquine for other reasons;<br><br>         12. Pregnancy.<br>",NA,Hospitalization,NA,NA,NA,NA,NA,2020-07-03
NCT04346329,https://clinicaltrials.gov/show/NCT04346329,Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2,COVID,Drug: Hydroxychloroquine;Drug: Placebo oral tablet,Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19,CT.gov,2020-04-10,2020-04-20,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Care Provider).",Phase 3,86,Universidad Nacional de Colombia,Colombia,FALSE,Yes,10/04/2020,"April 20, 2020",27 April 2020,Chloroquine UN,20200410,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,NA,NA,NA,NA,NA,NA,"<br>        Inclusion Criteria:<br><br>          -  Be part of the health personnel (intensivist doctor, hospital doctors, nurses,<br>             physical therapists and support staff in the care unit) who will work at the HUN in<br>             the period of May 1st, 2020 to August 1, 2020<br><br>          -  Be over 18 years old, exposed to patients with COVID-19. Not having symptoms<br>             compatible with an acute respiratory infection for the last 21 days.<br><br>          -  Willingness to donate blood samples and for diagnosis and monitoring of SARS-COV-2<br>             infection throughout the study period.<br><br>          -  Have a Smart Phone in order to facilitate permanent communication with you during the<br>             duration of the study.<br><br>          -  Signature of informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Allergy or hypersensitivity to hydroxychloroquine.<br><br>          -  Contraindications to the use of chloroquine (epilepsy, creatinine clearance <30mL /<br>             min).<br><br>          -  Be taking (Abiraterone Acetate, Agalsidase, Conivaptan, Dabrafenib, Dacomitinib,<br>             Enzalutamide, Idelalisib), or medications that cannot be discontinued.<br><br>          -  Retinal disease.<br><br>          -  Mifepristone, Mitotane, tiripentol.<br><br>          -  Already established hydroxychloroquine treatment.<br><br>          -  Pregnancy or suspected pregnancy.<br><br>          -  Women in breastfeeding.<br><br>          -  Chronic liver disease (Child-Pugh B or C).<br><br>          -  Kidney disease with a Glomerular Filtration Rate of less than or equal to 30mL / min.<br><br>          -  Cardiac, kidney, liver, ophthalmic, neurological or autoimmune disease previously<br>             diagnosed.<br><br>          -  Prolongation of the QT segment in the EKG.<br><br>          -  Previous diagnosis of COVID-19.<br><br>          -  Concomitant taking of medications that prolong the QT segment<br>",NA,Adverse effects,NA,NA,NA,NA,NA,2020-04-10
NCT04564716,https://clinicaltrials.gov/show/NCT04564716,"?linical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-?oV-2 Infection Prophylactic Treatment in Republic of Belarus",Covid19,Biological: Gam-COVID-Vac;Other: Placebo,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus",CT.gov,2020-09-24,2020-09-28,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).",Phase 3,100,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",Belarus,FALSE,Yes,24/09/2020,"September 28, 2020",12 October 2020,NA,20200924,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,60 Years,All,;,Roman Plotnikov;Roman Plotnikov,NA,;rplot@ipharma.ru,;+7 (495) 276-11-43,CRO: iPharma;,"<br>        Inclusion Criteria:<br><br>          -  The subject's written informed consent to participate in the study;<br><br>          -  Male and female subjects between the ages of 18 and 60 years (inclusive).<br><br>          -  A negative test result for HIV, hepatitis, syphilis;<br><br>          -  Negative result of research on antibodies IgM and IgG to SARS Cov2 by enzyme-linked<br>             immunosorbent assay;<br><br>          -  A negative result of the COVID-2019 study, as determined by the PCR method at the<br>             screening visit;<br><br>          -  Lack of COVID-2019 in anamnesis;<br><br>          -  Lack of contact of the subject with COVID-2019 patients for at least 14 days before<br>             inclusion in the study (according to the participant);<br><br>          -  Agreement to use effective contraceptive methods throughout the study period;<br><br>          -  Negative pregnancy test based on the results of a urine test at a screening visit (for<br>             women of childbearing age);<br><br>          -  A negative test for the presence of narcotic substances and psycho-stimulating drugs<br>             in the urine at the screening visit;<br><br>          -  Negative alcohol test at the screening visit;<br><br>          -  Lack of pre-existing post-vaccination reactions or post-vaccination complications<br>             following the use of immunobiological drugs;<br><br>          -  No acute infectious and/or respiratory diseases for at least 14 days before inclusion<br>             in the study.<br><br>        Exclusion Criteria:<br><br>          -  Any vaccination/immunization carried out within 30 days prior to enrollment in the<br>             study;<br><br>          -  Treatment with steroids (except hormonal contraceptives) and/or with immunoglobulins<br>             or other blood products not completed 30 days before inclusion in the study;<br><br>          -  Immunosuppressive therapy completed less than three months before inclusion in the<br>             study;<br><br>          -  Female subjects during pregnancy or breastfeeding;<br><br>          -  Acute coronary syndrome or stroke suffered less than one year before inclusion into<br>             the study;<br><br>          -  Tuberculosis, chronic systemic infections;<br><br>          -  Aggravated allergy anamnesis (anamnesis of anaphylactic shock, Quinque edema,<br>             polymorphic exudative eczema, atopia, serum disease), hypersensitivity or allergic<br>             reactions to immunobiological drugs, known allergic reactions to the components of the<br>             drug, aggravation of allergic diseases on the day of inclusion in the study;<br><br>          -  The presence of neoplasms in the anamnesis (codes C00-D09);<br><br>          -  Donated blood or plasma (450 ml or more) less than 2 months before inclusion in the<br>             study;<br><br>          -  Splenectomy in anamnesis;<br><br>          -  Neutropenia (decrease in absolute number of neutrophils less than 1000/mm3),<br>             agraneulocytosis, significant haemorrhage, severe anaemia (hemoglobin less than 80<br>             g/l), immunodeficiency in anamnesis for 6 months before inclusion in the study;<br><br>          -  Subjects with an active form of disease caused by human immunodeficiency virus,<br>             syphilis, hepatitis B and C;<br><br>          -  Anorexia, protein deficiency of any origin;<br><br>          -  Chronic autoimmune diseases or systemic collagenoses in anamnesis<br><br>          -  Extensive tattoos at the injection site (deltoid region) that do not allow for an<br>             assessment of the local response to IMP/placebo administration;<br><br>          -  Alcoholism and drug addiction in anamnesis;<br><br>          -  Participation of the subject in any other interventional clinical trial;<br><br>          -  Any other condition of the subject which, in the opinion of the researcher's medical<br>             practitioner, may prevent completion of the investigation according to the protocol;<br><br>          -  Staff of research centers and other staff directly involved in the study and their<br>             families.<br>",NA,percentage of trial subjects with coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose,NA,NA,NA,NA,NA,2020-09-24
NCT04365309,https://clinicaltrials.gov/show/NCT04365309,Protective Effect of Aspirin on COVID-19 Patients,Novel Coronavirus Pneumonia;Aspirin;Treatment,Drug: Aspirin 100mg,Protective Effect of Aspirin on COVID-19 Patients,CT.gov,2020-04-24,2020-02-10,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2/Phase 3,128,Xijing Hospital,China,FALSE,Yes,24/04/2020,"February 10, 2020",11 May 2020,PEAC,20200424,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,85 Years,All,NA,Cai Yue,NA,NA,NA,the first affiliated hospital of the Air force medical university,"<br>        Inclusion Criteria:<br><br>          1. The patient volunteered to participate in the study, approved the aspirin treatment,<br>             and was willing to randomly accept one of the aspirin treatment regimens, and provided<br>             written informed consent,<br><br>          2. Subject is required to meet one of the following criteria for confirmation of a novel<br>             coronavirus infection with pneumonia: 1.The detection of novel coronavirus nucleic<br>             acid is positive in respiratory or blood specimens by Real-time -PCR, 2. Virus gene<br>             sequencing of respiratory or blood specimen is highly homologous with known novel<br>             coronavirus,<br><br>          3. Chest image confirmed pulmonary involvement;<br><br>          4. fever: =36.7? under the armpit, =38.0? in the oral cavity or =38.6? in the rectum and<br>             eardrum; • respiratory frequency =24 times/min or at least one cough;<br><br>          5. Onset time =14 days;<br><br>          6. Agree not to participate in another study until completion of the 14-day study; If you<br>             need to withdraw from this study;<br><br>          7. The subjects had not taken aspirin for nearly one month prior to the screening period.<br><br>          8. Can follow the study or follow up procedure. -<br><br>        Exclusion Criteria:<br><br>          1. Women who have recently been pregnant or breast-feeding.<br><br>          2. Having a history of active gastrointestinal bleeding in the past 3 months.<br><br>          3. Blood routine examination showed that the platelet count was < 30×109/L.<br><br>          4. Patients with coagulation disorders.<br><br>          5. Unable to understand the potential risks and benefits of the study, and unable to<br>             follow up the evaluation as required.<br><br>          6. Having no capacity for civil conduct.<br><br>          7. A history of drug or alcohol abuse.<br><br>          8. Allergic to aspirin.<br><br>          9. Influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus,<br>             rhinovirus, human partial lung virus, mycoplasma pneumoniae, chlamydia pneumonia,<br>             bacterial pneumonia, organized pneumonia, etc.<br><br>         10. Patients with cardiac stent placement (< 1 year).<br><br>         11. Any more complex medical problems that may interfere with research behavior or lead to<br>             increased risk, such as malignant tumors, blood diseases, liver diseases, AIDS, viral<br>             hepatitis, etc.<br>",NA,the time of SARS-CoV2 overcasting;clinical recovery time (TTCR),NA,NA,NA,NA,NA,2020-04-24
NCT04468009,https://clinicaltrials.gov/show/NCT04468009,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,SARS-Associated Coronavirus;Covid19;SARS-CoV Infection,Biological: Convalescent plasma,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,CT.gov,2020-07-09,2020-06-25,FALSE,Interventional,Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,36,Hospital de Infecciosas Francisco Javier Muniz,Argentina,FALSE,Yes,09/07/2020,"June 25, 2020",17 August 2020,NA,20200709,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,100 Years,All,; ;,"Carlos A Gonzalez, MD;Carlos A Gonzalez, MD;Carlos A Gonzalez, MD",NA,;carlosgonzalez@buenosaires.gob.ar;carlosgonzalez@buenosaires.gob.ar,;+54 9 1157233801;+54 9 1157233801,Hospital de Infecciosas Francisco Javier Muniz;,"<br>        Inclusion Criteria:<br><br>          -  Age: 18 years or more.<br><br>          -  Patient with Covid-19 confirmed with nuclear acid testing<br><br>          -  Critically ill patients with Covid-19 on mechanical ventilation. Potencially<br>             critically ill patients (with acute respiratory distress syndrome, septic shock and/or<br>             multiple organ failure) with Covid-19.<br><br>          -  Diagnosed with acute respiratory distress syndrome.<br><br>          -  Informed consent.<br><br>        Exclusion Criteria:<br><br>          -  No consent.<br><br>          -  Symptoms for a period longer than 20 days.<br><br>          -  Not detectable by acid nuclear testing within 48 hours prior to elegibility.<br><br>          -  Descompensated congestive heart failure, in which receiving 500ml of intrasvascular<br>             volume signifies a life risk.<br><br>          -  History of severe adverse events or anaphylaxis to plasma components<br>",NA,Mortality at ICU at 30 days;Mortality at ICU at 90 days,NA,NA,NA,NA,NA,2020-07-09
NCT04397562,https://clinicaltrials.gov/show/NCT04397562,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19",COVID-19,Drug: Levilimab;Drug: Placebo,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,CT.gov,2020-05-19,2020-04-29,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 3,206,Biocad,Russian Federation,FALSE,Yes,19/05/2020,"April 29, 2020",30 November 2020,CORONA,20200519,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,NA,NA,NA,NA,NA,NA,"<br>        Inclusion Criteria:<br><br>          1. Signed informed consent (subject; legally authorized representative) or signed<br>             conclusion of panel of independent medical doctors<br><br>          2. Males and non-pregnant females aged 18 years or older at the IC date<br><br>          3. Positive test for SARS-CoV2 nucleic acid (RNA) at the IC date<br><br>          4. Admitted as inpatient to a hospital with radiologically confirmed pneumonia<br><br>          5. Severe form of COVID-19.<br><br>          6. Subjects meeting any of the following criteria:<br><br>               -  Total respiratory rate > 30 breaths per minute<br><br>               -  SpO2 = 93%<br><br>               -  PaO2 /FiO2 = 300 mmHg<br><br>               -  Chest imaging (X-ray, CT, US) showed lesion progression within 24-48 hours >50%<br><br>               -  Decrease of consciousness level, Psychomotor agitation/irritability<br><br>               -  Hemodynamically unstable (systolic blood pressure <90 mmHg or diastolic blood<br>                  pressure < 60 mmHg or urine output < 20 ml/h)<br><br>               -  Arterial lactate > 2 mmol/l<br><br>               -  qSOFA (quick sequential organ failure assessment score) > 2. Subjects meeting<br>                  three following criteria: Low blood pressure (SBP = 100 mmHg); High respiratory<br>                  rate (= 22 breaths/min); Altered mentation (Glasgow Coma Scale = 14)<br><br>        Exclusion Criteria:<br><br>          1. Critical COVID-19. Subjects meeting any of the following:<br><br>               -  Respiratory failure and requiring invasive mechanical ventilation (tracheal<br>                  intubation)<br><br>               -  Septic shock<br><br>               -  Multiple organ failure<br><br>          2. Life expectancy < 24h, in the opinion of the investigator,<br><br>          3. Unlikely to remain at the investigational site beyond 48 hours<br><br>          4. Use of other monoclonal antibodies for COVID-19 treatment<br><br>          5. Current treatment with immunosuppressive agents (including corticosteroids)<br><br>          6. Participating in other drug clinical trials at the IC date or within 60 days after<br>             randomization (participation in COVID-19 anti-viral trials may be permitted if<br>             approved by Sponsor)<br><br>          7. Laboratory values:<br><br>               -  ALT / AST > 10 ULN at screening<br><br>               -  Platelets < 50?109/l at screening<br><br>               -  Absolute Neutrophil Count < 1?109/l at screening<br><br>          8. Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)<br><br>          9. Confirmed active tuberculosis<br><br>         10. History of allergic reaction to monoclonal antibodies<br><br>         11. Pregnancy or breastfeeding<br><br>         12. Any illness or laboratory findings that, in the opinion of the study investigator,<br>             might pose an additional risk to the patient by their participation in the study,<br>",NA,Proportion of patients with sustained clinical recovery,NA,NA,NA,NA,NA,2020-05-19
NCT04541979,https://clinicaltrials.gov/show/NCT04541979,"Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19 - a Phase 2, Single-blinded, Randomized Study",COVID-19,Drug: aerosolized DNase;Drug: NaCl,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,CT.gov,2020-06-05,2020-06-04,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).,Phase 2,100,Region Skane,Sweden,FALSE,Yes,05/06/2020,"June 4, 2020",21 September 2020,NA,20200605,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ;,"Adam Linder, MD;Adam Linder, MD;Adam Linder",NA,;adam.linder@med.lu.se;adam.linder@med.lu.se,;004646171130;,Region Skåne;,"<br>        Inclusion Criteria:<br><br>          -  Age =18 years old<br><br>          -  Admitted to hospital ward or ICU<br><br>          -  A positive PCR test for SARS-CoV-2 from throat swab or nasopharynx<br><br>          -  An oxygen saturation =90% after maximum 15 minutes without supplemental oxygen<br><br>          -  Signed informed consent<br><br>        Exclusion Criteria:<br><br>          -  Mental inability, reluctance or language difficulties that result in difficulty<br>             understanding the meaning of study participation<br><br>          -  Known or suspected allergy against Pulmozyme<br><br>          -  Chronic obstructive pulmonary disease stage III-IV or another comparable chronic<br>             respiratory disease<br><br>          -  Participation in a clinical study with an investigational product during the last 30<br>             days<br><br>          -  Previous participation in this study<br><br>          -  Pregnancy. Women of childbearing potential must agree to use contraceptives for the<br>             duration of the study period<br><br>          -  Any condition that, in the opinion of the Investigator, would place the patient at<br>             increased risk or preclude the patient's compliance with the study<br>",NA,"Time to cessation of oxygen therapy DNase I to that of placebo (NaCl, 0.9%) on time to cessation of oxygen therapy hospitalized patients with COVID-19 and respiratory dysfunction.",NA,NA,NA,NA,NA,2020-06-05
NCT04540120,https://clinicaltrials.gov/show/NCT04540120,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome",Covid19;Cytokine Release Syndrome,Drug: dapansutrile capsules;Drug: placebo capsules,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,CT.gov,2020-08-13,2020-09-25,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",Phase 2,80,Olatec Therapeutics LLC,United States;Switzerland;United States,FALSE,Yes,13/08/2020,"September 25, 2020",24 November 2020,NA,20200813,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,NA,Clinical Trial Operations,NA,inquiries@olatec.com,+1 833-652-8321,NA,"<br>        Inclusion Criteria:<br><br>          1. Male and female subjects = 18 years of age;<br><br>          2. SARS-CoV-2-positive, confirmed by Food and Drug Administration (FDA)- or European<br>             Medicines Agency (EMA)-authorized COVID-19 test = 5 days prior to randomization;<br><br>          3. Less than or equal to 120 hours from first symptom onset to randomization;<br><br>          4. Subjects with moderate COVID-19 who have fever (temperature = 38 °C / 100.4 °F) and<br>             shortness of breath (with exertion), not requiring oxygen, and meeting the definition<br>             of ""moderate"" as set forth by the May 2020 FDA Guidance for Industry: COVID-19:<br>             Developing Drugs and Biological Products for Treatment or Prevention (FDA, 2020),<br>             which includes all of the following criteria:<br><br>               1. Respiratory rate: = 20 breaths/minute,<br><br>               2. SpO2: > 93% on room air at sea level, and<br><br>               3. Heart rate: = 90 beats/minute;<br><br>          5. Subject must possess at least one of the following high-risk conditions known to have<br>             an underlying increased level of cytokine production:<br><br>               1. 70 years or more of age,<br><br>               2. Obesity (BMI = 30 kg/m2),<br><br>               3. Diabetes (type 1 or 2),<br><br>               4. Uncontrolled hypertension, defined as diastolic > 100 mm Hg and/or systolic > 150<br>                  mm Hg without any current anti-hypertensive medications. At the time of screening<br>                  if the patient is on anti- hypertensive medication(s) and diastolic or systolic<br>                  rates are elevated, patient may be enrolled after consultation with the Medical<br>                  Monitor,<br><br>               5. Known respiratory disease (including asthma or chronic obstructive pulmonary<br>                  disease [COPD]),<br><br>               6. Known heart failure (note: subjects with New York Heart Association Class IV<br>                  congestive heart failure cannot be enrolled per Exclusion Criterion 4), or<br><br>               7. Known coronary disease;<br><br>          6. Plasma CRP level = 20 mg/L at Screening/Baseline/Day 1 Visit;<br><br>          7. Acceptable overall medical condition to be safely enrolled in and complete the study<br>             (with specific regard to cardiovascular, renal, and hepatic conditions) in the opinion<br>             of the Investigator;<br><br>          8. Ability to provide written, informed consent prior to initiation of any study- related<br>             procedures, and ability (in the opinion of the Investigator) to understand and comply<br>             with all the requirements of the study, which includes abstaining from the use of<br>             prohibited medications.<br><br>        Exclusion Criteria:<br><br>          1. Women of childbearing potential, or men whose sexual partner(s) is a woman of<br>             childbearing potential, who:<br><br>               1. Are or intend to become pregnant (including use of fertility drugs) during the<br>                  study;<br><br>               2. Are nursing (female subjects only);<br><br>               3. Are not using an acceptable, highly effective method of contraception until all<br>                  follow-up procedures are complete.<br><br>          2. Evidence of pre-existing or new-onset organ failure;<br><br>          3. Evidence of moderate concurrent nervous system, renal, endocrine, or gastrointestinal<br>             disease, unrelated to COVID-19 as determined by the Investigator;<br><br>          4. Evidence of cardiovascular disease with significant arrhythmia, congestive heart<br>             failure (New York Heart Association Class IV), unstable angina, cor pulmonale, or<br>             symptomatic pericardial effusion, not related to COVID-19 as determined by the<br>             Investigator;<br><br>          5. Required use of vasoactive drug support;<br><br>          6. History of myocardial infarction in the 6 months prior to the Screening/Baseline/Day 1<br>             Visit;<br><br>          7. Evidence of current liver disease, not related to COVID-19 as determined by the<br>             investigator;<br><br>          8. History or evidence of active tuberculosis (TB) infection at Screening/Baseline/Day 1<br>             Visit or one of the risk factors for tuberculosis such as but not limited or exclusive<br>             to:<br><br>               1. History of any of the following: residence in a congregate setting (e.g., jail or<br>                  prison, homeless shelter, or chronic care facility), substance abuse (e.g.,<br>                  injection or non-injection), health-care workers with unprotected exposure to<br>                  subjects who are at high risk of TB or subjects with TB disease before the<br>                  identification and correct airborne precautions of the subject or<br><br>               2. Close contact (i.e., share the same air space in a household or other enclosed<br>                  environment for a prolonged period (days or weeks, not minutes or hours)) with a<br>                  person with active pulmonary TB disease within the last 12 months.<br><br>          9. History of or currently active primary or secondary immunodeficiency;<br><br>         10. Past or present requirement for oxygen (e.g., nasal cannula, proning, mechanical<br>             ventilation and/or supplemental oxygen).<br><br>         11. Use of any prohibited concomitant medications/therapies over the defined or planned<br>             use of any concomitant medications/therapies during the<br><br>             Treatment Period, including specifically:<br><br>               1. use of ibuprofen or diclofenac<br><br>               2. use of colchicine<br><br>               3. use of systemic steroids within 30 days of randomization<br><br>               4. use of janus kinase (JAK) inhibitors<br><br>               5. use of off-label agents (e.g., hydroxychloroquine, remdesivir, dexamethasone) and<br>                  biologic and oral anti-cytokine agents (e.g., current treatment with adalimumab,<br>                  infliximab, etanercept, golimumab, certolizumab pegol, tocilizumab, sarilumab,<br>                  anakinra, canakinumab, rilonacept, baricitinib, tofacitinib, or upadacitinib);<br><br>             Note: During the treatment period a patient may meet the criteria for a treatment<br>             approved by the FDA specifically for COVID-19 (e.g. remdesivir). In this situation the<br>             investigator and medical monitor should confer and take the most appropriate decision<br>             for the patient. If possible, the preference would be for the patient to complete the<br>             14 days of dosing before adding on the 2nd treatment. If that is not possible the<br>             preference would be for the patient to continue their 14 days on dapansutrile and<br>             complete all study related visits.<br><br>         12. Known history of renal impairment (e.g., calculated glomerular filtration rate [GFR] <<br>             45 mL/min);<br><br>         13. Evidence of malignant disease, or malignancies diagnosed within the previous 5 years<br>             (except for local basal or squamous cell carcinoma of the skin or carcinoma in situ of<br>             the cervix uteri that has been excised and cured);<br><br>         14. History of infection or known active infection with human immunodeficiency virus<br>             (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);<br><br>         15. Any other concomitant medical or psychiatric conditions, diseases, or prior surgeries<br>             that, in the opinion of the Investigato",NA,Proportion of subjects with complete resolution of fever symptoms and shortness of breath,NA,NA,NA,NA,NA,2020-08-13
NCT04356690,https://clinicaltrials.gov/show/NCT04356690,"A Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 Infection",COVID-19,Drug: Etoposide,Etoposide in Patients With COVID-19 Infection,CT.gov,2020-04-17,2020-05-08,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).,Phase 2,64,Boston Medical Center,United States,FALSE,Yes,17/04/2020,"May 8, 2020",14 September 2020,NA,20200417,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ;,"John Mark Sloan, MD;John Mark Sloan, MD;Annie Jose, BS",NA,;mark.sloan@bmc.org;annie.jose@bmc.org,;617-638-7002;617-638-8213,Boston Medical Center;,"<br>        Inclusion Criteria:<br><br>          -  Confirmed COVID-19 infection<br><br>          -  Evidence of cytokine storm defined as:<br><br>               -  Peak ferritin > 10,000 ng/mL OR<br><br>               -  Peak ferritin > 500 ng/mL and one or more of the following at any time during<br>                  hospital admission: Lactate dehydrogenase > 500 U/L, d-dimer >1000 ng/mL,<br>                  C-reactive protein > 100 mg/L, or white blood count> 15 k/microlitre<br><br>        Cohort 1: Intubated status as a result of COVID infection-associated respiratory illness.<br><br>        Cohort 2 (if activated): Evidence of progressive respiratory failure (requiring >4 L/min of<br>        supplemental oxygen to maintain oxygen saturation greater than 92%) without intubation;<br><br>        Exclusion Criteria:<br><br>          -  Pregnancy or breastfeeding<br><br>          -  History of severe hypersensitivity to etoposide products<br><br>          -  Absolute neutrophil count (ANC) < 1000 cells/mm3<br><br>          -  Platelet count <50,000/mm3<br><br>          -  Bilirubin > 3.0 mg/dL<br><br>          -  Aspartate OR alanine aminotransferase > 5.0 x upper limit of normal<br><br>          -  Creatinine Clearance < 15 mL/min (calculated by Cockcroft Fault formula)<br><br>          -  Requiring continuous renal replacement therapy<br><br>          -  Requiring vasopressors<br><br>          -  Requiring extracorporeal membrane oxygenation (ECMO)<br><br>          -  Other active, life-threatening infections<br><br>          -  Anti-cytokine treatment (including anakinra or Interleukin 6 antibodies eg<br>             tocilizumab, sarilumab) administration within three half-lives of the medication used<br><br>          -  Hydroxychloroquine, colchicine, azithromycin, doxycycline-if administered for COVID<br>             infection-must be discontinued for at least 24 hours prior to randomization.<br><br>          -  Has a history or current evidence of any condition, therapy or laboratory abnormality<br>             that might confound the results of the study, interfere with subject participation, or<br>             is not in the best interest of the patient to participate, in the opinion of the<br>             investigator.<br><br>          -  Inability to consent and no legally authorized representative<br><br>          -  Poorly controlled HIV infection (CD4 count <100 cells/mm3)<br>",NA,Change in pulmonary status,NA,NA,NA,NA,NA,2020-04-17
NCT04382586,https://clinicaltrials.gov/show/NCT04382586,"A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress",COVID-19 Pulmonary Complications;COVID-19,Drug: Zanubrutinib;Drug: Supportive Care;Drug: Placebo,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,CT.gov,2020-05-07,2020-07-06,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 2,52,BeiGene,United States;Brazil;United States,FALSE,Yes,07/05/2020,"July 6, 2020",19 October 2020,NA,20200507,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,;,"Todd Zimmerman, MD;BeiGene",NA,;clinicaltrials@beigene.com,;+1-877-828-5568,BeiGene;,"<br>        Key Inclusion Criteria:<br><br>          1. Hospitalization for COVID-19 infection<br><br>          2. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by<br>             polymerase chain reaction (PCR)<br><br>          3. Cohort 1: Participant requires supplemental oxygen for pulmonary distress related to<br>             COVID-19 infection, and has been on supplemental oxygen for no more than 48 hours.<br>             Cohort 2: Participants will have been on mechanical ventilation for = 24 hours from<br>             the time of screening<br><br>          4. Radiographic evidence of pulmonary infiltrates<br><br>        Key Exclusion Criteria:<br><br>          1. Participant is on mechanical ventilation for > 24 hours<br><br>          2. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or<br>             resection of the stomach or small bowel, symptomatic inflammatory bowel disease or<br>             ulcerative colitis, or partial or complete bowel obstruction<br><br>          3. On a BTK inhibitor<br><br>          4. Planned or concurrent use of tocilizumab<br><br>          5. Participants with cancer<br><br>        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.<br>",NA,Respiratory failure-free survival rate at day 28,NA,NA,NA,NA,NA,2020-05-07
NCT04470531,https://clinicaltrials.gov/show/NCT04470531,Role of Co-trimoxazole in Severe COVID-19 Patients,Covid19;Severe COVID-19 Patients,Drug: oral co-trimoxazole,Role of Co-trimoxazole in Severe COVID-19 Patients,CT.gov,2020-07-11,2020-07-12,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,94,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Bangladesh,FALSE,Yes,11/07/2020,"July 12, 2020",27 July 2020,NA,20200711,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,70 Years,All,; ;,"Shohael Arafat;Shohael Arafat, FCPS;Shohael Arafat, FCPS",NA,;arafat2001@gmail.com;arafat2001@gmail.com,;01732330313;01732330313,ICMJE;,"<br>        Inclusion Criteria:<br><br>          1. Diagnosed COVID-19 patients ( RT-PCR positive for COVID-19)<br><br>          2. Age > 18 years<br><br>          3. Hypoxic respiratory failure (saturation <90% on air at rest or increasing oxygen<br>             requirement)<br><br>          4. Chest examination findings of bilateral crackles on auscultation or chest x-ray<br>             showing bilateral infiltrates<br><br>          5. C-Reactive Protein > 50mg/L<br><br>        Exclusion Criteria:<br><br>          1. Multi-organ failure<br><br>          2. Severe ARDS (requiring ventilator support on presentation in the form of invasive or<br>             non-invasive ventilation)<br><br>          3. Septic Shock<br><br>          4. Severe liver disease<br><br>          5. Acute Kidney Injury (where GFR< 15 and plasma-sulfamethoxazoleconcentration cannot be<br>             monitored)<br><br>          6. Drug allergy/intolerance to co-trimoxazole / Sulphar sensitivity<br><br>          7. Pregnancy<br><br>          8. Already receiving Tocilizumab or convalescent therapy<br>",NA,Length of stay in hospital (in days);In-patient mortality,NA,NA,NA,NA,NA,2020-07-11
NCT04362189,https://clinicaltrials.gov/show/NCT04362189,"A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19",COVID-19,Drug: HB-adMSC;Drug: Placebo,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,CT.gov,2020-04-21,2020-06-30,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,100,Hope Biosciences,United States,FALSE,Yes,21/04/2020,"June 30, 2020",2 November 2020,NA,20200421,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,N/A,N/A,All,NA,"Rajiv Thakur, MD",NA,NA,NA,Advanced Diagnostics Healthcare,"<br>        Inclusion Criteria:<br><br>          -  Men, and women, over 18 years of age inclusively<br><br>          -  Patient is hospitalized due to suspected COVID-19 infection<br><br>          -  Agrees to the collection of venous blood per protocol<br><br>        Exclusion Criteria:<br><br>          -  Pregnancy, lactation and those who are not pregnant but do not take effective<br>             contraceptive measures.<br><br>          -  Patients who are participating in other clinical trials or have intake of<br>             investigational drug within the previous 30 days.<br><br>          -  Inability to provide informed consent or to comply with test requirements.<br><br>          -  Acute intercurrent infections such as Hepatitis C Virus (HCV), Hepatitis B Virus<br>             (HBV), Human Immunodeficiency Virus (HIV) or Syphilis.<br><br>          -  Any medical disease or condition that, in the opinion of the site Principal<br>             Investigator or sub-investigator, precludes study participation. Including acute,<br>             subacute, intermittent or chronic medical disease or condition that would place the<br>             subject at an unacceptable risk of injury, render the subject unable to meet the<br>             requirements of the protocol, or may interfere with the evaluation of responses or the<br>             subject's successful completion of this trial.<br><br>          -  Receipt of any other SARS-CoV-2 or other experimental coronavirus vaccine at any time<br>             prior to or during the study.<br>",NA,Interleukin-6;C Reactive protein;Oxygenation;TNF alpha;IL-10;Return to room air (RTRA),NA,NA,NA,NA,NA,2020-04-21
NCT04380376,https://clinicaltrials.gov/show/NCT04380376,"Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19",COVID-19;Viral Pneumonia,Drug: Melphalan;Other: Standard of care,Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,CT.gov,2020-05-06,2020-04-30,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).,Phase 2,60,"Federal State Budgetary Institution, Pulmonology Scientific Research Institute",Russian Federation,FALSE,Yes,06/05/2020,"April 30, 2020",21 May 2020,MICOV,20200506,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,;,"Kirill A Zykov, Prof;Kiril A Zykov, Prof",NA,;kirillaz@inbox.ru,;+79257729462,"Federal State Budgetary Institution, Pulmonology Scientific Research Institute;","<br>        Inclusion Criteria:<br><br>          1. Age =18 years<br><br>          2. A patient must have confirmed the diagnosis of bi-lateral moderate / severe pneumonia<br>             ( viral or viral-bacterial with confirmed of suspected COVID-19).<br><br>          3. Presence new infiltrates or increase already available infiltrates of pulmonary<br>             infiltrates on lung CT within 48 hours before baseline.<br><br>          4. A patient has as minimum one of the following symptoms:<br><br>        fever >38 degrees Celsius, cough, dyspnea, SaO2 (arterial oxygen saturation) <95% (with<br>        room air)<br><br>        Exclusion Criteria:<br><br>          1. Informed consent is withdrawn by the patient.<br><br>          2. The patient doesn't follow the instructions of the research staff regarding the<br>             requirements of the research protocol.<br><br>          3. Unable to contact the patient.<br><br>          4. The researcher believes that participation in the study is not in the interests of the<br>             patient and / or further participation in the study is unsafe for the patient's<br>             health.<br><br>          5. There is a violation of the criteria for inclusion and / or non-inclusion in the<br>             study.<br><br>          6. The patient has developed an adverse event, which, according to the researcher, makes<br>             further participation in the study unsafe for the patient.<br><br>          7. The licensing authority or ethics committee, for any reason, decides to discontinue<br>             the entire study or close this research center.<br><br>          8. A female patient becomes pregnant, is planning a pregnancy, or is breastfeeding while<br>             participating in this study.<br>",NA,The changes of COVID Ordinal Outcomes Scale;Percentage of the patients with Clinical Recovery;The changes of the Borg's scale,NA,NA,NA,NA,NA,2020-05-06
NCT04412018,https://clinicaltrials.gov/show/NCT04412018,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19),COVID-19;Inflammatory Response,Drug: Icosapent ethyl,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,CT.gov,2020-05-29,2020-06-04,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,100,Canadian Medical and Surgical Knowledge Translation Research Group,Canada,FALSE,Yes,29/05/2020,"June 4, 2020",21 September 2020,NA,20200529,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,75 Years,All,; ;,"Subodh Verma, MD, PhD;Subodh Verma, MD, PhD;Subodh Verma, MD, PhD",NA,;subodh.verma@unityhealth.to;,;1-416-864-5997;,Canadian Medical and Surgical Knowledge Translation Research Group;,"<br>        Inclusion Criteria:<br><br>          1. Positive local SARS-CoV-2 test result within the preceding 72 hours<br><br>          2. At least one of the following symptoms<br><br>               1. Fever<br><br>               2. Cough<br><br>               3. Sore throat<br><br>               4. Shortness of breath<br><br>               5. Myalgia<br><br>        Exclusion Criteria:<br><br>          1. Individuals currently participating in another interventional trial that will or may<br>             interfere with the primary outcome<br><br>          2. Hospitalized individuals<br><br>          3. Individuals who have a current medical condition for which life expectancy is less<br>             than 3 months<br><br>          4. Individuals with a history of acute end-organ injury (e.g. myocardial infarction,<br>             stroke, hospitalization for acute lung, liver or kidney disease) within the last month<br><br>          5. Individuals with active severe liver disease<br><br>          6. Individuals with a history of acute or chronic pancreatitis<br><br>          7. Women who are pregnant, may be pregnant, are planning on becoming pregnant, or are<br>             lactating<br><br>          8. Women of child-bearing potential who are not using at least one form of highly<br>             effective (hormonal contraceptives [e.g. combined oral contraceptives, patch, vaginal<br>             ring, injectables, and implants]; intrauterine device or intrauterine system; tubal<br>             ligation or whose partner has had a vasectomy) and one effective (barrier methods such<br>             male condom, female condom, cervical cap, diaphragm, or contraceptive sponge) method<br>             of contraception<br><br>          9. Individuals with a history of hemodynamic instability within past 72 hours including a<br>             systolic blood pressure of <95 mmHg and/or a diastolic blood pressure of <50 mmHg<br><br>         10. Individuals with known hypersensitivity to fish and/or shellfish, or ingredients of<br>             IPE<br><br>         11. Individuals with any other condition which, in the opinion of the Investigator, would<br>             place the participant at increased risk, preclude obtaining voluntary consent or<br>             confound the objectives of study<br><br>         12. Individuals who are unable to swallow IPE capsules whole<br>",NA,Change in hs-CRP levels from the randomization visit (Day 1) to the Day 14 visit,NA,NA,NA,NA,NA,2020-05-29
NCT04345861,https://clinicaltrials.gov/show/NCT04345861,Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia,"Coronavirus Infection;Pneumonia, Viral",Drug: Hydroxychloroquine + placebo;Drug: hydroxychloroquine + azithromycin,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),CT.gov,2020-04-05,2020-04-11,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 2/Phase 3,7,"University Hospital, Montpellier",France,FALSE,Yes,05/04/2020,"April 11, 2020",22 June 2020,COVIDOC,20200405,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,75 Years,All,NA,"Jacques REYNES, MD,PhD",NA,NA,NA,Montpellier University Hospital,"<br>        Inclusion Criteria:<br><br>          -  18-75 years old SARS CoV-2 Infection confirmed by positive virologic test realised in<br>             the 96 h before randomization<br><br>          -  Beginning of COVID-19 symptoms < 10 days at the time of randomization<br><br>          -  Presence of symptom(s) of COVID-19 : fever (température > or = 37,5°C) or respiratory<br>             sign(s) (cough, breathing discomfort) or recent anosmia<br><br>          -  Presence of TDM/radiographic signs or pneumonia<br><br>          -  Hospitalization out of ICU for COVID with: moderate clinical form (no oxygenotherapy)<br>             or non critical severe form (oxygenotherapy)<br><br>        Exclusion Criteria:<br><br>          -  Absence of signed informed consent<br><br>          -  SpO2 < 90 % ambient air or < 94 % with oxygenotherapy > or = 3l/min<br><br>          -  Need of oxygenotherapy > 6 l/min or mechanical ventilation<br><br>          -  Need of hospitalization in ICU<br><br>          -  ALAT/ASAT > 5 LSN<br><br>          -  Renal failure (eGFR < 40 ml/min ) or dialysis<br><br>          -  Pregnancy or breastfeeding<br><br>          -  Retinopathy<br><br>          -  Known deficit in G6PD<br><br>          -  Cardiac rythm / lengthening QT disorders<br><br>          -  QT space lengthening on ECG with QTc > 450 ms<br><br>          -  Concomitant treatment :citalopram, escitalopram, hydroxyzine, domperidone,<br>             pipéraquine, anti-arhythmic class IA & III, antidepressive drugs,..<br>",NA,Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).,NA,NA,NA,NA,NA,2020-04-05
NCT04432324,https://clinicaltrials.gov/show/NCT04432324,"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19",COVID-19,Biological: Intravenous Immune Globulin;Drug: Standard Medical Treatment,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),CT.gov,2020-06-12,2020-06-02,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,100,"Instituto Grifols, S.A.",Spain,FALSE,Yes,12/06/2020,"June 2, 2020",19 October 2020,NA,20200612,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,NA,Navarro Puerto Jordi,NA,jordi.navarro@grifols.com,+34935712200,NA,"<br>        Inclusion Criteria:<br><br>          1. Hospitalized male or female subject = 18 years of age at time of Screening who is<br>             being treated for COVID-19.<br><br>          2. Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by<br>             qualitative Polymerase Chain Reaction (PCR) (reverse transcriptase [RT]-PCR), or other<br>             commercial or public health assay (of any type) in any specimen during the current<br>             hospital admission prior to randomization.<br><br>          3. COVID-19 illness (symptoms) of any duration with radiographic infiltrates by imaging<br>             (Chest X-Ray, Computed tomography (CT) scan, etc.).<br><br>          4. PaO2/FIO2 ratio > 300 to = 450 mmHg (i.e., arterial oxygen in mmHg divided by fraction<br>             inspired oxygen concentration [e.g., 0.21 for room air])<br><br>          5. Any one of the following related to COVID-19: i. Ferritin > 400 nanogram per<br>             milliliter (ng/mL), ii. Lactate dehydrogenase (LDH) > 300 units per liter U/L, iii.<br>             D-Dimers > reference range, or iv. C-reactive protein (CRP) > 40 milligram per liter<br>             (mg/L).<br><br>          6. Subject (or a legal representative or a nearest relative or a relative by marriage, as<br>             appropriate) provides oral informed consent prior to initiation of any study<br>             procedures.<br><br>        Exclusion criteria:<br><br>          1. Subject requires invasive mechanical ventilation or ICU admission.<br><br>          2. Clinical evidence of any significant acute or chronic disease that, in the opinion of<br>             the investigator may place the subject at undue medical risk.<br><br>          3. The subject has had a known (documented) serious anaphylactic reaction to blood, any<br>             blood-derived or plasma product or commercial immunoglobulin.<br><br>          4. Subject has known (documented) hereditary fructose intolerance (HFI).<br><br>          5. A medical condition in which the infusion of additional fluid is contraindicated.<br><br>          6. Shock that is unresponsive to fluid challenge and/or multiple vasopressors and<br>             accompanied by multiorgan failure considered by the Principal Investigator not able to<br>             be reversed.<br><br>          7. Subject with known (documented) thrombotic complications to polyclonal IVIG therapy in<br>             the past.<br><br>          8. Subject with current or prior (within the past 1 month) myocardial infarction, stroke,<br>             deep vein thrombosis, or thromboembolic event.<br><br>          9. Subject with limitations of therapeutic effort (eg, 'do not resuscitate' status).<br><br>         10. Female subject who are pregnant or of child-bearing potential with a positive test for<br>             pregnancy blood or urine human chorionic gonadotropin (HCG)-based assay at<br>             Screening/Baseline.<br><br>         11. Subject participating in another interventional clinical trial with investigational<br>             medical product or device.<br>",NA,Percentage of Participants Dying or Requiring ICU Admission;Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation,NA,NA,NA,NA,NA,2020-06-12
NCT04342897,https://clinicaltrials.gov/show/NCT04342897,"A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19",COVID-19;Pneumonia,Drug: LY3127804;Drug: Placebo,A Study of LY3127804 in Participants With COVID-19,CT.gov,2020-04-10,2020-04-20,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 2,95,Eli Lilly and Company,United States,FALSE,Yes,10/04/2020,"April 20, 2020",9 November 2020,NA,20200410,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,NA,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",NA,NA,NA,Eli Lilly and Company,"<br>        Inclusion Criteria:<br><br>          -  Are hospitalized with pneumonia, and presumed or confirmed COVID-19<br><br>          -  Are able and willing to give signed informed consent (legally authorized<br>             representative can provide informed consent if needed)<br><br>        Exclusion Criteria:<br><br>          -  Female participants must not be pregnant and/or lactating<br><br>          -  Have Acute Respiratory Distress Syndrome (ARDS) or will require immediate intermittent<br>             mandatory ventilation (IMV), or are ineligible for IMV<br><br>          -  Have any concurrent serious medical condition (for example dialysis) or concomitant<br>             medication that would preclude participation in the study<br><br>          -  Are moribund irrespective of the provision of treatments<br><br>          -  Have a known history or show evidence of human immunodeficiency virus (HIV) and/or<br>             hepatitis<br><br>          -  Have recently undergone major surgery or central venous access device placement<br><br>          -  Have a significant bleeding disorder or active vasculitis<br><br>          -  Have experienced a thromboembolic event<br><br>          -  Have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac<br>             arrhythmia<br><br>          -  Have a serious, nonhealing wound, peptic ulcer, or bone fracture<br><br>          -  Have liver cirrhosis<br><br>          -  Have a known sensitivity to monoclonal antibodies (mAbs) or other therapeutic proteins<br><br>          -  Have a history of hypertensive crisis or hypertensive encephalopathy or current,<br>             poorly controlled hypertension<br>",NA,Number of Ventilator Free Days,NA,NA,NA,NA,NA,2020-04-10
NCT04342728,https://clinicaltrials.gov/show/NCT04342728,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",COVID;Corona Virus Infection,Dietary Supplement: Ascorbic Acid;Dietary Supplement: Zinc Gluconate;Dietary Supplement: Ascorbic Acid and Zinc Gluconate;Other: Standard of Care,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,CT.gov,2020-04-08,2020-04-08,FALSE,Interventional,Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).,N/A,520,The Cleveland Clinic,United States,FALSE,Yes,08/04/2020,"April 8, 2020",24 August 2020,COVIDAtoZ,20200408,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,;,"Milind Desai, M. D.;Suma Thomas",NA,;,;,The Cleveland Clinic;The Cleveland Clinic,"<br>        Inclusion Criteria:<br><br>          -  Outpatients = 18 years presenting to Cleveland Clinic Health System in Ohio and<br>             Florida who test positive for COVID-19 having any of the following symptoms<br><br>               1. Fever or chills<br><br>               2. Shortness of breath or difficulty breathing<br><br>               3. Cough<br><br>               4. Fatigue<br><br>               5. Muscle or body Aches<br><br>               6. Headache<br><br>               7. New loss of taste<br><br>               8. New loss of smell<br><br>               9. Congestion or runny nose<br><br>              10. Nausea<br><br>              11. Vomiting<br><br>              12. Diarrhea<br><br>        Women of child bearing potential:<br><br>          1. have had a menstrual period within the past 30 days, or<br><br>          2. have had previous sterilization, or<br><br>          3. are perimenopausal (less than 1 year) who have a negative pregnancy test, or<br><br>          4. women of childbearing potential who do not meet the above and have a negative<br>             pregnancy test.<br><br>        Exclusion Criteria:<br><br>          -  Patients who are found to be positive during hospitalization<br><br>          -  Patients who reside outside Ohio or Florida.<br><br>          -  Pregnant women:<br><br>               1. Current known pregnancy<br><br>               2. Positive pregnancy test (women of child bearing potential who have not had<br>                  previous sterilization as defined as hysterectomy or tubal ligation)<br><br>          -  Women of childbearing potential who do not meet the above criteria, last menstrual<br>             period greater than 30 days and have a positive pregnancy test.<br><br>          -  Lactating Women<br><br>          -  End stage kidney disease<br><br>          -  Advanced liver disease awaiting transplant<br><br>          -  History of Calcium Oxalate kidney stones.<br>",NA,Symptom Reduction,NA,NA,NA,NA,NA,2020-04-08
NCT04348409,https://clinicaltrials.gov/show/NCT04348409,"Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.",COVID-19,Drug: Nitazoxanide Tablets;Drug: Placebo,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,CT.gov,2020-04-03,2020-05-25,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",N/A,50,Azidus Brasil,Brazil,FALSE,Yes,03/04/2020,"May 25, 2020",22 June 2020,NA,20200403,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,NA,"Florentino de Araujo Cardoso Filho, MD, PhD",NA,florentino.cardoso@hospitalcare.com.br,+55 19 991232882,NA,"<br>        Inclusion Criteria:<br><br>          1. Informed consent from patient or legal representative.<br><br>          2. Male or female, aged = 18 years;<br><br>          3. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase<br>             chain reaction (RT-PCR) from any diagnostic sampling source;<br><br>          4. Signs of respiratory failure requiring oxygen therapy<br><br>          5. Hospitalized for up to 36h with non-invasive ventilation<br><br>          6. Negative result for pregnancy test (if applicable).<br><br>        Exclusion Criteria:<br><br>          1. Participating in another RCT in the past 12 months;<br><br>          2. Known allergy to nitazoxanide<br><br>          3. Severely reduced LV function;<br><br>          4. Severely reduced renal function;<br><br>          5. Pregnancy or breast feeding;<br><br>          6. Use of hydroxychloroquine and/or azithromycin in the past 15 days;<br><br>          7. Any other clinical condition which, in the opinion of the principal investigator,<br>             would not allow safe completion of the protocol and safe administration of the<br>             investigational products<br>",NA,Viral load,NA,NA,NA,NA,NA,2020-04-03
NCT04454307,https://clinicaltrials.gov/show/NCT04454307,Safety and Efficacy of Tramadol Adjuvant Therapy to Standard Care for COVID-19 Egyptian Patients: A Randomized Double Blind Controlled Clinical Trial,COVID-19,Drug: Tramadol;Other: Standard care delivered in the isolation hospitals.,Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients,CT.gov,2020-06-29,2020-07-01,TRUE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",Phase 1/Phase 2,100,Tanta University,NA,FALSE,Yes,29/06/2020,July 2020,13 July 2020,NA,20200629,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,65 Years,All,;,"Nahla Elashmawy, PhD;Nahla Elashmawy, PhD",NA,;nahla.elashmawi@pharm.tanta.edu.eg,;201116721982,Tanta University;,"<br>        Inclusion Criteria:<br><br>          -  Newly diagnosed symptomatic COVID-19 patients with mild to moderate respiratory<br>             manifestations, adults (18-65 Years old), and both sexes.<br><br>        Exclusion Criteria:<br><br>          -  Patients with abnormal liver function (ALT, AST), chronic kidney disease or dialysis<br>             (CrCl< 30 ml/min)<br><br>          -  Pregnant women or women who are breastfeeding<br><br>          -  Immunocompromised patients taking medication upon screening<br><br>          -  Subjects with comorbid condition like hypertension, cardiovascular disease, diabetes<br>             mellites, asthma, COPD, malignancy<br><br>          -  Patients having allergy to Hydroxychloroquine and/or Nitazoxanide<br><br>          -  Patients with contraindication towards the study medication including retinopathy,<br>             G6PD deficiency and QT prolongation.<br>",NA,Number of COVID-19 PCR negative cases,NA,NA,NA,NA,NA,2020-06-29
NCT04452669,https://clinicaltrials.gov/show/NCT04452669,"Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation",COVID-19,Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system),VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,CT.gov,2020-06-29,2020-08-15,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,20,Aerogen Pharma Limited,United States,FALSE,Yes,29/06/2020,"August 15, 2020",10 August 2020,VPCOVID,20200629,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,; ;,"Veronica Franco, MD;Judy R Doto, RN, BSN;Joe Santiago, BS, RRT",NA,;judydoto@aerogenpharma.com;Joseph.santiago@osumc.edu,;4847165438;,Ohio State University;,"<br>        Inclusion Criteria:<br><br>          -  Confirmed COVID-19 positive by RT-PCR test<br><br>          -  Patients who require invasive mechanical ventilation.<br><br>          -  Consent or professional consent obtained<br><br>        Exclusion Criteria:<br><br>          -  Patients on ECMO support.<br><br>          -  Patients receiving another inhalation research medication or inhaled nitric oxide.<br><br>          -  Not expected to survive for 48 hours.<br><br>          -  Allergy to Epoprostenol and its diluent<br>",NA,Reduction in Respiratory Failure;Reduction in Cardiac/Circulatory Failure,NA,NA,NA,NA,NA,2020-06-29
CTRI/2020/10/028277,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47691,"A Double Blind, Multi-Center, Two- Arm, Randomized, Placebo Controlled, Phase III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin Î±-1 (TÎ±1) as an Add on Treatment to Existing Standard of Care Treatment 
in Moderate to Severe COVID-19 Patients

","Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
","Intervention1: Thymosin Î±-1-1.6 mg Injection <br> along with SOC: Each vial contains : Thymosin Alpha 1-1.6mg<br>Excipients...... q.s (Lyophilized)<br>Sterile water for Injections IP 1ml Ampoule<br>Manufactured by: Gufic Biosciences Ltd., India<br>Dose:Thymosin Î±-1-1.6 mg x 2 injections<br>Frequency: Twice daily(Moderate)and Thrice daily (Severe)<br>Route of administration: Subcutaneous <br>Total Duration 7 days<br><br><br>Control Intervention1: Placebo Injection along with SOC: Each vial contains : Excipients...... q.s (Lyophilized)<br>Sterile water for Injections IP 1Ml Ampoule<br>Manufactured by: Gufic Biosciences Ltd., India<br>Dose: Placebo x 2 injections<br>Frequency: Twice daily(Moderate)and Thrice daily (Severe)<br>Route of administration: Subcutaneous <br>Total Duration 7 days<br><br><br>","A study to assess the safety and effectiveness of Thymosin Î±-1 (TÎ±1) used for the treatment of Moderate to severe COVID 19 Patients.

",CTRI,2020-10-07,2020-10-12,FALSE,Interventional,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Centralized  Blinding and masking:Participant, Investigator and Outcome Assessor Blinded",Phase 3,120,Gufic Biosciences,India,FALSE,Yes,07-10-2020,12-10-2020,2 December 2020,NA,20201007,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Mr Vairamuthu Ammaiyappan,NA,4th Floor Ektha Serene located at 103 H  G B and 104  HIG B Survey No 132 APHB Colony Gachibowli,medicalaffairs@guficbio.com,912267261000,Gufic Biosciences Limited,Inclusion criteria: 1.	Male or female of more than or equal to  18 years of age at the time of consent <br/ ><br>2.	Patient who can and willing to provide written Informed Consent <br/ ><br>3.	Patient or patientâ??s LAR understands and is willing to participate in the clinical study and can comply with clinical trial protocol requirements <br/ ><br> <br/ ><br>Inclusion criteria for moderate COVID-19 patients	 <br/ ><br> <br/ ><br>4.	Moderate Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) test or any other confirmatory tests <br/ ><br>5.	Patient with pneumonia with no signs of severe disease <br/ ><br>6.	If the patient presents any one of the following features: <br/ ><br>-	Respiratory rate of more than or equal to â??24 breath per min  <br/ ><br>-	SpO2 (oxygen saturation) more than 90 percent to less than or equal to 94 percentage on room air    <br/ ><br> <br/ ><br>Inclusion criteria for severe COVID-19 patients <br/ ><br> <br/ ><br>7.	Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) test or any other confirmatory tests <br/ ><br>8.	If the patient presents any one of the following features: <br/ ><br>-	respiratory distress with a respiratory rate of more than or equal toâ??30 breath per min <br/ ><br>-	SpO2 (oxygen saturation) less than or equal toâ??90 percentage on room air <br/ ><br>-	PaO2 (arterial blood oxygen partial pressure) or FiO2 (Fraction of Inspired Oxygen) less than or equal toâ??200 mmHg (1 mmHgâ??equal toâ??0.133 kPa)  <br/ ><br>-	Patient presents respiratory failure and requires mechanical ventilation support <br/ ><br> <br/ ><br>,"Exclusion criteria: 1.	Patient who has participated in any other clinical trial of an experimental treatment for COVID-19 <br/ ><br>2.	Patients with the presence of any pre-existing illness that, in the opinion of the investigator, would place the patient at an unreasonably increased risk through participation in this study. <br/ ><br>3.	Patient who has participated in another trial with an investigational drug within 1 month prior to this trial. <br/ ><br>4.	Female patient who is breast-feeding, pregnant, or intends to become pregnant during the study <br/ ><br>5.	Patients who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol <br/ ><br>","1. Incidences of all-cause hospital mortality [Time Frame: From the date of Drug administered until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 28 days]  <br/ ><br>2.Evaluation of Clinical progression/deterioration based on an 8-point ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&D) [time frame up to 7 days] on Day 1, Screening and End of treatment (Day 7) <br/ ><br>Timepoint: 1.Day 1 to Day 28 <br/ ><br>2.Day 1 to Day 7 <br/ ><br>3.From baseline to hospital <br/ ><br>discharge",NA,NA,NA,NA,NA,2020-10-07
CTRI/2020/07/026514,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45580,"A Phase-II, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment  Or Sodium-Copper-Chlorophyllin Plus Standard Treatment  Versus Standard Treatment  in Cancer patients with  SARS-CoV-2 Infection who are Symptomatic Or have Pneumonia for Covid 19.","Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
","Intervention1: Resveratrol-Copper tablets: Patients will be administered orally, tablets of R-Cu containing 5.6 mg of Resveratrol and 560 ng of copper, 1 tablet once every 6 hours, from the date of randomization till the day of discharge, or death, whichever is earlier. They will also receive the Standard Treatment<br>Intervention2: Chlorophyllin tablets: Patients will be administered orally, tablets of chlorophyllin, 1 tablet of 750 mg once every day, on empty stomach in the morning, from the date of randomization till the day of discharge, or death, whichever is earlier. They will also receive the Standard Treatment .<br>Control Intervention1: Standard treatment: Patients in this arm can receive all standard treatment that the treating team considers appropriate including any other antibiotic, antibacterial, antiviral or antimicrobial drugs. However, patients in this arm cannot receive Resveratrol -Copper treatment. The treatment proptocol will be in sync with the emerging scientific evidence and evolving national guidelines<br>",Randomized Controlled Trial Of Resveretrol-Copper OR Sodium-Copper-Chlorophyllin Versus Standard Treatment In Severe Covid-19 Cancer Patients.,CTRI,2020-07-13,2020-07-22,FALSE,Interventional,"Randomized, Parallel Group, Multiple Arm Trial
  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label",Phase 2,200,Tata Memorial Centre,India,FALSE,Yes,13-07-2020,22-07-2020,2 December 2020,NA,20200713,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,VIKRAM GOTA,NA,"Room No.102,Khanolkar Shidhika,
Department of Clinical Pharmacology,
ACTREC,Sector No.22,Kharghar, Navi Mumbai",vikramgota@gmail.com,7715019117,"ACTREC, Tata Memorial Centre","Inclusion criteria: 1.Male and non-pregnant female patients 18 years of age or older. <br/ ><br>2.Positive reverse-transcriptaseâ??polymerase polymerase chain-reaction (RT-PCR) in a diagnostic specimen. <br/ ><br>3.Pneumonia confirmed by chest imaging <br/ ><br>3.Oxygen saturation (Sao2) of 94% or less while they were breathing ambient air  <br/ ><br>4.Either normal levels of haematological, liver and renal functions, and electrolytes OR no worse than Grade 3 (CTCAE Version 5.0) 5.Abnormalities in any of these parameters. <br/ ><br>6.Patients with high blood sugar or glycosylated haemoglobin, of any degree will be eligible. <br/ ><br>7.Arterial blood gas, if done, could have abnormal values of pH, PO2, PCO2 and bicarbonate levels.     <br/ ><br>",Exclusion criteria: Asymptomatic or only mildly symptomatic,"The time to clinical improvement, defined as a 2-point improvement on a 7-point ordinal scale will be the primary endpoint.Timepoint: 10 Days",NA,NA,NA,NA,NA,2020-07-13
CTRI/2020/06/025650,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44412,A Prospective Cohort Interventional Study Assessing the Safety and Outcome of Unani Medicine as a Prophylaxis in Population at risk of COVID-19,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",Intervention1: Joshanda (Decoction) and Khameera Marwareed: Joshanda (Decoction) of the following<br><br>1. Behidana (Cydonia oblonga) 3 gm<br>2. Unnab (Zizyphus jujube)<br>5 in number <br>3. Sapistan (Cordia myxa)<br>9 in numbers<br><br>Dose: 125 ml OD morning<br>Route of Administration: Orally<br><br>and<br><br>Khameera Marwareed<br><br>Dose: 5g OD morning<br>Route of Administration: Orally<br>Control Intervention1: NIL: Subjects not receiving Unani prophylactic regimen<br>,To assess the safety and outcome of herbal medicine in prevention of COVID-19 infection among high risk population,CTRI,2020-06-05,2020-06-15,FALSE,Interventional,"Other
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label",Phase 2,4000,Ministry of AYUSH Government of India,India,FALSE,Yes,05-06-2020,15-06-2020,2 December 2020,NA,20200605,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Prof Abdul Wadud,NA,"Dept. of Ilmul Advia
National Institute of Unani Medicine
Kottigepalya Magadi Main Road
Bangalore",drwadud87@gmail.com,9916608881,National Institute of Unani Medicine,Inclusion criteria: 1. Population as described in High/Moderate/Low Risk <br/ ><br>2. Individuals who are from the identified containment zone/ quarantine facility with at least 1 confirmed COVID-19 positive case. <br/ ><br>3. Subjects who are ready to provide written/digital informed consent and who are willing to participate and follow the protocol requirements of the clinical study <br/ ><br>,"Exclusion criteria: 1. Persons with severe primary respiratory disease or related complications that may be identified with COVID-19 <br/ ><br>2. Laboratory confirmed COVID-19 with or without symptoms <br/ ><br>3. Pregnant and lactating mothers and those who have a pregnancy plan. <br/ ><br>4. Persons with serious critical illness, or severe mental illnesses <br/ ><br>5. Individuals with uncontrolled, unstable co-morbidities  <br/ ><br>6. Immuno-compromised individuals or those on immune-suppressants and steroids  <br/ ><br>7. Subjects having a past history of allergy to any medicine that is part of the Unani intervention","1. Incidence of COVID-19 cases in control as well in interventional group  <br/ ><br>2. Improvement in immune status using Immune Status Questionnaire (ISQ)Timepoint: 0th Day, 10th Day, 20th Day and 35th Day",NA,NA,NA,NA,NA,2020-06-05
CTRI/2020/09/027904,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47392,Autologous whole blood injection as treatment for Covid-19 infection,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",Intervention1: Autologous whole blood injection: 2.5 ml of blood will be drawn from a vein in the cubital fossa with a 20G needle and a 5 ml syringe and the drawn blood will be<br>immediately (within 2 minutes) injected intramuscularly into the gluteal muscle of the same subject (once a day) from whom the blood was drawn on day on Day 1 and Day 3.<br>Control Intervention1: Standard therapy for Covid therapy: Treatment protocol for Covid 19 infection will be followed as per ICMR recommendations<br>,Autologous whole blood injection as treatment for Covid-19 infection,CTRI,2020-09-18,2020-10-02,FALSE,Interventional,"Randomized, Parallel Group Trial
  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label",N/A,60,Dr M Christopher,India,FALSE,Yes,18-09-2020,02-10-2020,2 December 2020,NA,20200918,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr M Christopher,NA,"Shifa Hospitals,
Department of Anesthesiology,
82, Near Junction Flyover,
Kailashapuram Middle Street,
Tirunelveli Junction,
Tirunelveli",dr.judith.chris@gmail.com,9487410467,Shifa Hospitals,"Inclusion criteria: 1) Patients in the age group of 14 years and above <br/ ><br>2) Both male and female patients <br/ ><br>3) Confirmed cases of COVID 19 admitted for treatment in Shifa hospital; COVID positive confirmed by RT-PCR <br/ ><br>4) Presence of IgM antibodies through rapid test kit <br/ ><br>5) Willing to give consent for the study and take part actively <br/ ><br>6) Patients willing to adhere to drugs protocol as per ICMR guidelines/ WHO guidelines <br/ ><br>7) In test arm, patients who are accepting to AWB therapy in addition to standard drugs",Exclusion criteria: 1) Children lesser than 14 years of age <br/ ><br>2) Presence of IgG antibodies through rapid test kit <br/ ><br>3) Patients hypersensitive to blood products or blood transfusion <br/ ><br>4) Any Co-morbid conditions  <br/ ><br>5) Patients who are critically ill are excluded from the study,RT-PCR test turning negative is the end pointTimepoint: 14days,NA,NA,NA,NA,NA,2020-09-18
CTRI/2020/08/027503,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44980,Low Dose Aspirin in Moderate to Severe SARS- CoV-2 Infected Patients: A Pilot Randomized Controlled Trial,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",Intervention1: Aspirin: Low dose aspirin (75 mg OD) for 10 days along with standard of care<br>Control Intervention1: Standard of Care: Standard of care will included standard practice of the institute at that time<br>,Effect of blood thinning medicine in COVID-19 infection,CTRI,2020-08-31,2021-06-15,FALSE,Interventional,"Randomized, Parallel Group Trial
  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Outcome Assessor Blinded",N/A,60,Dr Souvik Maitra,India,FALSE,Yes,31-08-2020,15-06-2021,2 December 2020,NA,20200831,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Souvik Maitra,NA,"Room No: 5011, 5th Floor Teaching Block, All India Institute of Medical Sciences, New Delhi",souvikmaitra@live.com,08146727891,"All India Institute of Medical Sciences, New Delhi",Inclusion criteria: Adult (aged between 18 and 65y) patients with laboratory confirmed SARS- CoV-2 infection with hypoxemia (defined by room air SpO2 â?¤ 94%) at the time of randomization will be included.,"Exclusion criteria: 1.	Refusal to participate <br/ ><br>2.	Mechanically ventilated patients <br/ ><br>3.	Patients with P/F ratio  < 150 mm Hg <br/ ><br>4.	Patients with any known coagulation disorder <br/ ><br>5.	Patients with known platelet function disorder <br/ ><br>6.	Patients who are already on antiplatelet therapy <br/ ><br>7.	Patients with thrombocytopenia (platelet count  < 100,000/ cmm) <br/ ><br>8.	Patients with any previous intracranial pathology <br/ ><br>9.	Patients with known gastric/ duodenal ulcer  <br/ ><br>10.	Patients with history of gastro-intestinal bleeding within 3 months <br/ ><br>11.	Pregnancy women or women who are breastfeeding their children <br/ ><br>12.	Known allergy to aspirin <br/ ><br>",To compare SpO2/ FiO2 ratio in day 1- 7 post randomization in both the groupsTimepoint: day 1- 7 post randomization,NA,NA,NA,NA,NA,2020-08-31
CTRI/2020/07/026789,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45111,"A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiC","Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
","Intervention1: ArtemiC medical spray: ArtemiC is a Oromucosal  medical spray combined of Artemisinin (6 mg/ml), Curcumin (20 mg/ml), Frankincense (15 mg/ml) and vitamin C (60 mg/ml) in spray administration.<br>given as add-on therapy, 2 times a day, on Days 1 and 2.Each dose contains 1ml (10 puffs-pushes on the spray bottle) , total daily dose 2ml (20 puffs- pushes on the spray bottle).The total treatment is 40 puffs for 2 days.<br>Control Intervention1: Placebo: Placebo is a Oromucosal  medical spray will be given as add-on therapy, 2 times a day, on Days 1 and 2.<br>Each dose contains 1ml (10 puffs-pushes on the spray bottle) , total daily dose 2ml (20 puffs- pushes on the spray bottle).The total treatment is 40 puffs for 2 days.<br>",A clinical study to see effect of  ArtemiC in patients with COVID-19,CTRI,2020-07-25,2020-07-31,FALSE,Interventional,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Participant and Investigator Blinded",Phase 2,50,MGC Pharmaceuticals Ltd,India,FALSE,Yes,25-07-2020,31-07-2020,2 December 2020,NA,20200725,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Neeta Nargundkar,NA,"Office No. 02, 03 & 04, 2nd Floor Highland Corporate Center,
Kapurbawdi Junction,
Thane
MAHARASHTRA",drneeta@biospherecro.com,02241006794,Biosphere Clinical Research Pvt.Ltd,"Inclusion criteria: 1. Confirmed SARS-CoV-2 infection. <br/ ><br>2. Hospitalized patient with COVID-19 of moderate stable or worsening severity not requiring ICU admission, and on the other hand not experiencing clinical improvement under ongoing standard care. <br/ ><br>3. Age: 18 years old and above. <br/ ><br>4. Subjects must be under observation or admitted to a controlled facility or hospital (home quarantine is not sufficient). <br/ ><br>5. Ability to receive treatment by spray into the oral cavity","Exclusion criteria: 1. Tube feeding or parenteral nutrition. <br/ ><br>2. Oxygen requirements beyond use of nozzles or simple mask as per score 4 <br/ ><br>3. Respiratory decompensation requiring mechanical ventilation. <br/ ><br>4. Uncontrolled diabetes type 2. <br/ ><br>5. Autoimmune disease. <br/ ><br>6. Pregnant or lactating women. <br/ ><br>7. Need for admission to ICU in the course of the present hospitalization at any time prior to completion of the recruitment to the study. <br/ ><br>8. Any condition which, in the opinion of the Principal Investigator, would prevent full participation in this trial or would interfere with the evaluation of the trial endpoints.","1.Time to clinical improvement, defined as a national Early Warning Score 2 (NEWS2) of â?¤ 2 Maintained for 24 Hours in comparison to routine treatment <br/ ><br>2.Percentage of participants with definite or probable drug related adverse eventsTimepoint: 15 Days",NA,NA,NA,NA,NA,2020-07-25
CTRI/2020/10/028635,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48783,Clinical evaluation of Virunil a standardized ayurvedic herbal compound as an adjuvant in management of COVID-19,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Health Condition 2: J99- Respiratory disorders in diseasesclassified elsewhere
",Intervention1: Virunil 500mg Capsules: 1500mg per day in divided doses (3doses per day) with water.<br>for up to maximum of 10 days. Mode of Administration: Oral<br><br>Control Intervention1: Standard Supportive Care: These patients will be managed by standard supportive care.<br>,use of VIRUNIL an Ayurvedic medicie as a supportive treatment in management of COVID-19.,CTRI,2020-10-26,2020-11-02,FALSE,Interventional,"Randomized, Parallel Group, Active Controlled Trial
  Method of generating randomization sequence:Other  Method of allocation concealment:Alternation  Blinding and masking:Open Label",Phase 2/ Phase 3,150,NRI ACADEMY OF SCIENCES,India,FALSE,Yes,26-10-2020,02-11-2020,2 December 2020,NA,20201026,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr V Siva Prabodh,NA,"VICE PRINCIPAL ACADEMIC SECTION , ROOM NO-3.
NRI Medical College & GH,
CHINNA KAKANI, GUNTUR DISTRICT.",srivatsa.sivakrishna@gmail.com,7075096010,N R I MEDICAL COLLEGE AND GENERAL HOSPITAL,Inclusion criteria: Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF); willingness and capability to complete all the study procedures. <br/ ><br>Patient who are present in the stages of 1 and 2 of the COVID-19 disease.,"Exclusion criteria: 1.	Patients with Auto Immune Disorders. <br/ ><br>2.	Patients with Co morbid conditions such as Diabetes Mellitus and Hypertension. <br/ ><br>3.	Patients Under any kind of Anti-Cancer medication, Immunosuppressants. <br/ ><br>4.	Patients who are under anti-platelet medication. <br/ ><br>5.	Patients with history of Organ Transplantation. <br/ ><br>6.	Patients with compromised pulmonary function. <br/ ><br>7.	Patients receiving antiviral drugs. <br/ ><br>8.	Pregnant and lactating mothers are also excluded from the study. <br/ ><br>9.	Any other condition, where investigators jeopardize the outcomes of the trials <br/ ><br>","The drug may reduce the hospital stay & inflammatory condition of COVID19 patientsTimepoint: At base line, 7th day and 10th day",NA,NA,NA,NA,NA,2020-10-26
CTRI/2020/08/027038,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46197,"A Prospective ,randomized ,double blind,placebo controlled study to access effects of nano ozonized hydrogen peroxide nebulization on results of RTPCR for noval corona virus thus infectivity and clinical course among mild to moderate sick Covid 19 patients HOPE in Covid 19(Hydrogen Peroxide Inhalation).","Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",Intervention1: Triozone: 1 ml of trio zone mixed with 4 ml of normal saline given 3 times a day from nasal route   . a cumulative 5ml  single dose is used for nebulisation by nasal route once a day  .<br>Control Intervention1: Placebo: 5ml of 0.9 % normal saline will be used as placebo given by nasal route . thrice  a day  at same doses of trial drug. Normal saline do not have any effects over virus replication and free of any side effects.<br>,Study  to assess effects of nano ozonised hydrogen peroxide nebulisation on results of RT-PCR for novel corona Virus thus infectivity and clinical course among mild to moderate sick COVID-19 Patients,CTRI,2020-08-07,2020-08-20,FALSE,Interventional,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:On-site computer system  Blinding and masking:Participant and Investigator Blinded",Phase 3,100,SN medical College,India,FALSE,Yes,07-08-2020,20-08-2020,2 December 2020,NA,20200807,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,DrAshish Gautam,NA,Department of Medicine SN Medical College  Raja Mandi near Central library Agra-282003,ppagrawal120@gmail.com,9319250485,S N Medical College,Inclusion criteria: All newly diagnosed patients  <br/ ><br>Not requiring mechanical ventilation <br/ ><br>on oxygen therapy <br/ ><br>Tolerating hydrogen peroxide nebuliser <br/ ><br>Consenting patients <br/ ><br>On same treatment protocol,Exclusion criteria: Patients not giving consent <br/ ><br>Patient not tolerating nebulization,Proportion of patients who turned negative on RT-PCR for for nCOV for two consecutive days.Timepoint: 6 month,NA,NA,NA,NA,NA,2020-08-07
CTRI/2020/09/028088,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47829,"Open Label Randomized trial of Colchicine, Aspirin and Montelukast for prevention of Adult Multisystem Inflammatory Syndrome in SARS-CoV-2 patients - CAM-Covid-19","Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Health Condition 2: J128- Other viral pneumonia
","Intervention1: Colchicine, Aspirin and Montelukast: Intervention: The intervention arm will receive, in addition to the standard of care, the following drugs:<br>	Colchicine - 0.6 mg per oral, 12 hourly till discharge<br>	Aspirin - 325 mg per oral 6 hourly till discharge<br>	Montelukast - 10 mg per oral once a day till discharge<br><br>Control Intervention1: Standard of Care: Standard of Care in Covid-19<br>","Open Label Randomized trial of Colchicine, Aspirin and Montelukast in Covid-19",CTRI,2020-09-28,2020-10-31,FALSE,Interventional,"Randomized, Parallel Group Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label",N/A,34,Vivek Chauhan,India,FALSE,Yes,28-09-2020,31-10-2020,2 December 2020,NA,20200928,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Vivek Chauhan,NA,"Unit 1, Department of Medicine, IGMC SHIMLA",drvivekshimla@yahoo.com,9418341202,IGMC Shimla,Inclusion criteria: Diagnosis of SARS-CoV-2 admitted in our tertiary care hospital in Shimla with an oxygen saturation of  <90% on room air,Exclusion criteria: o	Patients unwilling to provide consent for the drug regimen. <br/ ><br>o	Patients who die within 48 hours of admission in our hospital. <br/ ><br>o	Patients having GFR  < 30 or Severe Asthma or Severe COPD <br/ ><br>,"Primary Outcome: Change in the marker of Adult Multi-system Inflammatory Syndrome i.e. C-reactive Protein <br/ ><br>Secondary Outcomes: Change in other markers of AMIS (Ferritin, D-dimer), Need for Ventilation (invasive or non-invasive), Mortality, Duration of Hospital Stay, Change in CT severity score at 1 month. <br/ ><br>Timepoint: 4 month",NA,NA,NA,NA,NA,2020-09-28
CTRI/2020/06/025998,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44707,To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients: A Double-Blind Randomized Controlled Trial - RNB,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",Intervention1: Raj Nirwan Bati capsule: 1. Mercury (Para)<br>2. Sulphur (Gandhak)<br>3. Gold (Sona)<br>4. Silver (Chandi)<br>5. Clamina Perpeta<br>6. Arsenic Trioxide (Hartal Bhasma)<br>7. Black pepper (Kaali Mirch)<br>8. Naag Damanti (Snake Plant)<br>9. Celery (Azwaiyan)<br>10. Zinc<br>11. Niramish (Mahamash oil)<br><br>One Raj Nirwan Bati capsule of 125 mg (1 Ratti) twice a day empty stomach for 12 days<br>Control Intervention1: Placebo: Sugar gelatin capsule<br>with 4 small balls of sugar <br>twice a day empty stomach for 12 days<br>,Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients,CTRI,2020-06-20,2020-06-30,FALSE,Interventional,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Case Record Numbers  Blinding and masking:Participant and Investigator Blinded",Phase 3,60,Uttar Pradesh University of Medical Sciences,India,FALSE,Yes,20-06-2020,30-06-2020,2 December 2020,NA,20200620,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Raj Kumar,NA,"Uttar Pradesh University of Medical Sciences, Saifai, Etawah",nareshpalsingh@gmail.com,09458641119,Uttar Pradesh University of Medical Sciences,"Inclusion criteria: 1.	RT-PCR confirmed SARS-CoV-2 infected symptomatic patients admitted to the COVID-19 hospital of UPUMS <br/ ><br>2.	Patients falling in mild, moderate and severe category of COVID-19 illness <br/ ><br>3.	Patients more than 18 years of age <br/ ><br>",Exclusion criteria: 1.	All critically ill patients of COVID-19 <br/ ><br>2.	Patients not providing informed written consent for the study <br/ ><br>3.	Pregnant and lactating females <br/ ><br>4.	Patients of Chronic kidney disease (CKD) more than stage three <br/ ><br>5.	Asymptomatic cases <br/ ><br>6.	Study participants becoming critically ill during the course of intervention. <br/ ><br>,"Micro-biologically becoming RT-PCR negative for SARS-CoV-2Timepoint: Micro-biologically RT-PCR results for SARS-CoV-2 shall be evaluated at baseline, day 6 and day 12",NA,NA,NA,NA,NA,2020-06-20
CTRI/2020/07/026471,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45318,"A prospective, non-randomized, single-arm interventional study to assess the safety and efficacy of Siddha Sasthric Medicines â?? Fixed Regimen in the prevention of COVID-19 disease progression of asymptomatic, and mild at Siddha COVID Care Centre, Chennai, 2020 (SSM-FiRe) - SSM-FiRe","Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",Intervention1: Kaba Sura Kudineer: 60ml BD for 14 days<br>Intervention2: Tab. Amukkarachooranam: 2 BD for 14 days<br>Intervention3: Tab. Athimathuram: 2 BD for 14 Days<br>Intervention4: Tab. Brahmanandha Bairavam: 100mg 1BD for 14 days<br>Intervention5: Adathodai Manappagu: 10ml with 30ml water  BD for 14 days<br>Intervention6: Thippili Rasayanam: 5gm BD for 14 days<br>Intervention7: Notchi Kudineer: 60ml BD for 14 Days<br>Control Intervention1: Not Applicable: Not Applicable<br>,A clinical trial to study the effect and safety of the Siddha medicines in patients with Corona Virus disease,CTRI,2020-07-10,2020-07-20,FALSE,Interventional,"Single Arm Trial
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable",Phase 2,60,The Directorate of Indian Medicine and Homoeopathy,India,FALSE,Yes,10-07-2020,20-07-2020,2 December 2020,NA,20200710,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr D Sasikumar,NA,"Research & Development Wing
Directorate of Indian Medicine and Homoeopathy, Arumbakkam, Chennai",siddha2k6@gmail.com,9443579540,Siddha Central Research Institute,"Inclusion criteria: COVID -19 Positive as determined by RT-PCR or other approved commercial or public health assay <br/ ><br>Willing to provide written/digital informed consent. <br/ ><br>COVID - 19 Positive with no clinical signs <br/ ><br>COVID - 19 Positive with mild symptoms â?? Fever, Cough, Sneezing, Sore Throat, Throat Pain, Malaise, Tiredness <br/ ><br>","Exclusion criteria: Pregnant and lactating females  <br/ ><br>COVID - 19 Positive with Severe symptoms â?? Respiratory distress ( >24 breath per minute), Oxygen saturation  <90% at rest, Respiratory failure, Need of Mechanical Ventilation, Septic shock, Non-respiratory organ failure  <br/ ><br>Chronic Renal Failure requiring dialysis (eGFR  < 30) <br/ ><br>Known cases of uncontrolled Diabetes ( >10% HbA1c)  <br/ ><br>Subjects having any medical or surgical condition that would require immediate medical or surgical intervention at the time of screening  <br/ ><br>Subjects having immune-compromised status like HIV, Hepatitis, Tuberculosis, Cancer, etc.   <br/ ><br>Participants taking Steroid treatment and or any kind of immunosuppressive therapy <br/ ><br>Participants participating in any other clinical study or having participated in any other study 1 month prior to screening in the present study.  <br/ ><br>Participants having a past history of allergy to Siddha medicine. <br/ ><br>Participants with Hb -  <7 g/dL",Reduction in incidence of clinical symptoms of COVID-19 or Negative conversion of SARS-CoV-2Timepoint: 14 Days,NA,NA,NA,NA,NA,2020-07-10
EUCTR2020-001511-25-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001511-25,Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19 - COL-COVID,COVID19;Therapeutic area: Body processes [G] - Immune system processes [G12],<br>Trade Name: COLCHICINE<br>Product Name: COLCHIMAX<br>Product Code: M04AX<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: COLCHICINA<br>CAS Number: 64-86-8<br>Other descriptive name: COLCHICINE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: .5-<br><br>,Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19,EUCTR,2020-04-15,2020-04-14,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 2
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",102,FFIS,Spain,FALSE,No,15/04/2020,14/04/2020,20 April 2020,NA,20200415,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,SPONSOR,NA,LUIS FONTES PAGAN 9,Lola.serna@carm.es,34968359763,FFIS,"Inclusion criteria: <br>1.Infection confirmed by SARS-CoV-2 by RT-PCR.<br>2. Hospital admission in the previous 48 hours for clinical involvement in groups 3, 4 or 5 of the WHO clinical scale.<br>3. Age over 18 years.<br>4. Granting of informed consent in writing.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 51<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 51<br>","Exclusion criteria: <br>1. Need for invasive ventilatory support<br>2. Limitation of therapeutic effort due to poor vital prognosis<br>3. Inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption.<br>4. Previous neuromuscular disease<br>5. Different disease with estimated life prognosis less than 1 year.<br>6. Severe kidney failure (glomerular filtration rate <30 mL / m in / 1.73m2)<br>7. History of cirrhosis, active chronic hepatitis, or severe liver disease defined by GOT (AST) or GPT (ALT) values ??that exceed 3 x upper limit of normality<br>8. Patient who is taking colchicine for other indications (mainly chronic prescriptions for family Mediterranean fever or gout) (No washout period will be required for patients who have been treated with colchicine and have stopped treatment before randomization).<br>9. Patient with a history of allergic reactions or significant sensitivity to colchicine.<br>10. Treatment with immunosoppressants, corticosteroids, interleukin-1 antagonists in the 6 months prior to inclusion.<br>11. Pregnant or lactating women, where pregnancy is defined as the state of a woman after conception and until the end of gestation, confirmed by a positive result in the analysis of human chorionic gonadotropin (hCG).<br>12. Fertile, or postmenopausal female patient less than 1 year old, and not surgically sterilized. Women of childbearing potential who are using at least one contraceptive method and preferably two complementary methods of contraception, including a barrier method (male or female condoms, spermicides, sponges, foams, contraceptive gels, diaphragms, intrauterine device) may be included throughout the entire study and up to 30 days after the end of the study.<br>13. Use of other investigational drugs at the time of enrollment, or during the 30 days prior to enrollment.<br>","Timepoint(s) of evaluation of this end point: END OF STUDY;Primary end point(s): 1. Ordinal 7-point clinical evaluation scale (WHO R&D Blueprint expert group (31).<br>2. IL-6 concentrations, which together with the rest of the laboratory result variables will be measured together at the end of the study.;Secondary Objective: 1. Improvement of clinical status defined as time to reduction of at least 2 points on the WHO 7-point ordinal scale.<br>2. Changes in the Sequential Organ Failure Scale (SOFA,) during hospitalization and time to 50% reduction with respect to randomization.<br>3. Changes in NEWS severity scale score (33) during hospitalization and time to NEWS score =2 or 50% reduction from randomization.<br>4. Number of days in invasive mechanical ventilation or ECMO<br>5. Number of days with oxygen at high flow.<br>6. Changes of other inflammatory markers: C-reactive protein, TNF-alpha, GDF-15, IL-1ß up to 28 days with respect to randomization.<br>7. Changes in severity markers: D-dimer, leukocytes, lymphocytes, platelets, LDH and ferritin up to 28 days with respect to randomization.<br>8. Changes in markers of myocardial damage: hsTnT and NT-proBNP up to 28 days with respect to randomization.<br>9. Time to viral negative by RT-PCR<br>10. Duration in days of hospital stay<br>11. ICU income<br>12. Mortality from causes;Main Objective: To study whether the administration of colchicine, compared to a control group, improves the clinical evolution of patients and prevents the inflammatory response.<br>1. Changes in the clinical status of patients on the 7-point ordinal scale (WHO R&D Blueprint expert group) (34) at 7, 14 and 28 days:<br>2. Change in IL-6 concentrations up to 28 days.",NA,NA,NA,NA,NA,2020-04-15
EUCTR2020-004123-16-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004123-16,"A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom","Prevention of COVID-19 caused by SARS-CoV-2 <br>MedDRA version: 23.1
Level: LLT
Classification code 10084465
Term: COVID-19 vaccination
System Organ Class: 100000004865
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",<br>Product Name: SARS-CoV-2 rS with Matrix-M1™ Adjuvant<br>Product Code: NVX-CoV2373<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: SARS-CoV-2 recombinant spike protein (SARS-CoV-2 rS) Drug Substance<br>Other descriptive name: NVX-CoV2373<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>,Study to evaluate the efficacy and safety of a SARS-CoV-2 rS vaccine with Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom,EUCTR,2020-09-11,2020-09-23,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: yes<br>Other trial design description: Observer-Blinded<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",15000,"Novavax, Inc.",United Kingdom,FALSE,Yes,11/09/2020,23/09/2020,3 November 2020,NA,20200911,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,Lakshmi Kumar,NA,21 Firstfield Road,LKumar@Novavax.com,+1540326 5856,"Novavax, Inc.","Inclusion criteria: <br>1. Adult males or females aged 18 to 84 years (inclusive) at screening.<br>2. Able and willing (in the investigator’s opinion) to comply with all study requirements.<br>3. Willing to allow the investigators to discuss the volunteer’s medical history with their General Practitioner and access all medical records when relevant to study procedures.<br>4. Willing and able to give informed consent prior to study enrolment.<br>5. Female participants of childbearing potential (defined as any female who has experienced menarche and who is NOT surgically sterile [i.e., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months or > 1 documented plasma follicle-stimulating hormone level = 40 mIU/mL]) must agree to be heterosexually inactive from at least 28 days prior to enrolment and through 3 months after the last study vaccination OR agree to consistently use any of the following methods of contraception from at least 28 days prior to enrolment and through 3 months after the last study vaccination:<br>a. Condoms (male or female)<br>b. Diaphragm with spermicide<br>c. Cervical cap with spermicide<br>d. Intrauterine device<br>e. Oral or patch contraceptives<br>f. Norplant®, Depo-Provera®, or other in country regulatory-approved contraceptive method that is designed to protect against pregnancy<br>g. Abstinence, as a form of contraception, is acceptable if in line with the participant’s lifestyle (Other approaches to abstinence are not acceptable) <br>NOTE: Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.<br>6. Room air oxygen saturation >95% at Screening/Day 0<br><br>Seasonal Influenza Vaccine Co-Administration Sub-Study Only <br>7. Participant should not have received a current season influenza vaccine, have no contraindication to the specific vaccine to be administered in the study, and no prior history of allergy or severe reaction to seasonal influenza vaccines.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 11250<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 3750<br>","Exclusion criteria: <br>1. Participation in COVID-19 prophylactic drug trials for the duration of the study.<br>2. Future participation in SARS-CoV-2 serological surveys where<br>participants are informed of their serostatus for the duration of the<br>study.<br>3. Participation in research involving an investigational product<br>(drug/biologic/device) within 45 days prior to first study vaccination.<br>4. History of laboratory-confirmed (by PCR or serology to SARS-CoV-2)<br>COVID-19 infection at any time prior to randomisation.<br>5. Administration of immunoglobulins and/or any blood products within the 3 months preceding the planned administration of the study vaccine<br>candidate.<br>6. Any confirmed or suspected immunosuppressive or immunodeficient state; chronic administration (defined as more than 14 continuous days) of immunosuppressant medication within the past 3 months, except<br>topical steroids or short-term oral steroids (course lasting = 14 days).<br>NOTE: An immunosuppressant dose of glucocorticoid is defined as a<br>systemic dose = 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted if other chronic disease conditions are not exclusionary. HIV-positive participants receiving highly active antiretroviral therapy and a history within 6 months of screening of viral load < 1000 copies/mL or CD4 count > 300 cells/mm3 would be eligible.<br>7. History of allergic disease or reactions likely to be exacerbated by any component of the study vaccines.<br>8. Any history of anaphylaxis to any prior vaccine.<br>9. Pregnancy, lactation or willingness/intention to become pregnant within 3 months following the last study vaccination.<br>10. Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ, at the discretion of the investigator).<br>11. Bleeding disorder (e.g., factor deficiency, coagulopathy or platelet<br>disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture.<br>12. Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e., warfarin) or novel oral anticoagulants/anti-platelet<br>agents. (NOTE: The use of = 325 mg of aspirin per day as prophylaxis is<br>permitted)<br>13. Suspected or known current alcohol or drug dependency.<br>14. Study team member or first-degree relative of any study team<br>member (inclusive of sponsor, contract research organisation (CRO), and site personnel involved in the study).<br>15. Participants who are having any current workup of undiagnosed<br>illness within the last 8 weeks that is either participant-reported or has<br>been clinician-assessed, which could lead to a new condition or<br>diagnosis.<br>16. Received any live vaccine within 4 weeks or any vaccine (excluding<br>influenza) within 2 weeks prior to first study vaccination or any licensed influenza vaccine within 1 week prior to first study vaccination or plans to receive any vaccine from these time periods until 28 days after second study vaccination. NOTE: In addition, a licensed seasonal influenza vaccine may be given 7 days after dose 1 and dose 2 but should not be given within 7 days of dose 2.<br>17. Have clinically significant chronic cardiovascular, endocrine,<br>gastrointestinal, hepatic (including hepatitis B and C), renal,<br>neurological, respiratory, psychiatric or other medical disorders not<br>excluded by other exclusion criteria, that are assessed by the investigator as being clinically unstable within the prior 4 weeks as evidenced by:<br>a. Hospitalisation","Timepoint(s) of evaluation of this end point: This will be an event-driven study for the assessment of vaccine efficacy (VE) and will end when a sufficient number of events have been observed, yet all participants will be followed for the entire study duration for safety endpoints.;Primary end point(s): First occurrence of virologically confirmed (by PCR to SARS-CoV-2), symptomatic mild, moderate or severe COVID-19 with onset at least 7 days after second study vaccination (e.g., Day 28) in serologically negative (to SARS-CoV-2) adult participants at baseline until the endpoint-driven efficacy analysis is triggered by the occurrence of a prespecified number of blinded endpoints.<br> ;Secondary Objective: To demonstrate efficacy of the study drug in prevention of virologically confirmed, symptomatic COVID-19, versus placebo, regardless of<br>serostatus at baseline.<br>To assess efficacy of the study drug on:<br> - SARS-CoV-2 seropositive participants requiring specific medical interventions.<br> - mild COVID-19 symptoms.<br> - occurrence of asymptomatic or undetected infections with SARSCoV-2.<br>In a subset of participants, evaluate the immunogenicity of study drug.<br>To evaluate safety in terms of:<br> - SAEs and MAAEs related to study vaccination during entire study.<br> - AESI, which encompasses PIMMCs and AESIs relevant to COVID-19 including possible vaccine-enhanced disease, at any time after the first dose.<br> - All MAAEs for 14 days after second vaccination and unsolicited AEs for 21 days after first and 28 days after second study vaccinations.<br>In a subset, to evaluate safety and reactogenicity in terms of solicited local and systemic AEs for 7 days after each vaccination.;Main Objective: To demonstrate the efficacy of SARS-CoV-2 rS with Matrix-M1 adjuvant in the prevention of virologically confirmed (by polymerase chain reaction [PCR]) to SARS-CoV-2, symptomatic COVID-19, when given as a 2-dose vaccination regimen, as compared to placebo, in serologically negative (to SARS-CoV-2) adult participants.",NA,NA,NA,NA,NA,2020-09-11
EUCTR2020-001498-63-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001498-63,"Adaptive design phase 2 to 3, randomized, double- blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterioration in hospitalized patients with COVID-19 pneumonia (severe stage)","Confirmed infection with SARS-CoV-2 (COVID-19) <br>MedDRA version: 20.0
Level: HLT
Classification code 10047465
Term: Viral infections NEC
System Organ Class: 10021881 - Infections and infestations
 <br>MedDRA version: 23.0
Level: PT
Classification code 10084268
Term: COVID-19
System Organ Class: 10021881 - Infections and infestations
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",<br>Product Name: BIO101<br>Product Code: BIO101<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: NA<br>CAS Number: 5289-74-7<br>Current Sponsor code: BIO101<br>Other descriptive name: 20-hydroxyecdysone<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 175-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>,"Testing the Efficacy and Safety of BIO101, for the Prevention of Respiratory Deterioration, in Patients with COVID-19 Pneumonia (COVA study)",EUCTR,2020-05-03,2020-05-18,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: yes
Other trial design description: placebo-controlled, group sequential and adaptive
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",465,Biophytis S.A.,United States;France;Brazil;Belgium;United Kingdom,TRUE,Yes,03/05/2020,18/05/2020,6 October 2020,NA,20200503,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,Yes,NA,NA,<br>Female: yes<br>Male: yes<br>,Mounia Chabane De Saint Aubin,NA,14 Avenue de l' Opéra,mounia.chabane@biophytis.com,+33(0)144 27 23 87,Biophytis S.A.,"Inclusion criteria: <br>1. Age: 45 and older. <br>2. A confirmed diagnosis of COVID-19 infection, within the last 14 days, prior to randomization, as determined by PCR or other approved commercial or public health assay, in a specimen as specified by the test used.<br>3. Hospitalized, in observation or planned to be hospitalized due to COVID-19 infection symptoms with anticipated hospitalization duration >=3 days<br>4. With evidence of pneumonia based on all of the following:<br>a. Clinical findings on a physical examination<br>b. Respiratory symptoms developed within the past 7 days<br>5. With evidence of respiratory decompensation that started not more than 4 days before start of study medication and present at screening, meeting one of the following criteria, as assessed by healthcare staff:<br>a. Tachypnea: =25 breaths per minute<br>b. Arterial oxygen saturation =92%<br>c. A special note should be made if there is suspicion of COVID-19-related myocarditis or pericarditis, as the presence of these is a stratification criterion<br>6. Without a significant deterioration in liver function tests:<br>a. ALT and AST = 5x upper limit of normal (ULN)<br>b. Gamma-glutamyl transferase (GGT) = 5x ULN<br>c. Total bilirubin = 5×ULN<br>7. Willing to participate and able to sign an informed consent form (ICF).Or, when relevant, a legally authorized representative (LAR) might sign the ICF on behalf of the study participant<br>8. Female participants should be:<br>at least 5 years post-menopausal (i.e., persistent amenorrhea 5 years in the absence of an alternative medical cause) or surgically sterile;<br>OR<br>a. Have a negative urine pregnancy test at screening<br>b. Be willing to use a contraceptive method as outlined in inclusion criterion 9 from screening to 30 days after last dose.<br>9. Male participants who are sexually active with a female partner must agree to the use of an effective method of birth control throughout the study and until 3 months after the last administration of investigational product;<br>Note: medically acceptable methods of contraception that may be used by the participant and/or partner include combined oral contraceptive, contraceptive vaginal ring, contraceptive injection, intrauterine device, etonogestrel implant, each supplemented with a condom, as well as sterilization and vasectomy.<br>10. Female participant who are lactating must agree not to breastfeed during the study and up to 14 days after the intervention.<br>11. Male participants must agree not to donate sperm for the purpose of reproduction throughout the study and until 3 months after the last administration of investigational product;<br>12. For France only: Being affiliated with a European Social Security.<br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 100<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 100<br>","Exclusion criteria: <br>1. Not needing or not willing to remain in a healthcare facility during the entire study medication (i.e. while receiving study medication)<br>2. Moribund condition (death likely in days) or not expected to survive for >7 days – due to other and non-COVID-19 related conditions<br>3. Participant on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ECMO), or high-flow-Oxygen*<br>4. Participant not able to take medications by mouth (as capsules or as a powder, mixed in water).<br>5. Disallowed concomitant medication:<br>a. Consumption of any herbal products containing 20 hydroxyecdysone and derived from Leuzea carthamoides; Cyanotis vaga or Cyanotis arachnoidea is not allowed (e.g. performance enhancing agents)<br>6. Any known hypersensitivity to any of the ingredients, or excipients of the study medication, BIO101<br>7. Renal disease requiring dialysis, or known renal insufficiency (eGFR=30 mL/min/1.73 m2, based on Cockroft & Gault formula)<br>8. In France:<br>o Non-affiliation to compulsory French social security scheme (beneficiary or right-holder)<br>o Being under tutelage or legal guardianship<br>* High-flow oxygen is defined as deliverey of oxygen at a flow =of 16L/min<br>","Main Objective: Part 1<br>• Ascertain the safety and tolerability of BIO101, in order to begin recruitment to part 2<br>• Obtain preliminary indication of activity of BIO101, in preventing respiratory deterioration in the target population<br><br>Part 2<br>• Re-assess the sample size that is needed for the confirmatory part of the study<br>• Provide confirmation on the benefit of BIO101 in the target population<br>• Identify and assess potential biomarkers for further understanding of the effect of BIO101 in the target population<br>;Secondary Objective: Not applicable;Primary end point(s): For end-of-part-1 interim analysis:<br><br>For safety analysis intended to facilitate the decision to begin part 2, time frame – up to 28 days:<br><br>Safety and tolerability to BIO101:<br><br>• SUSARs, SAEs, AESIs, AEs<br>• Vital signs<br>• Safety labs (including testicular biomarkers)<br>• ECGs<br><br>For interim analysis intended to obtain indication of activity of BIO101, time frame – up to 28 days:<br><br>Primary:<br><br>• Proportion of participants with ‘negative’ events, of either of the following: <br>o All-cause mortality<br>o Respiratory failure, defined as any of the following:<br>- Requiring mechanical ventilation (including cases that will not be intubated due to resource restrictions and triage)<br>- Requiring ECMO<br>- Requiring high-flow oxygen <br><br>Secondary:<br><br>• SpO2/FiO2<br>• Inflammatory markers including:<br>o IL 6<br>o TNFa <br>o D-dimer <br>• RAS / MAS biomarkers:<br>o Angiotensin 2<br>o Angiotensin-converting enzyme (ACE) levels<br><br>For part-2 sample size interim analysis:<br><br>For sample size re-assessment for part 2, time frame – up to 28 days:<br><br>• Proportion of participants with ‘negative’ events, of either of the following:<br>o All-cause mortality<br>o Respiratory failure, defined as any of the following: <br>- Requiring mechanical ventilation (including cases that will not be intubated due to resource restrictions and triage)<br>- Requiring ECMO<br>- Requiring high-flow oxygen<br><br>For the final analysis:<br><br>Primary, time frame – up to 28 days: <br><br>• Proportion of participants with ‘negative’ events, of either of the following:<br>o All-cause mortality  <br>o Respiratory failure, defined as any of the following: <br>- Requiring mechanical ventilation (including cases that will not be intubated due to resource restrictions and triage)<br>- Requiring ECMO<br>- Requiring high-flow oxygen<br>;Timepoint(s) of evaluation of this end point: For end-of-part-1 interim analysis:<br>For safety analysis intended to facilitate the decision to begin part 2, time frame – up to 28 days:<br><br>For interim analysis intended to obtain indication of activity of BIO101, time frame – up to 28 days:<br><br>For part-2 sample size interim analysis:<br>For sample size re-assessment for part 2, time frame – up to 28 days:<br><br>For the final analysis:<br>Primary, time frame – up to 28 days: <br>",NA,NA,NA,parent,NA,2020-05-03
EUCTR2020-002037-15-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002037-15,"Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized Patients",SARS-CoV-2 infected patients with pneumonia;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08],<br>Trade Name: Kevzara 200 mg solution for injection in pre-filled syringe<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: SARILUMAB<br>Other descriptive name: SARILUMAB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>,"Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized Patients",EUCTR,2020-05-26,2020-05-25,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",200,Cristina Avendaño Sola,Spain,FALSE,No,26/05/2020,25/05/2020,30 November 2020,NA,20200526,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,Belen Ruiz Antorán,NA,c/ Manuel de Falla 1,mariabelen.ruiz@salud.madrid.org,0034911917479,Hospital Universitario Puerta de Hierro Majadahonda,"Inclusion criteria: <br>Inclusion Criteria<br>1.	Patients willing to provide written informed consent to participate in this study. Witnessed oral consent will be accepted in order to avoid paper handling. Written consent by patient or representatives will be obtained as soon as possible.<br>2.	The patient is at least 18 years of age. <br>3.	The patient is positive for novel coronavirus by real-time RT-PCR<br>4.	The patient is hospitalized for COVID-19 without either mechanical ventilation (invasive or non-invasive) or oxygen mask with reservoir bag and at least one of the following:<br>-Radiographic evidence of pulmonary infiltrates by imaging (chest x-ray, CT scan, etc.), OR clinical assessment (evidence of rales/crackles on exam)<br>- AND SpO2 = 94% on room air that requires supplemental oxygen.<br><br>5.	More than 7 days between the onset of symptoms (fever, dysnea, and/or cough) and treatment administration day. In the absence of fever, cough, or dyspnea, other symptoms like asthenia, headache, or gastrointestinal symptoms may be considered<br>6.	The patients presents progressive elevation of inflammatory parameters suggestive of a hyperinflammatory syndrome:<br>Presence of elevated IL-6 (>40pg/ml) <br>or<br>Elevated d-dimer (>1.0 mcg/ml), or alternatively, progressive worsening in at least two of these inflammatory parameters in the prior 48h: CRP, LDH, serum ferritin, lymphopenia, or d-dimer.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 160<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 40<br>","Exclusion criteria: <br>Exclusion Criteria<br>1.	Requiring mechanical ventilation (invasive or non-invasive) or oxygen mask with reservoir bag at screening.<br>2.	Participation in any other clinical trial of an experimental treatment for COVID-19. <br>3.	In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.<br>4.	Any incompatibility or allergy to the administration of sarilumab or corticosteroids.<br>","Main Objective: To evaluate the efficacy of an early intervention with sarilumab in the prevention of progression to severe respiratory failure/ICU admission or death in SARS-CoV-2 infected patients with pneumonia and regular oxygen supplement requirements -(Brescia-COVID Score= 1).;Secondary Objective: 1.	To assess differences between both strategies in the following: <br>•	Time to respiratory failure<br>•	Time to reduction of supplemental oxygen requirements<br>•	Time to non-invasive or invasive ventilation.<br>•	The duration of hospitalization <br>•	Mortality rate and survival.<br>•	Rate of ICU admission<br><br>2.	To evaluate the efficacy of sarilumab in in COVID-19 infected patients with pneumonia Brescia-COVID- >2 (open-label follow up phase).<br>3.	To evaluate safety of sarilumab treatment in treating patients with COVID-19 pneumonia.<br>4.	To evaluate differences in the effect of sarilumab on the serum levels of inflammatory cytokines.<br>5.	To evaluate differences in the proportion of patients showing more than >1 organ failure, e.g.  cardiovascular, liver and kidney failure<br>6.	To identify prognosis factors of sarilumab efficacy related to laboratory parameters or disease features.;Primary end point(s): The primary endpoint is the proportion of patients progressing to severe respiratory failure (Brescia-COVID Scale =2), ICU admission, or death.;Timepoint(s) of evaluation of this end point: From baseline up to Day-15",NA,NA,NA,NA,NA,2020-05-26
EUCTR2020-001766-11-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001766-11,Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCE,Patients with Covid-19;Therapeutic area: Diseases [C] - Virus Diseases [C02],"<br>Trade Name: LOSARTAN ARROW 50 mg, comprimé pelliculé sécable<br>Product Name: Losartan<br>Product Code: Losartan<br>Pharmaceutical Form: Pillules<br>INN or Proposed INN: LOSARTAN<br>CAS Number: 114798-26-4<br>Current Sponsor code: losartan<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>Trade Name: SPIRONOLACTONE ARROW 25 mg,<br>comprimé pelliculé sécable<br>Product Name: SPIRONOLACTONE<br>Product Code: SPIRONOLACTONE<br>Pharmaceutical Form: Pillules<br>INN or Proposed INN: SPIRONOLACTONE<br>Current Sponsor code: SPIRONOLACTONE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 25-<br><br>",Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit,EUCTR,2020-04-15,2020-04-29,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: group control
Number of treatment arms in the trial: 2
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",90,ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE,France,FALSE,Yes,15/04/2020,29/04/2020,11 May 2020,NA,20200415,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,clinical project manager,NA,"DRS, 80 Rue Brochier",promotion.interne@ap-hm.fr,0491382183,ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE,"Inclusion criteria: <br>Major patient<br>Patient with respiratory distress requiring oxygen support greater than or equal to 6 liters per minute.<br>News-Score greater than 6<br>PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample,<br>Informed Consent<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 45<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 45<br>","Exclusion criteria: <br>Minor patient,<br>Patient deprived of liberty,<br>Patient's refusal to participate in the study,<br>Patient for whom therapeutic limitation measures have been issued justifying the absence of mechanical ventilation,<br>Patient aged 80 or over,<br>Hypotension justifying treatment with noradrenaline,<br>Acute renal failure with a clearance of less than 60ml / min,<br>Severe liver failure.<br>Intolerance or contraindication to losartan or spironolactone.<br>","Main Objective: To show the interest of treatment with losartan and spironolactone in patients infected with COVID-19 and suffering from acute respiratory distress syndrome on the impact of organ failures judged on the SOFA score on the 7th day post-inclusion;Secondary Objective: Show the interest of ARA2 / Spironolactone treatment on organ failures judged on the SOFA score on the 3rd, 14th, 21st, 28th day post-inclusion.<br>Show the interest of ARA2 / Spironolactone treatment on oxygenation based on the PaO2 / FiO2 ratio.<br>Show the interest of ARA2 / Spironolactone treatment for the duration of mechanical ventilation.<br>To show the interest of ARA2 / Spironolactone treatment on mortality.<br>Evaluate the clinical and biological tolerance of these treatments.;Primary end point(s): Organ failures will be assessed on the SOFA score;Timepoint(s) of evaluation of this end point: 7th day post-inclusion",NA,NA,NA,NA,NA,2020-04-15
EUCTR2020-001882-36-GR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001882-36,ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY: THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIAL,"Management of infection by SARS-CoV-2 (COVID-19) <br>MedDRA version: 20.0
Level: LLT
Classification code 10035738
Term: Pneumonia viral NOS
System Organ Class: 100000004862
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",<br>Trade Name: Klaricid<br>Product Name: Clarithromycin<br>Pharmaceutical Form: Tablet<br><br>,CLARITHROMYCIN IN COVID-19,EUCTR,2020-04-30,2020-05-07,FALSE,Interventional clinical trial of medicinal product,"Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",90,Hellenic Institute for the Study of Sepsis,Greece,FALSE,Yes,30/04/2020,07/05/2020,11 May 2020,NA,20200430,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,President of the Board,NA,88 Michalakopoulou Street,insepsis@otenet.gr,+302107480662,Hellenic Institute for the Study of Sepsis,"Inclusion criteria: <br>• Age =18 years<br>• Male of female gender<br>• Written informed consent provided by the patients or by a first-degree relative in case of patients unable to consent<br>• In case of women, unwillingness to remain pregnant during the study period achieved either by their partner using condom or by themselves using oral contraceptives.<br>• Confirmed infection by SARS-CoV-2 virus <br>• Infection of the upper respiratory tract or of the lower respiratory tract<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 45<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 45<br>","Exclusion criteria: <br>• Age below 18 years<br>• Denial of written informed consent<br>• Presence of severe respiratory failure<br>• Intake of any macrolide for the current episode of infection under study<br>• Intake of hydroxychloroquine or chloroquine phosphate.<br>• Oral or intravenous intake of corticosteroids defined as any more than 0.4mg/kg daily intake of equivalent prednisone for the last 3 days<br>• Neutropenia defined as an absolute neutrophil count below 1,000/mm3<br>• Presence of any contraindications for the study drugs as stated in local label information<br>• QTc interval at rest ECG =500 msec or history of known congenital long QT syndrome<br>• Pregnancy or lactation<br>","Main Objective: Recent information appearing from different countries suggest that treatment of Covid-19 with hydroxychloroquine or with a combination of hydroxychloroquine and azithromycin has either an indifferent effect on viral replication or substantial cardiotoxicity. This is a clinical trial aiming to prove that addition of oral clarithromycin to treatment regimen of Covid-19 is associated with early clinical improvement and attenuation of the high inflammatory burden of the host. The study will not comprise a placebo-comparator group since this is considered inappropriate in an era of a pandemic with substantial global mortality.;Secondary Objective: Not applicable;Primary end point(s): This is defined on day 8 (EOT visit). This is a composite score since it is defined differently for patients with upper respiratory tract infection or lower respiratory tract infection by SARS-CoV-2.<br>• For patients with an upper respiratory tract infection this is defined as no need for hospital admission in case of earlier discharge or as lack of progression into lower respiratory tract infection.<br>• For patients with a lower respiratory tract infection this is defined as at least 50% decrease of the score of respiratory symptoms from the baseline. This score is the sum of scoring for the symptoms of cough, dyspnea, purulent sputum expectoration and pleuritic chest pain.<br>Patients who develop by day 8 severe respiratory failure do not meet the study primary endpoint;Timepoint(s) of evaluation of this end point: Day 8",NA,NA,NA,NA,NA,2020-04-30
EUCTR2020-002728-35-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002728-35,"An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia
- An open-label randomized controlled study -
","Patients with new type of coronavirus (SARS-CoV-2) infection proven by RT-PCR test  with mild pneumonia. <br>MedDRA version: 23.0
Level: PT
Classification code 10084268
Term: COVID-19
System Organ Class: 10021881 - Infections and infestations
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",<br>Trade Name: AVIGAN Tablets 200 mg<br>Product Name: AVIGAN<br>Pharmaceutical Form: Tablet<br><br>,Clinical trial of Favipiravir treatment of patients with COVID-19,EUCTR,2020-08-13,2020-09-17,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: Supportive care (symptomatic therapy)<br>Number of treatment arms in the trial: 2<br>","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",150,Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium,Hungary,FALSE,Yes,13/08/2020,17/09/2020,28 September 2020,NA,20200813,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,CRO,NA,Völgy street 41.,krisztina.hracs@adwareresearch.com,+36205967957,AdWare Research Ltd.,"Inclusion criteria: <br>1)	Age: 18 to 74 years (at the time of informed consent)<br>2)	Gender: Male or female<br>3)	Patients who meet all of the following criteria 1), 2), and 3) at the time of enrolment<br>o	Patients with SARS-CoV-2-positive airway specimens such as nasopharyngeal swab, nasal aspirate, or airway aspirate by RT-PCR test<br>o	Patients with new lung lesions on chest images<br>o	Patients with a fever of 37.5°C or more<br>4)	For premenopausal female patients, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug<br>5)	Patients who understand the contents of this study and are able to provide written consent by themselves without assistance, or as appropriate with their assent and consent of their parents<br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 100<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 50<br>","Exclusion criteria: <br>1)	Fever (37.5°C) more than 10 days after the onset of fever<br>2)	Patients with SpO2 less than 95% without oxygen therapy <br>3)	Patients who show increased procalcitonin levels before the start of study drug administration or are suspected to have concurrent bacterial infection<br>4)	Patients with suspected concomitant fungal infections prior to initiation of study drug.<br>5)	Patients with concurrent congestive heart failure (NYHA III-IV)<br>6)	Patients with severe hepatic impairment equivalent to Grade C on Child-Pugh classification<br>7)	Patients with renal impairment requiring dialysis<br>8)	Patients with disturbed consciousness such as disturbed orientation<br>9)	Pregnant or possibly pregnant patients<br>10)	Female patients who are woman of childbearing potential and unable to consent to the use of dual contraception from the start of favipiravir administration to 30 days after the end of favipiravir administration. Dual contraception is a combination of two of the following: Barrier method of contraception: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide; IUD; Hormone-based contraceptive; Tubal ligation.<br>11)	Male patients who are unable to consent to the use of the barrier method of contraception (condom) the start of favipiravir administration to 90 days after the end of favipiravir administration. Male patients who are planning to donate sperm from the start up until 90 days after the end of favipiravir administration. <br>12)	Female patients who intend to breastfeed from the start of favipiravir administration until 7 days after discontinuation of favipiravir administration <br>13)	Patients with hereditary xanthinuria<br>14)	Patients who have previously been diagnosed with hyperuricemia (> 1 mg/dL) or xanthine urinary calculi<br>15)	Patients with a history of gout or on treatment for gout or hyperuricemia<br>16)	Patients receiving immunosuppressants<br>17)	Patients who have received interferon-alpha or drugs with reported antiviral activity against SARS-CoV-2 (hydroxychloroquine sulfate, chloroquine phosphate, lopinavir-ritonavir combination, ciclesonide, nafamostat mesylate, camostat mesylate, remdesivir, etc.) within 9 days after fever onset (37.5°C or more)<br>18)	Patients in whom this episode of infection is a recurrence or a reinfection with the SARS-CoV-2 infection<br>19)	Patients who have previously received favipiravir (T-705a)<br>20)	Other patients judged ineligible by the investigator, sub-investigator, or assigned physician <br><br>","Main Objective: To verify that the efficacy of favipiravir exceeds that of the actual supportive care (symptomatic therapy) in SARS-CoV-2 infected patients (COVID-19 patients) with mild pneumonia, using the time required to improve clinical symptoms as the primary endpoint;Secondary Objective: Not applicable;Primary end point(s): Time to improvement in body temperature, SpO2, chest imaging findings and negative SARS-CoV-2.;Timepoint(s) of evaluation of this end point: Days 4,7,10,13,16,19,22,25,28.",NA,NA,NA,NA,NA,2020-08-13
EUCTR2020-001675-33-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001675-33,"A phase III, randomized, double-blind, placebo-controlled, multicentre, clinical trial to assess the efficacy and safety of VPM1002 in reducing hospital admissions and/or severe respiratory infectious diseases in elderly in the SARS-CoV-2 pandemic by modulating the immune system","infectious respiratory diseases (e.g. COVID-19) <br>MedDRA version: 20.0
Level: HLGT
Classification code 10024970
Term: Respiratory tract infections
System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]",<br>Product Name: VPM1002<br>Pharmaceutical Form: Lyophilisate for suspension for injection<br>INN or Proposed INN: VPM1002<br>Current Sponsor code: VPM1002<br>Other descriptive name: Recombinant Mycobacterium bovis rBCG?ureC::hly; VPM1002<br>Concentration unit: CFU/ml colony forming unit(s)/millilitre<br>Concentration type: range<br>Concentration number: 2000000-8000000<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intradermal use<br><br>,A study to investigate whether vaccination with VPM1002 can reduce elderly people's days with severe respiratory infectious diseases at hospital and/or at home,EUCTR,2020-04-17,2020-05-29,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",2038,Vakzine Projekt Management GmbH,Germany,TRUE,Yes,17/04/2020,29/05/2020,26 October 2020,NA,20200417,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,Yes,NA,NA,<br>Female: yes<br>Male: yes<br>,Clinical Trial Information,NA,Mellendorfer Str. 9,info@vakzine-manager.de,+495111699080,Vakzine Projekt Management GmbH,"Inclusion criteria: <br>1. Male or female adult (= 60 years)<br>2. Subject is contractually capable, able to understand information on study<br>and has signed informed consent sheet<br>3. Subject has access to an internet-enabled electronic device<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 500<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 1538<br>","Exclusion criteria: <br>1. Known active or latent Mycobacterium tuberculosis infection<br>2. Fever (> 38 °C) or respiratory tract infection within the past 24 hours<br>3. Current active viral or bacterial infection<br>4. Expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with = 4 weeks between these vaccinations and the trial vaccination<br>5. Participation in another interventional study within 30 days before screening and during this study<br>6. Known hypersensitivity or allergy to (components of) the VPM1002 vaccine or serious adverse reactions to prior Bacille Calmette-Guérin (BCG) administration<br>7. Severely immunocompromised subjects, including:<br>(a) subjects with known infection by the human immunodeficiency<br>virus (HIV-1);<br>(b) subjects with solid organ transplantation;<br>(c) subjects with bone marrow transplantation;<br>(d) subjects under chemotherapy, immunotherapy, or radiotherapy;<br>(e) subjects with primary immunodeficiency;<br>(f) treatment with any anti-cytokine therapies;<br>(g) treatment with oral or intravenous steroids defined as daily doses<br>of 10 mg prednisone or equivalent for longer than 3 months, or<br>likely use of oral or intravenous steroids in the next 4 weeks;<br>8. History of malignancies, unless the subject has been free of the disease for = 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial<br>9. Previous positive SARS-CoV-2 test result<br>10. Person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator<br>","Main Objective: To assess the reduction of days with severe respiratory infectious diseases at hospital and/or at home in elderly subjects during the pandemic of SARS-CoV-2;Secondary Objective: To assess the reduction of disease severity, the duration of hospital admission, intensive care unit (ICU) admission, or death in elderly subjects during the pandemic of SARS-CoV-2;Primary end point(s): Number of days with severe respiratory disease at hospital and/or at home;Timepoint(s) of evaluation of this end point: From day 0 to day 240",NA,NA,NA,parent,NA,2020-04-17
EUCTR2020-001635-27-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001635-27,"A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.","Hospitalized Moderate and Severe COVID-19 Patients <br>MedDRA version: 20.0
Level: SOC
Classification code 10021881
Term: Infections and infestations
System Organ Class: 10021881 - Infections and infestations
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Product Name: Masitinib<br>Product Code: AB1010<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Masitinib mesilate<br>CAS Number: 790299-79-5<br>Current Sponsor code: AB1010<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Masitinib<br>Product Code: AB1010<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Masitinib mesilate<br>CAS Number: 790299-79-5<br>Current Sponsor code: AB1010<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: Isoquercetin <br>Product Code: IQC950AN <br>Pharmaceutical Form: Capsule, soft<br><br>Trade Name: Plaquenil 200 mg<br>Pharmaceutical Form: Coated tablet<br>CAS Number: 747-36-4<br>Current Sponsor code: SAR321068<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>",Evaluation of a combination of Masitinib and Isoquercetin in the Treatment of Hospitalized COVID-19 Patients.,EUCTR,2020-04-06,2020-05-04,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 2
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",NA,AB Science,France,FALSE,Yes,06/04/2020,04/05/2020,11 May 2020,NA,20200406,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,Alain Moussy,NA,3 avenue George V,DL_MEDICALWRITERS@ab-science.com,033147202311,AB Science,"Inclusion criteria: <br>Participants are eligible to be included in the study only if all of the following criteria apply:<br>1.	Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen < 72 hours prior to randomization.<br>2.	Hospitalized patients<br>3.	Patients not requiring ICU at admission with moderate and severe pneumopathy according to the OMS Criteria of severity of COVID pneumopathy.<br>Moderate cases i.e. cases meeting all of the following criteria:<br>•	Showing fever and respiratory symptoms with radiological findings of pneumonia.<br>•	Requiring between 3L/min and 5L/min of oxygen to maintain SpO2 >97%<br>Severe cases i.e. cases meeting any of the following criteria:<br>•	Respiratory distress (?30 breaths/ min);<br>•	Oxygen saturation=93% at rest in ambient air; or Oxygen saturation =97 % <br>with O2 > 5L/min.<br>•	PaO2/FiO2?300mmHg <br><br>4.	Male or non-pregnant female adult = 18 and < 80 years of age at time of enrolment.<br>5.	Patient with body weight > 45 kg and body mass index (BMI) between 18 and 35 kg/m2 (inclusive).<br>6.	Patient must be able and willing to comply with study visits and procedures.<br>7.	Patient agrees to the collection of oropharyngeal swabs and venous blood per protocol<br>8.	Patient able to understand, sign, and date the written informed consent form at the screening visit prior to any protocol-specific procedures.<br>9.	Patient able to understand the patient card and follow the patient card procedures in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity.<br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 140<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 60<br>","Exclusion criteria: <br>Participants are excluded from the study if any of the following criteria apply:<br>1.	Recent history of severe cardiovascular disease including acute myocardial infarction, unstable angina pectoris, coronary revascularization procedure, congestive heart failure of NYHA Class III or IV, stroke, including a transient ischemic attack, edema of cardiac origin and left ventricular ejection fraction = 50%. <br>2.	Patient who had major surgery within 2 weeks prior to screening visit.<br>3.	Concomitant use of strong inducer of CYP3A4, substrate of CYP3A4 with narrow therapeutic index.<br>4.	Concomitant treatment with anti-viral drugs, anti-interleukins, anti-interleukins receptors, any investigational drugs<br>5.	Patient with concomitant treatment or therapies associated with severe drug-induced skin toxicity.<br>6.	Pregnancy and lactation.<br>7.	Patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication:<br>•	Absolute neutrophils count (ANC) = 1.5 x 109/L <br>•	Haemoglobin = 10 g/dL <br>•	Platelets (PLT) = 100 x 109/L <br>•	Albuminemia = 1 x LLN <br>8.	Patient with any condition that the physician judges could be detrimental to patient participating in this study, including any clinically important deviations from normal clinical laboratory values or concurrent medical conditions.<br><br>","Main Objective: To compare the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients<br>;Secondary Objective: Secondary objectives are to assess the safety and efficacy of the combination of Masitinib and Isoquercetin in the patients under study by evaluating various parameters related to clinical status.  ;Primary end point(s): •	Clinical status of patients at day15 using the 7-point ordinal scale.<br><br>The 7-point ordinal scale for clinical status is: 1. Not hospitalized, no limitations on activities; 2.Not hospitalized, limitation on activities; 3. Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalized, on invasive mechanical ventilation or ECMO; 7. Death.<br>;Timepoint(s) of evaluation of this end point: Day 15",NA,NA,NA,NA,NA,2020-04-06
EUCTR2020-001321-31-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001321-31,"Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUF",Pneumonia due to SARS Cov2 (COVID-19);Therapeutic area: Diseases [C] - Virus Diseases [C02],<br>Trade Name: Dolquine<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: Dolquine<br>CAS Number: 747-36-4<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Trade Name: Kaletra versus Aluvia<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: RITONAVIR<br>CAS Number: 155213-67-5<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>INN or Proposed INN: LOPINAVIR<br>CAS Number: 192725-17-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>Trade Name: Imatinib<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: Imatinib<br>CAS Number: 152459-95-5<br>Other descriptive name: IMATINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 400-300<br><br>Trade Name: Olumiant<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: BARICITINIB<br>Other descriptive name: Olumiant<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 4-2<br><br>,Clinical trial phase II to evaluate the efficacy of  3 types of treatment in patients with pneumonia by COVID-19,EUCTR,2020-04-13,2020-04-11,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: No comparator
Number of treatment arms in the trial: 3
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",165,Hospital Universitario de Fuenlabrada,Spain,FALSE,No,13/04/2020,11/04/2020,20 April 2020,NA,20200413,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,Comisión de Investigación,NA,Calle Camino del Molino 2,fernando.bermejo@salud.madrid.org,34916006000,Hospital Universitario de Fuenlabrada,"Inclusion criteria: <br>i. Signed informed consent form<br>ii. =18 years<br>iii. Confirmed diagnosis Pneumonia Covid19 +<br>iv. ECOG functional state 0 or 1<br>v. Less than 7 days from onset of symptoms<br>saw. NO contraindication for medication<br>vii. ECG QT <0.4<br>viii. Adequate liver, kidney and hematological function (or within the safety range to use these drugs)<br>1. Absolute granulocyte count> 1.5 x 109 / L<br>2. Absolute platelet count> 100 x 109 / L<br>3. Hb> 10 g / dL<br>4. Cr <1.5 mg / dL or Clearance> 50mL / min<br>5. Bilirubin <3 ULN<br>6. AST / ALT = 2.5 times ULN<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 80<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 85<br>",Exclusion criteria: <br>i. No Covid confirmation<br>ii. No pneumonia<br>iii. Previous treatment with any of the study drugs<br>iv. Concomitant serious medical condition<br>1. ICC<br>2. IAM 6 months prior<br>3. Unstable Angina<br>4. Cardiomyopathy<br>5. Unstable Ventricular Arrhythmia<br>6. uncontrolled HTA<br>7. Uncontrolled psychotic disorders<br>8. Serious active infections<br>9. HIV<br>10. Active hepatitis<br>11. Neoplasia in active cancer treatment<br>v. Inability to take oral medication or malabsorption syndrome<br>saw.<br>vi. Inability to comply with study and follow-up procedures<br>vii. History of only relevant thromboembolic or hemorrhagic episodes in the last 6 months<br>viii. Contraindication to any study medication<br>ix. Pregnant women<br>,"Timepoint(s) of evaluation of this end point: Baseline, 7 days during treatment, day 14, day 35+/-5 and day 70+/-5;Primary end point(s): 8.1 Demographics<br>Age<br>Sex<br>Tobacco<br>Alcohol<br>Significant comorbidity<br>- HTA<br>- Cardiovascular disease<br>- DM<br>- COPD<br>- Cancer<br>- Chronic liver disease<br>- I kidney<br>- Known immunosuppression<br><br>8.2 Laboratory parameters<br>COVID BIOMARKERS<br>- PCR<br>- Procalcitonin<br>- LDH<br>- Dimero D<br>-	Ferritin<br>- IL6<br>BIOCHEMICAL PARAMETERS<br>- Enzymatic creatinine<br>- ALT<br>- AST<br>- Bilirubin<br>- GGT<br>- F Alkaline<br>- Albumine<br>- Venous lactate<br>- Ultrasensitive Troponin I<br>- Creatin Kinasa (CK)<br><br>HEMATOLOGICAL PARAMETERS<br>- White Series<br>- Leukocytes (in absolute value)<br>- Neutrophils (in absolute value)<br>- Lymphocytes (in absolute value)<br>- Neutrophil / lymphocyte ratio<br>- Platelet / lymphocyte ratio<br>- Red Series<br>- erythrocytes<br>- Hb<br>- Platelets<br>- Coagulation<br>- Fibrinogen<br>- Coagulation Study<br><br>MICROBIOLOGICAL PARAMETERS<br>- SARS-Cov2 PCR in nasopharyngeal exudate<br><br>8.3 Radiodiagnosis<br>- Unilateral, unilobar, bilobar pneumonia ...<br>- Bilateral pneumonia<br>- Resolution infiltrators<br>- Infiltration resolution days<br>- Stabilization<br>- Radiological progression<br><br>8.4 Clinical variables<br>- Symptom onset days<br>- Days resolution symptoms<br>- Fever days<br>- Respiratory improvement (days)<br>- Temperature (<38.4 / 38.4-39.4 /> 39.4) * From The The Hscore11<br>- Organomegaly (No, liver or spleen, both) * From The Hscore11<br>-	Fever<br>-	Dry cough<br>- productive cough<br>- Hemoptysis<br>- dyspnea<br>- Asthenia<br>- Myalgia<br>- headache<br>- nausea<br>Vomiting<br>-	Diarrhea<br>- Abdominal discomfort<br>- ARDS<br>- I cardiac<br>- FRA<br>- SHOCK<br>- death<br>- Secondary infection<br>- O2 saturation levels.<br>- Need O2, nasal goggles, liters VM non-invasive reservoir Intubation<br><br>8.5 Clinical management variables<br>-	Hospital stay<br>- ICU admission<br>- No. of registrations;Secondary Objective: To assess the safety (serious adverse effects, premature discontinuation of treatment), tolerability and secondary efficacy parameters of the 3 treatment guidelines, understood as: absence of progression to respiratory failure, absence of increased O2 requirements; need for mechanical ventilation; reduction of analytical parameters associated with poor prognosis; radiological progression of the disease on day + 7 of starting treatment; average hospital stay, intensification treatments, such as steroid boluses and tocilizumab, ICU admission,% mortality at the end of follow-up.<br>In addition, in those patients who consent and participate in an additional sub-study, possible biomarkers and genetic markers of susceptibility to SARS-CoV-2 will be evaluated using high-performance techniques with serum DNA from the participants.;Main Objective: To compare and evaluate the efficacy of 3 treatment regimens (Hydroxychloroquine in combination with baricitinib, imatinib or lopinavir / ritonavir) in SARS-CoV-2 patients with severe pneumonia requiring admission, considering primary efficacy as time to clinical improvement.",NA,NA,NA,NA,NA,2020-04-13
EUCTR2020-002668-29-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002668-29,"A Randomised Controlled Trial of plasma exchange with standard of care compared to standard of care alone in the treatment of severe COVID-19 infection (COVIPLEX)

 - PEX in severe COVID-19","COVID-19;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]",<br>Trade Name: OctaplasLG<br>Product Name: OctaplasLG<br>Pharmaceutical Form: Solution for infusion<br><br>,plasma exchange in severe COVID-19 infection,EUCTR,2020-06-10,2020-06-25,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: standard of care<br>Number of treatment arms in the trial: 2<br>","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",40,University College London,United Kingdom,FALSE,Yes,10/06/2020,25/06/2020,27 July 2020,NA,20200610,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,NA,NA,NA,NA,NA,NA,"Inclusion criteria: <br> <br>•	Age 18-70<br>•	Proven Covid-19/high clinical suspicion of Covid-19<br>•	Hypoxia/respiratory compromise defined as requiring respiratory support of >2L/min of oxygen by nasal cannulae to maintain SpO2<96%. <br>•	Raised inflammatory parameters: at least 2 of the following: <br>a.	Raised LDH  (> 2 x ULN)<br>b.	Raised D Dimers (> 2X ULN)<br>c.	Raised CRP (>2X ULN)<br><br>• Females of childbearing potential have a negative pregnancy test within 7 days prior to being randomised.  Participants are considered not of child bearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal<br><br><br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: 0<br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 20<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 20<br>",Exclusion criteria: <br>•        Significant co-morbid illness with treatment escalation limited to CPAP<br>•	Active bleeding<br>•	PF ratio < 100 on mechanical ventilation OR noradrenaline  requirement > 0.5mcg/kg/min to maintain MAP > 65mmHg (suggests futility)<br>•	Pregnancy<br>•	Known allergies to Octaplas or excipients<br>,"Timepoint(s) of evaluation of this end point: These parameters will be analysed at the beginning of the trial to assess eligibility and at the end when all the data has been collected;Primary end point(s): To compare the  reduction in inflammatory markers between Plasma Exchange (PEX) and the control group in patients with severe COVID;Secondary Objective:  <br><br>Among patients requiring CPAP/ NIV at treatment onset, the ability to prevent deterioration to requiring mechanical ventilation<br><br>Reduction in clinical thrombotic events documented by DVT, or arterial thrombus (cardiac, neurological and peripheral vascular) <br><br>Reduction in the inflammatory-thrombotic response by monitoring VWFAg/ADAMTS 13 activity ratio by 50% from baseline pre PEX to the end of treatment.<br><br>Stable cardiac function throughout period of PEX based on echocardiogram/troponin/BNP measurements<br><br>28 day mortality<br><br>;Main Objective: Compare reduction in inflammatory markers between PEX and a control group in patients with severe COVID",NA,NA,NA,NA,NA,2020-06-10
EUCTR2020-001296-33-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001296-33,"Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial","COVID-19 induced respiratory failure <br>MedDRA version: 20.0
Level: LLT
Classification code 10038696
Term: Respiratory failure (excl neonatal)
System Organ Class: 100000004855
 <br>MedDRA version: 20.0
Level: LLT
Classification code 10040050
Term: Sepsis NOS
System Organ Class: 100000004862
;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]",<br>Trade Name: Ilomedin<br>Product Name: Ilomedin<br>Pharmaceutical Form: Concentrate and solvent for solution for infusion<br>INN or Proposed INN: Iloprost<br>CAS Number: 78919-13-8<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,"Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial",EUCTR,2020-04-03,2020-05-06,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",80,"Section for Transfusion Medicine, Capital Region Blood bank, Copenhagen University Hospital",Denmark,FALSE,Yes,03/04/2020,06/05/2020,2 June 2020,NA,20200403,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,Kristine Pedersen,NA,Blegdamsvej 9,kristine.holst.pedersen.01@regionh.dk,+4535453489,"Section for Transfusion Medicine, Capital Region Blood Bank, Copenhagen University Hospital","Inclusion criteria: <br>Adult intensive care patients (aged 18 years or above)<br>Confirmed COVID-19 infection<br>Need for mechanical ventilation (< 72 hours)<br>Endothelial biomarker (sTM) = 4 ng/mL<br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 25<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 55<br>","Exclusion criteria: <br>Pregnancy (non-pregnancy confirmed by patient being postmenopausal (age 60 or above) or having a negative urine- or plasma-hCG) <br>Known hypersensitivity to iloprost or to any of the other ingredients.<br>Consent cannot be obtained<br>Previously included in this trial or a prostacyclin trial within 30 days<br>Withdrawal from active therapy <br>Life-threatening bleeding defined by the treating physician<br>Known severe heart failure (NYHA class IV)          <br>Suspected acute coronary syndrome<br><br>",Timepoint(s) of evaluation of this end point: Day 28;Primary end point(s): Days alive without mechanical ventilation in the ICU at day 28;Secondary Objective: Not applicable;Main Objective: The primary objective is to investigate whether continuous infusion of iloprost at a dose of 1 ng/kg/min for 72-hours reduces the severity of respiratory failure in the ICU as compared to placebo.,NA,NA,NA,NA,NA,2020-04-03
EUCTR2020-001310-38-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001310-38,"A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 - Convalescent Plasma against COVID-19","Patients with SARS-CoV-2 infection and:
1.	age = 18 years and = 75 years
2.	SARS-CoV-2 infection confirmed by PCR (BAL, sputum, nasal and/or pharyngeal 
                    swap)
3.	severe disease defined by at least one of the following:
  a.	respiratory rate = 30 breaths / minute under ambient air
  b.	requirement of any type of ventilation support
  c.	needs ICU treatment
 <br>MedDRA version: 20.1
Level: LLT
Classification code 10047475
Term: Viral pneumonia, unspecified
System Organ Class: 100000004862
 <br>MedDRA version: 23.0
Level: LLT
Classification code 10070267
Term: SARS virus test positive
System Organ Class: 100000004848
 <br>MedDRA version: 20.0
Level: LLT
Classification code 10021433
Term: Immunization
System Organ Class: 100000004865
 <br>MedDRA version: 21.1
Level: LLT
Classification code 10054540
Term: Passive immunization
System Organ Class: 100000004865
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Trade Name: Fresh frozen plasma (FFP) with marketing authorisation in Germany issued by PEI<br><br>Product Name: For example ""Gefrorenes Frischplasma / Apherese DRK Blutspendedienst""<br>Pharmaceutical Form: Solution for infusion<br><br>",Clinical Study to assess positive value of blood plasma from donors having built immunity against the new corona virus (SARS-CoV-2) transfused to patients suffering from SARS-CoV-2 infection,EUCTR,2020-03-31,2020-04-06,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: yes
Other trial design description: Cross-over allowed for patients with progressive COVID-19
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: Best supportive care
Number of treatment arms in the trial: 2
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",120,DRK-Bluspendedienst Baden-Württemberg - Hessen gGmbH,Germany,TRUE,Yes,31/03/2020,06/04/2020,30 November 2020,NA,20200331,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,Yes,NA,NA,<br>Female: yes<br>Male: yes<br>,Sixten Körper,NA,Helmholtzstr. 10,s.koerper@blutspende.de,0049731150519,IKT Ulm,"Inclusion criteria: <br>Patients with SARS-CoV-2 infection and:<br>1.	age = 18 years and = 75 years<br>2.	SARS-CoV-2 infection confirmed by PCR (BAL, sputum, nasal and/or pharyngeal <br>                    swap)<br>3.	severe disease defined by at least one of the following:<br>  a.	respiratory rate = 30 breaths / minute under ambient air<br>  b.	requirement of any type of ventilation support<br>  c.	needs ICU Treatment<br>4.                 Written informed consent by patient or legally authorized representative<br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 88<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 32<br>","Exclusion criteria: <br>1.	Accompanying diseases other than COVID-19 with an expected survival time of <br>                    less than 12 months<br>2.	In the opinion of the clinical team, progression to death is imminent and <br>                    inevitable within the next 48 hours, irrespective of the provision of treatment<br>3.	Interval > 72 hours since start of ventilation support<br>4.	Not considered eligible for extracorporeal oxygenation support  (even in case of <br>                     severe ARDS according to Berlin classification with Horovitz-Index < 100 mg Hg) <br>5.	Chronic obstructive lung disease (COPD), stage 4<br>6.	Lung fibrosis with UIP pattern in CT and severe emphysema<br>7.	Chronic heart failure NYHA = 3 and/or pre-existing reduction of left ventricular <br>                    ejection fraction to = 30%<br>8.	Cardiovascular failure requiring = 0.5 µg/kg/min noradrenaline (or equivalent) or <br>                     requiring more than two types of vasopressor medication<br>9.	Liver cirrhosis Child C<br>10.	Liver failure: Bilirubin > 5 x ULN and elevation of ALT or AST (> 10 x ULN)<br>11.	Any history of adverse reactions to plasma proteins<br>12.	Known deficiency of immunoglobulin A<br>13.	Pregnancy<br>14.	Breastfeeding women<br>15.	Volume overload until sufficiently treated<br>16.	Pulmonary edema<br>17.	Participation in another clinical trial for treatment of COVID-19<br><br>","Main Objective: To improve survival <br><br>AND<br><br>remove criteria of severe COVID-19 (CoV-2 infection) within 21 days after randomization;Secondary Objective: - Time to clinical improvement on WHO R&D Blueprint seven-category ordinal scale by 2 <br>- Adverse events <br>- Case fatality rate on days 21, 35 and 60<br>- Length of hospital stay<br>- Length of ICU stay <br>- Duration of ventilation Support / ECMO<br>- Time until negative SARS-CoV-2 PCR<br>- Predictive value of comorbidities and inflammation markers <br>- Feasibility of collection of plasma units <br>- Kinetics of anti-SARS-CoV-2 antibodies in plasma of patients = plasma donors who recovered <br>   from a SARS-CoV-2 infection<br>- Titer of anti-SARS-CoV-2 in transfused plasma units<br>- Impact of donor characteristics on anti-SARS-CoV-2 humoral response<br>- Course of anti-SARS-CoV-2 titer in patients <br>- Effect of timing of plasma transfusions on outcome<br>;Primary end point(s): Composite endpoint of:<br><br>- Survival <br><br>AND<br><br>- no longer fulfilling criteria of severe COVID-19 within 21 days after randomization<br><br>All criteria must be met in order to fulfill the primary endpoint.<br>;Timepoint(s) of evaluation of this end point: Treatment group: Day 21<br><br>Control group: Days 14 and 21",NA,NA,NA,parent,NA,2020-03-31
EUCTR2020-002225-29-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002225-29,Evaluation of the effects of bradykinin antagonists on pulmonary manifestations of COVID-19 infections.,"COVID positive patients with respiratory impairment <br>MedDRA version: 23.1
Level: LLT
Classification code 10084437
Term: COVID-19 PCR test positive
System Organ Class: 100000004848
 <br>MedDRA version: 23.1
Level: PT
Classification code 10084460
Term: COVID-19 treatment
System Organ Class: 10042613 - Surgical and medical procedures
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Trade Name: BERINERT<br>Pharmaceutical Form: Concentrate and solvent for solution for injection/infusion<br>INN or Proposed INN: C1-esterase inhibitor, human<br>Other descriptive name: C1 ESTERASE INHIBITOR (HUMAN)<br>Concentration unit: U unit(s)<br>Concentration type: equal<br>Concentration number: 2000-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>Trade Name: FIRAZYR<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: ICATIBANT<br>CAS Number: 138614-30-9<br>Other descriptive name: ICATIBANT ACETATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 30-<br>Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>Route of administration of the placebo: Subcutaneous use<br><br>",Evaluation of the effects of bradykinin antagonists on pulmonary manifestations of COVID-19 infections.,EUCTR,2020-04-30,2020-11-12,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: yes
Other: no
Number of treatment arms in the trial: 3
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",45,Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche,France,FALSE,Yes,30/04/2020,12/11/2020,16 November 2020,NA,20200430,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,SAHBANE,NA,114 AVENUE CHARLES DE GAULLE,s.sahbane@vivactis-m2research.com,+330170922454,VIVACTIS M2RESEARCH,"Inclusion criteria: <br>- Patient over 18 years of age, having read and signed the informed consent form for participation in the study after a reflection period (= 15 minutes)<br>- Patient screened for COVID+ by RT-PCR on nasopharyngeal swab <br>- Patient with at least three of the following respiratory signs:<br>o   Temperature >38° C<br>o   Non-productive dry cough<br>o   Presence of crackling rales at auscultation<br>o   Respiratory discomfort felt by the patient <br>o   Heart rate > 90/min <br>o   Respiratory rate >20/min <br>o   O2 saturation = 93%<br>- Patient whose clinical condition, in the opinion of the investigator, requires hospital monitoring.<br>- Patient who would have been monitored and treated outside of study participation, including prevention of thromboembolic risk with LMWH. <br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 10<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 35<br>","Exclusion criteria: <br>- Patient with pre-existing respiratory disease (cancer, COPD, asthma, emphysema) or smoking history of > 25 years)<br>- Patient with a known allergy to one of the study products<br>- Patient treated with anti TNF, IL1 or IL6<br>- Patient requiring immediate intubation<br>- Patient on a low sodium diet<br>- Patient under protective custody, guardianship or trusteeship<br>- Patient not affiliated to the French social security system<br>- Patient participating in another therapeutic protocol <br>- Patient pregnant or likely to become pregnant (woman of childbearing age without effective contraception and without HCG dosage)<br>- Patient unable to understand information and/or give written informed consent: dementia, psychosis, consciousness disorders, non-French speaking patient<br>","Timepoint(s) of evaluation of this end point: total number of evaluations = 11 <br>(H0, H4, H12, H24, H36, H48, H60, H72 and H96, follow up: D7 and D10) ;Primary end point(s): Therapeutic success will be assessed at each evaluation. It is defined by the presence of all of the following 4 criteria during two successive examinations with stable results at 72 hours: Absence of respiratory discomfort + Heart rate between 60 and 90 /min + Respiratory rate less than 20/min + Saturation without external O2 greater than 95%.<br><br>Failure to meet one of the above criteria at h72 and/or h96 defines a therapeutic failure, and imposes a change in medical care.;Secondary Objective: -Describe the effect of treatments on C1 inhibitor activity and kinin metabolism <br>-Describe the effect of treatment on the cytokine imbalance induced by the infection. <br>-Evaluate individual factors and genetic enzyme factors that may be considered predictive of a therapeutic response.<br>-Evaluate the tolerance of the study products;Main Objective: To evaluate the efficacy of human C1 inhibitor, administered alone or in combination with icatibant (specific bradykinin B2 receptor antagonist) on the pulmonary manifestations of COVID-19 infections.",NA,NA,NA,NA,NA,2020-04-30
EUCTR2020-003368-24-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003368-24,"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19 - MK-4482 Ph 2/3 Study in Non-Hospitalized Adults with COVID-19","COVID-19 <br>MedDRA version: 23.0
Level: LLT
Classification code 10084382
Term: Coronavirus disease 2019
System Organ Class: 100000004862
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Product Name: MK-4482<br>Product Code: MK-4482<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: MK-4482<br>CAS Number: 2349386-89-4<br>Current Sponsor code: MK-4482<br>Other descriptive name: [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>",MK-4482 Ph 2/3 Study in Non-Hospitalized Participants with COVID-19,EUCTR,2020-09-21,2020-10-05,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",1450,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",United States;Philippines;Spain;Ukraine;Chile;Israel;Russian Federation;Colombia;United Kingdom;Italy;France;Mexico;Canada;Brazil;South Africa;Germany;Sweden,TRUE,Yes,21/09/2020,05/10/2020,16 November 2020,NA,20200921,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,Yes,NA,NA,<br>Female: yes<br>Male: yes<br>,Tayeb Naveed,NA,"2 Pancras Square, Kings Cross",tayeb.naveed@msd.com,NA,Merck Sharp & Dohme (UK) Limited,"Inclusion criteria: <br>1. Has documentation of PCR-confirmed SARS-CoV-2 infection with sample collection =7 days prior to randomization.<br>2. Has initial onset of signs/symptoms attributable to COVID-19 for =7 days prior to randomization and at least 1 of the following signs/symptoms attributable to COVID-19 on the day of randomization:<br>-Cough<br>-Sore throat<br>-Nasal congestion<br>-Runny nose<br>-Shortness of breath or difficulty breathing<br>-Muscle or body aches<br>-Fatigue<br>-Fever 38.0?C<br>-Chills<br>-Headache<br>-Nausea<br>-Vomiting<br>-Diarrhea<br>-Loss of smell<br>-Loss of taste<br>3. Has mild or moderate COVID-19; participants with mild COVID-19 must have at least 1 characteristic or underlying medical condition associated with an increased risk of severe illness from COVID-19.<br>4. Has oxygenation saturation of >93% (on room air OR on supplemental oxygen prior to randomization which has not increased since onset of COVID-19 signs/symptoms) obtained at rest by study staff at randomization.<br>5. Is willing and able to take oral medication.<br>6. Is male or female =18 years of age, at the time of providing informed consent.<br>7. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of study intervention:<br>• Refrain from donating sperm<br>PLUS either:<br>• Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent<br>OR<br>• Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause) as detailed below:<br>Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant. <br>• Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.<br>8. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:<br>• Is not a WOCBP<br>OR<br>• Is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), during the intervention period and for at least 7 months after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention.<br>• A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention.<br>• The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.<br>• Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.<br>• If contraceptives are interrupted as standard of care management of COVID-19 patients and resumed at a later time point, such as at hospital discharge, then abstinence must be practiced for the defined period of back-up contraception per the contraceptive product labeling. After this period, contraceptive use must","Exclusion criteria: <br>1. Is currently hospitalized or is expected to need hospitalization for COVID-19 within 48 hours of randomization.<br>2. Is on dialysis or has reduced eGFR <30 mL/min/1.73 m2 (by the MDRD equation).<br>3. Has any of the following conditions:<br>-HIV with a recent viral load >50 copies/mL or CD4 <200 cell/mm³<br>-Chemotherapy required within 6 weeks before randomization<br>-A neutrophilic granulocyte absolute count <500/mm3<br>-Autologous or allogeneic hematopoietic stem cell transplant recipient<br>4. Has an active diagnosis of hepatitis due to any cause, including active HBV infection (defined as HBsAg-positive) or HCV infection (defined as detectable HCV RNA).<br>5. Has a platelet count <100,000/µL or received a platelet transfusion in the 5 days prior to randomization.<br>6. Has a history of acute pancreatitis within 3 months prior to randomization or a history of chronic pancreatitis.<br>7. Has a baseline heart rate of <50 beats per minute at rest.<br>8. Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator.<br>9. Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to:<br>-Participants who are not expected to survive longer than 48 hours after randomization, or<br>-Participants with a recent history of mechanical ventilation not associated with COVID-19, or<br>-Participants with conditions that could limit gastrointestinal absorption of capsule contents.<br>10. Is taking or is anticipated to require any prohibited therapies as outlined in Protocol.<br>11. Is unwilling to abstain from participating in another interventional clinical study through Day 29 with an investigational compound or device, including those for COVID-19 therapeutics.<br>12. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.<br>","Main Objective: 1. To evaluate the efficacy of MK-4482 compared to placebo as assessed by the percentage of participants who are hospitalized and/or die from randomization through Day 29.<br>2. To evaluate the safety and tolerability of MK-4482 compared to placebo.<br>;Secondary Objective: 1. To evaluate the efficacy of MK-4482 compared to placebo as assessed by time to improvement/resolution, and time to progression of targeted self-reported signs/symptoms of COVID 19 from randomization through Day 29.<br>2. To evaluate the efficacy of MK-4482 compared to placebo as assessed by the odds of a more favorable response on the World Health Organization (WHO) 11-point ordinal scale on Day 3, End of Therapy (EOT), Day 10, Day 15, and Day 29.<br>;Timepoint(s) of evaluation of this end point: 1. Up to Day 29<br>2. Up to Month 7 <br>3. Up to Day 5<br>;Primary end point(s): 1. Percentage of participants who are hospitalized and/or die<br>2. Percentage of participants with an adverse event (AE)<br>3. Percentage of participants who discontinued study intervention due to an AE<br>",NA,NA,NA,parent,NA,2020-09-21
EUCTR2020-002394-94-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002394-94,"Pulsed, inhaled nitric oxide (iNO) for the treatment of patients with mild or
moderate corona virus disease (COVID-19)","Corona virus disease <br>MedDRA version: 23.0
Level: LLT
Classification code 10084355
Term: COVID-19 virus test positive
System Organ Class: 100000004848
 <br>MedDRA version: 23.0
Level: LLT
Classification code 10084383
Term: Novel COVID-19-infected pneumonia
System Organ Class: 100000004862
 <br>MedDRA version: 23.0
Level: LLT
Classification code 10084401
Term: COVID-19 respiratory infection
System Organ Class: 100000004862
;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]",<br>Product Name: iNO<br>Pharmaceutical Form: Pressurised inhalation<br><br>,"Pulsed, inhaled nitric oxide (iNO) for the treatment of patients with mild or
moderate corona virus disease (COVID-19)",EUCTR,2020-06-04,2020-06-22,FALSE,Interventional clinical trial of medicinal product,"Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",6,Dr. De Backer Wilfried BV,Belgium,FALSE,Yes,04/06/2020,22/06/2020,7 September 2020,NA,20200604,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,Clinical Trial Information Desk,NA,Lange Lozanastraat 142 (Regus 2nd floor),wilfried.debacker@outlook.com,0032476084883,Dr. De Backer Wilfried BV,Inclusion criteria: <br>1. Signed Informed Consent Form (and assent as appropriate) prior to<br>the initiation of any study mandated procedures or assessments.<br>2. At least 18 years old<br>3. Hospitalized patients with proven or high suspicion of SARS-CoV-2<br>infection and on supplemental oxygen >2 L/minute and = 10 L/minute<br>4. Suspected or proven pneumonia on chest imaging<br>5. Female patients of childbearing potential must have a negative pretreatment<br>pregnancy test (serum or urine). All female patients should<br>take adequate precaution to avoid pregnancy.<br>6. Willing and able to comply with treatment schedule and study<br>procedures.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 3<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 3<br>,"Exclusion criteria: <br>1. Participating in any other clinical trial of an experimental treatment<br>for COVID-19<br>2. Gas exchange and ventilation requiring the use of any continuous<br>positive airway pressure (CPAP), or any system of Non Invasive<br>Ventilation (NIV), with Positive End-Expiratory Pressure (PEEP) = 10<br>cmH2O prior to initiation of iNO<br>3. Pregnancy, or positive pregnancy test in a pre-dose examination<br>4. Open tracheostomy<br>5. Clinical contra-indication, as deemed by the attending physician including chronic lung disease<br>6. Use of a nitric oxide donor agent such as nitroglycerin or drugs<br>known to increase methemoglobin such as lidocaine, prilocaine,<br>benzocaine or dapsone at screening<br>7. Known history or clinical evidence of heart failure, left ventricular<br>dysfunction (LVEF < 40 %)<br>8. Patients reporting hemoptysis<br>","Main Objective: The objective of this study is to examine the utility of high resolution<br>computed tomography (HRCT) to measure changes in functional<br>pulmonary imaging parameters as a function of iNO administration using<br>the device INOpulse in relation to the corona virus disease. Changes<br>from baseling to at least 5 minutes of iNO and after 5 days using iNO 8 to<br>24 h/day.<br>Clinical evaluation of INOpulse for patients with COVID-19 using clinical<br>and imaging endpoints;Secondary Objective: Not applicable;Primary end point(s): Clinical evaluation of INOpulse for patients with COVID-19 using clinical<br>1. Death<br>2.  Hospitalized, requiring mechanical ventilation or ECMO<br>3. Hospitalized, requiring non-invasive ventilation or high flow oxygen<br>4. Hospitalized, requiring supplemental oxygen<br>5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)<br>6. Hospitalized, not requiring supplemental oxygen - not requiring ongoing medical care (COVID-19 related or otherwise)<br>7. Not hospitalized - limitation on activities and/or requiring home oxygen<br>8. Not hospitalized, no limitations on activities;Timepoint(s) of evaluation of this end point: Assessed at the start of iNOpulse treatment,during treatment, upon completion of treatment and at follow up (Day 28).",NA,NA,NA,NA,NA,2020-06-04
IRCT20200317046797N1,http://en.irct.ir/trial/46573,Effect of Camostate mesylate on clinical improvement and outcome of  Coronavirus (COVID-19)-induced pneumonia,"Condition 1: Coronavirus (COVID-19)-induced pneumonia. Condition 2: COVID-19. <br>Other viral pneumonia <br>COVID-19, virus identified;J12.89;U07.1","Intervention 1: Intervention group: Twenty patients with Coronavirus (COVID-19)-induced pneumonia in addition to standard regimen of covid-19, will receive Camostate mesylate tablets for 3 days (200 mg three times daily). Intervention 2: Control group: they will receive standard regimen for COVID-19 patients.",Effect of Camostate mesylate on the outcome of Coronavirus (COVID-19)-induced pneumonia,IRCT,2020-04-03,2020-04-08,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: Simple randomization sequence will be generated with a computer from 1 to 40. The computer will divide the digits between the two groups. According to the sequence of admission, the patients will be allocated to the control or the Camostate mesylate groups regarding the sequence of computerized random list.",3,40,Tabriz University of Medical Sciences,Iran (Islamic Republic of),FALSE,Yes,2020-04-03,2020-04-08,21 April 2020,NA,20200403,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,80 years,Both,Dr Khalil Ansarin,NA,Imam Reza Hospital; Golgasht street,dr.ansarin@gmail.com,+98 41 3335 2898,Tabriz University of Medical Sciences,Inclusion criteria: Moderate to severe 2019-nCoV-infected patients<br>Being at the age of 18 to 80 years<br>Patients or authorized family members volunteered to participate in this study and signed informed consent.<br>Both genders<br>pulmonary involvement in CT scan<br>PCR positive,Exclusion criteria: Patient with elevated liver enzymes 3 time the upper limit of normal<br>Patients who are participating in other drug clinical trials<br>Patients with active pulmonary tuberculosis<br>Patients with definite bacterial and fungal infections<br>Pregnant or lactating women<br>Patient with active thrombotic event,Lung symptoms. Timepoint: At baseline (before intervention) and after drug administration. Method of measurement: Lung CT scan.;Hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: Counting the day.;Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: Observation.;Need for intubation. Timepoint: At baseline and discharge time. Method of measurement: Observation.,NA,NA,NA,NA,NA,2020-04-03
IRCT20151227025726N15,http://en.irct.ir/trial/48018,Evaluation the efficacy and safety of Umifenovir (Arbidol) Administration in comparison with Lopinavir-ritonavir (Kaletra) in COVID-19 patients,"COVID-19 pneumonia. <br>COVID-19, virus identified;U07.1",Intervention 1: Intervention group: Patients in Umifenovir received Umifenovir 200 mg TDS for 7 days. Intervention 2: Control group: Patients received Lopinavir-Ritonavir 50-200 mg in 2 Tab BID for 7 days.,Evaluating the effects of Umifenovir (Arbidol) in COVID-19,IRCT,2020-05-18,2020-04-08,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization method was used in this study. 25 blocks including 4 patients generated with online website. In each block, two patients will be assigned to Umifenovir group and two patients will be assigned to Lopinavir-ritonavir group.",3,100,Shahid Beheshti University of Medical Sciences,Iran (Islamic Republic of),FALSE,No,2020-05-18,2020-04-08,15 June 2020,NA,20200518,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,100 years,Both,Payam Tabarsi,NA,"Dr. Masih Daneshvari Hospital, Daar-Abad, Niavaran",tabarsi@nritld.ac.ir,+98 21 2712 3000,Shahid Beheshti University of Medical Sciences,Inclusion criteria: <br>                Laboratory confirmed COVID-19  with RT-PCR<br>                Oxygen saturation < 93%<br>                Fever more than 72 hours before admission<br>                Bilateral pulmonary infiltration<br>                Age over 18 years old<br>,Exclusion criteria: <br>                Chronic kidney disease (Stage IV and V)<br>                Acute kidney injury<br>                Pregnancy or breastfeeding<br>                Drug allergy history<br>                Chronic liver disease (Child pugh C)<br>                Mild phase of COVID-19<br>                Critical phase of COVID-19<br>,Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.,NA,NA,NA,NA,NA,2020-05-18
IRCT20160310026998N11,http://en.irct.ir/trial/46690,Effect of metformin in COVID-19 mortality rate and symptom improvement,"corona virus or COVID-19. <br>Coronavirus infection, unspecified;B34.2",Intervention 1: Intervention group: in addition to standard regimen of covid-19 patients will be administered Metformin 500 mg BID  orally for 2 weeks. Intervention 2: Control group: standard regimen of covid-19 patients.,Effect of metformin in COVID-19  symptom improvement and death,IRCT,2020-03-27,2020-03-20,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization generated with computer from 1 to 200. Computer will divide digits between two groups. According to the sequences of admission they will go to control or metformin group regarding computerized random list.",3,200,Tabriz University of Medical Sciences,Iran (Islamic Republic of),FALSE,No,2020-03-27,2020-03-20,21 April 2020,NA,20200327,12/3/2020 5:31:55 PM,IRCT,Not Recruiting,No,18 years,no limit,Both,Saba Ghaffary,NA,"Shahid Ghazi hospital, Tabriz University of Medical Sciences, Daneshgah Street",ghaffarys@tbzmed.ac.ir,+41 33365010,Tabriz University of Medical Sciences,"Inclusion criteria: All patients with Covid-19 symptoms in patients with the history of close contact with suspected people in the last 14 days<br>fever<br>pulmonary involvement<br>normal or reduced cbc<br>reduced lymphocyte,<br>positive PCR",Exclusion criteria: patients with type I diabetes<br>Ketoacidosis<br>decompensated heart failure<br>severe kidney failure (GFR<30 ml/min)<br>metabolic acidosis<br>severe respiratory  failure<br>immediate need for intubation,Decreased hospitalization period. Timepoint: at baseline and discharge time. Method of measurement: counting the day.;Mortality rate. Timepoint: at baseline and discharge time. Method of measurement: observation.;Decreased need for intubation. Timepoint: at baseline and discharge time. Method of measurement: observation.,NA,NA,NA,NA,NA,2020-03-27
IRCT20180923041093N3,http://en.irct.ir/trial/46721,Efficacy of the myrtle (Myrtus Communis) syrup in the treatment of suspected novel coronavirus pneumonia (COVID-19),COVID-19. <br>COVID-19;U07.1,"Intervention 1: Intervention group: Patients in this group receive medication for treatment of Covid-19 based on Fifth Edition of the Novel Corona Virus Guidelines, in addition they recieve myrtle syrup for 5 days  (Patients daily boil the contents of a pack containing 10 grams of myrtle fruit and 10 grams of sugar in 3 glasses of water gently to stay 2 glasses, then smooth it and drink one glass in the morning and one glass in the evening.). Intervention 2: Control group: Patients in this group receive medication according to the novel Corona virus country guideline version 5.",Efficacy of the myrtle syrup in the treatment of novel corona,IRCT,2020-03-28,2020-04-02,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be selected according to the inclusion criteria and then randomly assigned to the experimental and control groups according to the random sequence obtained through random allocation software.",3,70,Kerman University of Medical Sciences,Iran (Islamic Republic of),FALSE,Yes,2020-03-28,2020-04-02,15 June 2020,NA,20200328,12/3/2020 5:31:55 PM,IRCT,Not Recruiting,No,18 years,65 years,Both,Maryam Azimi,NA,"Crossroad Amir kabir, Jomhuri eslami Blvd",dr.azimm@gmail.com,+98 34 3211 0860,Kerman University of Medical Sciences,Inclusion criteria: <br>                18-65 years old<br>                Developed mild to moderate COVID-19 based on Fifth Edition of the Novel Corona Virus Guidelines<br>                Candidate for outpatient treatment<br>,Exclusion criteria: <br>                Allergy to myrtle<br>                Asthma or allergy<br>                Hypertension<br>                Diabetes<br>                Pregnancy/lactation<br>                Congestive heart failure<br>                Chronic renal failure<br>                Chemotherapy<br>                Taking Corticosteroid<br>                Immune deficiency<br>,Temperature. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Termometer.;Cough (severity-frequency). Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Fisman Cough Severity Score.;Weakness. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Muscular pain. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Respiratory rate. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Counting the number of breaths per minute.,NA,NA,NA,NA,NA,2020-03-28
IRCT20200409047007N1,http://en.irct.ir/trial/47058,The effect of plasma administration of COVID-19 survivors in patients with acute respiratory distress syndrome due to COVID-19,COVID-19 Disease. <br>COVID-19 Disease;U07.02,"Intervention 1: Intervention group: In the intervention group, patients, in addition to the current standard treatments, also receive 600 cc survivor's plasma. For the preparation of fresh plasma products, survivors with 18 to 60 years old were contacted and tested for CRP, CBC, HBS Ag, HCV Ab, HIV Ab, HTLV1 Ab, COVID 19 PCR and COVID 19 IgM & IgG antibody if they were without symptoms for at least 14 days.  If all tests are normal, 600 cc plasma will be taken from them and are prescribed to patients in less than 12 hours. Survivors should have a positive initial PCR test for coronavirus, be male, or have no history of pregnancy if they are female. The donor and the patient must be the same in blood group. Intervention 2: Control group: Patients in the control arm are selected based on information recorded in the university registry system and will be similar to the control group in terms of age, sex, underlying disease and severity of respiratory disease. In the control arm, the necessary care  and first-line therapies such as corticosteroids, antibiotics, and hydroxychloroquine will be prescribed according to the current symptoms.",Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS,IRCT,2020-04-12,2020-04-13,FALSE,interventional,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.",N/A,64,Mashhad University of Medical Sciences,Iran (Islamic Republic of),FALSE,Yes,2020-04-12,2020-04-13,7 September 2020,NA,20200412,12/3/2020 5:31:55 PM,IRCT,Not Recruiting,No,18 years,75 years,Both,Dr Mohsen Seddigh Shamsi,NA,"Department of Internal Medicine, Taqi abad Square, Mashhad",seddighshamsim@mums.ac.ir,+98 51 3859 8818,Mashhad University of Medical Sciences,Inclusion criteria: Po2 / FIO2 ratio less than 300 despite receiving standard treatment<br>The patient should be between 18 and 75 years old<br>Normal IgA level<br>Less than a week has passed since the patient entered the ICU,Exclusion criteria: Uncontrolled HTN<br>Advanced heart failure<br>Systolic blood pressure less than 90 mm Hg<br>COPD<br>The patient is intubated<br>Chronic renal failure with GFR less than 30<br>Advanced hepatic failure,Mortality rate in 4 weeks from the time of entry into the study. Timepoint: The first month of entering the study. Method of measurement: Continuous clinical evaluation.,NA,NA,NA,NA,NA,2020-04-12
IRCT20161206031256N3,http://en.irct.ir/trial/48329,Evaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19,COVID-19. <br>the code for the confirmed diagnosis of COVID-19;RA01.0.,Intervention 1: Intervention group 1: patients who will receive standard care plus 4 consecutive doses of intramuscular injection of beta-interferon (each vial contains 30 micrograms of interferon equivalent to 6 million international units. Intervention 2: Intervention group 2:  : patients who will receive standard care plus 2 doses of subcutaneous injection of Alpha-interferon (each vial contains 180 micrograms of interferon) with 7 day interval. Intervention 3: Control group 1: patients who will receive standard care plus beta-interferon placebo. Intervention 4: Control group 2: patients who will receive standard care plus alpha-interferon placebo.,Using interferon to treat COVID-19,IRCT,2020-06-02,2020-05-23,FALSE,interventional,"Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Crossover, Purpose: Treatment, Randomization description: Simple Randomization using the envelope placement method, Blinding description: Eligible patient will be randomized in 4 groups, two groups will receive interferon (alpha or beta) and two group will receive placebo. the subjects, investigator, and the data analysts will remain blinded.",2-3,76,Mashhad University of Medical Sciences,Iran (Islamic Republic of);Iran (Islamic Republic of),FALSE,No,2020-06-02,2020-05-23,15 June 2020,NA,20200602,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,no limit,Both,maryam Khoshkhui,NA,"Ghaem hospital, Ahmad abad St, Mashhad, Khorasan Razavi",b.ghaem@mums.ac.ir,+98 51 3840 0001,Mashhad University of Medical Sciences,Inclusion criteria: <br>                Adult over 18 years<br>                Clinical diagnosis of COVID-19<br>,Exclusion criteria: History of allergy to human albumin or interferon,"Body temperature. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Thermometer, Celsius.;Respiratory rate. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Pulse oximeter, Breaths per minute.;The ratio of arterial oxygen partial pressure to fractional inspired oxygen. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Ventilator, Millimeter of mercury (mmHg).;Blood gas level. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Blood Gas Analyzer, percent.",NA,NA,NA,NA,NA,2020-06-02
IRCT20200705048011N1,http://en.irct.ir/trial/49481,The effect of garlic and cinnamon essential oil on the treatment of patients with  corona (COVID-19),"Covid-19. <br>Coronavirus infection, unspecified;B34.2","Intervention 1: Intervention group: Recipient of garlic essential oil. Patients in the intervention group will take the drug prepared from garlic for 1 week. A drop of garlic made by Amin Pharmaceutical Company is consumed ten drops daily for a week. Each 10 drops of Garlic contains 250 grams of garlic extract. It should be noted that patients will receive routine medication for coronary artery disease. The trained nurse will perform the intervention. Intervention 2: Control group: No intervantion. Intervention 3: Intervention group: Intervention group: Recipients of cinnamon essential oil. Patients of the second intervention group will take cinnamon medicine for 1 week. Cinnamon drops made by Zardband pharmaceutical company .It will be use three times a day and 5 drops in a glass of water, tea each time. It should be noted that patients will receive routine medication for the treatment of coronary heart disease.",Garlic and cinnamon on the treatment of patients with corona,IRCT,2020-08-16,2020-08-22,FALSE,interventional,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.",N/A,45,Sabzevar University of Medical Sciences,Iran (Islamic Republic of),FALSE,Yes,2020-08-16,2020-08-22,7 September 2020,NA,20200816,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,10 years,no limit,Both,Nasrin Fazel,NA,"No 2,Tohid Shahr Ave, Campus University Building,Sabzevar",shohreh1368@yahoo.co.uk,+98 51 4401 1000,Sabzevar University of Medical Sciences,Inclusion criteria: Inclusion criteria include all patients with corona virus who had a positive RT-PCR test.,"Exclusion criteria: Exclusion criteria for patients with corona negative test<br>Those who are not willing to continue participating in the study.<br>Patients with allergies to garlic and cinnamon,<br>Patients taking anticoagulants,  having diabetes,<br>Insomnia,<br>Pemphigus, asthma,<br>Transplantation,<br>Pregnancy.",Headache. Timepoint: The first day and the last day of the intervention. Method of measurement: Visual Analogue Scale.;Body pain. Timepoint: The first day and the last day of the intervention. Method of measurement: Visual Analogue Scale.,NA,NA,NA,NA,NA,2020-08-16
IRCT20170207032444N3,http://en.irct.ir/trial/47119,The efficacy and safety of Thalidomide in severe Covid19 pneumonia: Arandomized controlled clinical trial,COVID19. <br>disease diagnosis of COVID-19 confirmed by laboratory testing.;U07.1,"Intervention 1: Intervention group: Tab Thalidomide ( Talidex) from Alan pharmaceuticals, daily until 14 days. Both case and control group will be received hydroxychloroquine tablet 100 mg BD, methylprednisolon 50 mg IV, antibiotic depend on physician choice (Ceftriaxone, Azithromycin, Vancomycin), Syrup Diphenhydramine and acetaminophen codeine for symptom control and amp Enoxaparin 40 mg SC daily during hospitalization. Intervention 2: Control group: this group doesnt receive extra drugs. Both groups receive tab hydroxychloroquine 200 mg BID for 5 days, Tab Acetaminophen Codeine and syrup diphenhydramine for symptom control, Antibiotics depend on physician choice (Ceftriaxone, Azithromycin, Vancomycin), Amp Enoxaparin 40 mg SC daily during hospitalization and amp Methylprednisolone 50 mg IV daily for 7 days.",Thalidomide in COVID19,IRCT,2020-04-17,2020-04-15,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization will be done. We use random allocation service for randomization. There is no allocation concealment.",3,60,Esfahan University of Medical Sciences,Iran (Islamic Republic of),FALSE,No,2020-04-17,2020-04-15,18 May 2020,NA,20200417,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,75 years,Both,Farzane Ashrafi,NA,Ostanadari street,farashrafi@yahoo.com,+98 31 3222 2127,Esfahan University of Medical Sciences,Inclusion criteria: 18-75 year old men and 50-75 year old women admitted in hospital<br>Spo2 less than 85% in admission<br>Clinical symptoms and signs compatible with COVID19 infection and positive PCR test or lung HRCT abnormalities compatible with COVID19 pneumonia<br>No need to intubation in first 24 hour of admission<br>No multiorgan failure at presentation<br>No shock state at presentation<br>Obtained informed consent,"Exclusion criteria: Hepatic failure (Child Pugh score = C, AST> 5 times of the upper limit normal)<br>Severe renal dysfunction (GFR less than 30cc per min)","Efficacy of Thalidomide in severe Covid19 pneumonia. Timepoint: Daily until discharge and then weekly until 28 days. Method of measurement: history, pulse oximetry, sphygmomanometer.",NA,NA,NA,NA,NA,2020-04-17
IRCT20080901001165N48,http://en.irct.ir/trial/47318,Investigating the efficacy of Zofa (a herbal medicine) in symptom management of patients with COVID-19,COVID-19. <br>Covid-19;U07.1,"Intervention 1: Intervention group: Syrup Zofa 10 ml every 8 hours, for 7 days. (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2: Control group: Routine treatment according to the latest national guideline for the treatment of new corona-virus.",Investigating the efficacy of Zofa (a herbal medicine) in symptom management of patients with COVID-19,IRCT,2020-04-22,2020-03-30,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block Randomization method is used to randomized the patients.",3,100,Niak pharmaceutical company,Iran (Islamic Republic of),FALSE,No,2020-04-22,2020-03-30,18 May 2020,NA,20200422,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,no limit,Both,Ali Ghazvini,NA,"Baqiyatallah university of medical science, south Sheikh-Bahaei St., Mollasadra St., Vanak Sq., Tehran, Iran",qazvinia@gmail.com,+98 21 8245 5393,Bagheiat-allah University of Medical Sciences,"Inclusion criteria: age equal or more than 18 years;<br>The patient have written consciously and freely consent to participate in the study.<br>Confirmed diagnosis of COVID-19, with Laboratory (RT-PCR) confirmation.<br>Confirmed diagnosis of COVID-19, with lung CT-Scan result, which is typical for COVID-19 pulmonary involvement.<br>The patient has clinical symptom of COVID-19 (dry cough, respiratory distress, fever)<br>Less than 7 days have passed since the onset of symptoms;",Exclusion criteria: The patient is in another clinical trial at the same time.<br>The patient needs to receive medical care from the intensive care unit,"Clinical symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: pulse oxymetery device.;Clinical symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer.",NA,NA,NA,NA,NA,2020-04-22
IRCT20160131026298N4,http://en.irct.ir/trial/49925,Pilot clinical trial to evaluate the effectiveness of Herbal Cyclotide complex syrup as a prevention of disease complications in people exposed to COVID-19 virus,"COVID-19 viral disease. <br>Coronavirus infection, unspecified;B34.2","Intervention 1: Intervention group: Consumable product includes herbal syrup composed of cyclopeptide fraction with Ziziphus spina-cristi and Pimpinela anisum hydroalcoholic extract and orange peel. The dose of the product is 20 ml every 8 hours after eating, which is prepared by Herbi Pharmed Pharmaceutical Company. Intervention 2: Control group: do not use any drugs for prevention and only follow health protocols to prevent infection.",Evaluation of the effectiveness of Cyclotide complex herbal syrup in preventing COVID-19 virus in exposed individuals,IRCT,2020-08-04,2020-04-20,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Randomization will be by block randomization (quadruple random blocks). Randomization units are individuals. 60 outpatients referred to the hospital emergency department are allocated in one of the two intervention and control groupsaccording to  form of random string produced by online random allocation . This study is a non-concealed method and people in the intervention group will receive the intervention drug to prevent COVID-19 complications, but in the control group the drug is not used.",2-3,60,Bagheiat-allah University of Medical Sciences,Iran (Islamic Republic of),FALSE,No,2020-08-04,2020-04-20,17 August 2020,NA,20200804,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,70 years,Both,Shiva Shamshiri,NA,"No.4, Gholhak Ave, Shari'ati Blvd",shiva.shamshiri90@yahoo.com,+98 21 2642 1927,Tehran University of Medical Sciences,"Inclusion criteria: People over the age of 18 who have had close contact with a person with COVID-19 in the last 4 days and signed an informed consent form (close contact is defined as those who live at home with an infected person or depending on their employment situation in Less than two meters away from the infected person.) And have no previous or current history of COVID-19.<br>Age between 18 and 70 years<br>No previous diagnosis of COVID-19 (if possible, test negative for IgG and IgM antibodies.)<br>Absence of symptoms such as fever, body aches, olfactory and taste disturbances, cough, shortness of breath, diarrhea in the last 1 month",Exclusion criteria: Current incidence of COVID-19 is confirmed by PCR and clinical signs.<br>History of autoimmune disease<br>History of rheumatic disease<br>Pregnancy and lactation<br>Age under 18 years<br>People sensitive to any component of the product<br>People who can not follow up.<br>Any clinical reason that may prevent you from entering the study.<br>Do not take two doses of the drug,Polymerase chain reaction (PCR) analysis result. Timepoint: At the beginning of the intervention and the day 14. Method of measurement: Polymerase chain reaction (PCR) analysis.;Liver function test result. Timepoint: At the beginning of the intervention and the day 14. Method of measurement: Measurement of aspartate aminotransferase (AST) and Alanine transaminase (ALT) factors.;Fragment D-dimer test result. Timepoint: At the beginning of the intervention and the day 14. Method of measurement: Blood test - Fragment D-dimer measurement.;Measurement of serum iron. Timepoint: At the beginning of the intervention and the day 14. Method of measurement: Blood test - Total iron binding capacity factor (TIBC) measurement.;COVID-19 Antibodies. Timepoint: At the beginning of the intervention and the day 14. Method of measurement: Measurement of IgG COVID-19 and IgM COVID-19 factors.,NA,NA,NA,NA,NA,2020-08-04
IRCT20201004048922N1,http://en.irct.ir/trial/51443,Evaluation of the effectiveness of intravenous infusion of human COVID-19 hyperimmune plasma with specific antibody titer in hospitalized patients with Covid-19: a randomized clinical trial,COVID-19. <br>Covid-19;U07.1,"Intervention 1: Intervention group: Human COVID-19 hyperimmune plasma with a specific antibody titer, volume 500ml, intravenous infusion over 4 hours; In addition to routine treatment based on the latest update of the national protocol. Intervention 2: Intervention group: Routine Human COVID-19 hyperimmune plasma, volume 500ml, intravenous infusion over 4 hours; In addition to routine treatment based on the latest update of the national protocol. Intervention 3: Control group: Routine treatment based on the latest update of the national protocol.",Evaluation of the effectiveness of intravenous infusion of human COVID-19 hyperimmune plasma with specific antibody titer in hospitalized patients with Covid-19: a randomized clinical trial,IRCT,2020-10-10,2020-10-11,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the Block Randomization method will be used. To perform, by visiting the site www.sealedenvelope.com, while entering the number of intervention groups, sample size, block size (which was selected according to the number of study groups, 6), a random list of patients in 3 groups will be obtained that this list will be used for random allocation of patients.",3,75,Tehran University of Medical Sciences,Iran (Islamic Republic of),FALSE,Yes,2020-10-10,2020-10-11,9 November 2020,NA,20201010,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,no limit,Both,Hamidreza Abtahi,NA,"Imam Khoemini Complex hospital, Dr.Gharib St., End of Keshavarz Blvd.",hrabtahi@sina.tums.ac.ir,+98 21 6693 9001,Tehran University of Medical Sciences,"Inclusion criteria: Confirmed or suspected COVID-19 pneumonia based on PCR or pulmonary imaging;<br>Presenting clinical symptoms of COVID-19 (fever, cough, dyspnea);<br>O2 saturation equal or less than 93%;<br>Age equal or more than 18 years old;<br>The patient has informed and free written consent to participate in the study;<br>Less than 7 days passed from the onset of clinical symptoms to the time of enrollment;<br>The patient should not attend another clinical trial at the same time.",Exclusion criteria: Advanced renal or liver disease;<br>Active cancer;<br>Known Hypersensitivity reaction to Plasma-derived drugs;<br>Pregnancy;<br>Lactation;<br>The patient may be excluded from the study during the first 48 hours.,Length of hospital stay due to covid-19. Timepoint: Daily until discharge or death. Method of measurement: Count the days of hospitalization from the time of admission to the hospital until discharge or death.,NA,NA,NA,NA,NA,2020-10-10
IRCT20200324046850N3,http://en.irct.ir/trial/46718,The effect of naproxen on the healing process of patients with COVID-19,"corona virus disease. <br>COVID-19, virus not identified;U07.2","Intervention 1: Control group: Standard drugs of the national protocol (hydroxychloroquine sulfate 200mg, two single-dose tablets (Tehran Daru) , two single-dose tablets (Pars), Kaletra tablets (Lupinavir / Ritonavir) every 12 hours 2 tablets 50/200)+ A placebo every 12 hours (in terms of appearance and color similar to 500 mg naproxen). Intervention 2: Intervention Group: Standard Protocol Drugs For 5 days (Hydroxychloroquine Sulfate 200mg Two Single Dose tablets (Tehran Daroo) , Kaletra tablets (Lupinavir / Ritonavir)  every 12 hours, 2 tablets 50/200) + Naproxen 500 mg every 12 hours (Pars Daru) For 5 days.",The effect of naproxen on the healing process of patients with COVID-19,IRCT,2020-03-30,2020-04-20,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, block randomization was performed using block size: 6. Allocation sequence and concealment codes are generated by www.sealedenvelope.com. The closed envelope method was used to hide the allocation sequence, Blinding description: Participants and researchers in this study are blind, and the placebo used in the control group is the pill, which is similar in appearance and color to naproxen.",3,80,Abadan University of Medical Sciences,Iran (Islamic Republic of),FALSE,Yes,2020-03-30,2020-04-20,15 June 2020,NA,20200330,12/3/2020 5:31:55 PM,IRCT,Not Recruiting,No,15 years,no limit,Both,Sara Mobarak,NA,"Abadan School of Medical Sciences,Beginning of the  30 meters Ave, Zolfaghari street, Abadan city.",s.mobarak@abadanums.ac.ir,+98 61 5338 4004,Abadan University of Medical Sciences,Inclusion criteria: <br>                COVID-19 patients that have positive PCR test of nasopharyngeal sample or have positive CT Scan<br>                Having consent to participate in the intervention<br>,Exclusion criteria: <br>                pregnant or breast feeding women<br>                Those taking losartan and captopril.<br>                Those with a history of intestinal ulcers or gastrointestinal bleeding.<br>                Children under 14 years<br>,"Time to clinical improvement defined as start of taking medication time to   the next 28 days. Timepoint: The beginning of the study ,the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Medical record.",NA,NA,NA,NA,NA,2020-03-30
IRCT20160118026097N5,http://en.irct.ir/trial/48401,Evaluation of the effectiveness of plasmapheresis treatment in comparison with standard treatment in improving the symptoms of high-risk patients,"COVID19. <br>COVID-19, virus identified;U07.1","Intervention 1: ""control group:"" receiving the treatment protocol of the Ministry of Health as hydroxychloroquine sulfate tablets 200 mg or two chloroquine phosphate tablets 250 mg and kaletra tablets (lupinavir / ritonavir) 50/200 mg or tablets (atazanavir / ritonavir) 300 / 100 mg. Intervention 2: ""The intervention group:"" receiving the treatment protocol of the Ministry of Health and plasmapheresis treatment as 2 liters daily for 3 to 5 sessions (Estimated volume of plasma (in liters) = weight 0.07 x (kg) x (1 -hematocrit) and FFP replacement method 4 units, albumin 5 vials, calcium 2 ampoules, the rest of normal serum.",Effect of plasmapheresis in the treatment of high-risk covid patients in Qom province,IRCT,2020-09-19,2020-03-29,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: does not have.",3,60,Ghoum University of Medical Sciences,Iran (Islamic Republic of),FALSE,No,2020-09-19,2020-03-29,6 October 2020,NA,20200919,12/3/2020 5:31:55 PM,IRCT,Not Recruiting,No,18 years,60 years,Both,jamshid vafaeemanesh,NA,beheshti blv,jvafaeemanesh@yahoo.com,+98 25 3612 2526,Ghoum University of Medical Sciences,"Inclusion criteria: Adults (defined) as older than 18 years and younger than 60 years<br>Laboratory confirmation of Covid19 infection with reverse transcription polymerase chain reaction (RT-PCR) from oropharyngeal or nasopharyngeal swab<br>Covid19-related new organ dysfunction, including hypoxia due to the need for supplemental oxygen to maintain oxygen saturation greater than 94%, hypotension (systolic blood pressure less than 90 mm Hg) or the need for vasopressor, an inotropic drug ( Renal impairment (increase in creatinine by more than 50% from baseline, decrease in glomerular filtration rate by more than 25% from onset or urination less than 0.5 ml / kg for 6 hours, decrease in Glasgow scale by 2 or more, ie 13 or less Out of 15 points, thrombocytopenia less than 150,000 platelets per millimeter, gastrointestinal symptoms requiring hospitalization (eg severe nausea, vomiting, diarrhea or abdominal pain)","Exclusion criteria: Sensitivity or sensitivity to Lopinavir or Ritonavir or recombinant IFN-ß1b, including, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema or angioedema syndrome.<br>Use of drugs that are contraindicated with lopinavir/ritonavir and should not be substituted or discontinued during the study period, such as inhibitors CYP3A<br>Pregnancy-Eligible female participants of childbearing age are tested for pregnancy before enrolling in the study<br>HIV infection is known to cause concern about the resistance to lepinavir / ritonavir if used in combination with other anti-HIV drugs.<br>Hemoglobin  under 8<br>Known heart failure EF  under 50%<br>According to the 31st National Guide, all vulnerable groups, such as the mentally disabled, emergency patients, or prisoners, are excluded from the study.","The primary outcome (mortality within 30 days after hospitalization). Timepoint: After 24 hours in the hospital, every day. Method of measurement: View.",NA,NA,NA,NA,NA,2020-09-19
IRCT20200518047497N1,http://en.irct.ir/trial/48289,Effect of Laris - Hyssop combined herbal distilled on the improving clinical and paraclinical symptoms in patients with COVID-19: A Randomized Controlled Trial,COVID-19. <br>Novel Cronavirus Disease (COVID-19);U07.01,"Intervention 1: Intervention group: In the intervention group, participants will receive Laris-Hyssop distillate (including hyssop, Echium amoenum, Adiantum capillus-veneris, Hollyhocks, Eucalyptus, Malva, Platanus, chamomilla), 10 ml every 8 hours for 14 days orally. Both groups will receive routine treatments. Intervention 2: Control group: The control group will receive a placebo (no therapeutic value), resembled the Laris-Hyssop distillate with the same prescription. Both groups will receive routine treatments.",Effect of Laris - Hyssop combined herbal distilled on the improving clinical and paraclinical symptoms in patients with COVID-19,IRCT,2020-05-21,2020-05-25,FALSE,interventional,"Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be allocated to trial groups (intervention and placebo groups) randomly using Random Allocation Software (RAS) trough random block sizes of 4 and 6 with an allocation ratio of 1:1. Patients will receive a sealed bottle containing Laris-Hyssop distillate or placebo by giving 10 ml every 8 hours for 14 days. Random sequencing allocation will be produced by the person who has not to participate in the research. Bottles will be numbered from 1 to 80 according to the sequence generated. Both groups will receive routine treatments, Blinding description: This study is a randomized controlled triple blinded trial, meaning that the patients, researcher, and statistical analyst will be blind to the received active drug or placebo. Random sequencing allocation will be produced by the person who has not to participate in the research. Each",N/A,80,Tabriz University of Medical Sciences,Iran (Islamic Republic of);Iran (Islamic Republic of),FALSE,Yes,2020-05-21,2020-05-25,15 June 2020,NA,20200521,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,15 years,no limit,Both,Javad Ahmadian heris,NA,"Sheshgelan, Tabriz, East Azerbaijan Province",Jahmadian75@gmail.com,+98 41 3526 2280,Tabriz University of Medical Sciences,Inclusion criteria: <br>                COVID-19 patients aged 15 years and older<br>                Newly admitted people (first day of hospitalization)<br>                Obtaining informed consent  to participate in the trial<br>                Non-participation in another clinical trial  simultaneously<br>,"Exclusion criteria: <br>                Epilepsy<br>                Having liver or kidney failure according to the patient's statement, and doctor examination or based on creatinine, SGOT, SGPT, LDH tests.<br>                Having a chronic disease (cardiovascular disease, uncontrolled high blood pressure (hypertension above 160/100 despite taking medication), complicating diabetes,  respiratory diseases, BMI> 40 according to the  patient's statement, and  doctor examination<br>                Immunodeficiency (treated with Corticosteroids over 12.5 mg / d Prednisolone for more than two weeks, chemotherapy, malignancies, organ transplants, HIV patients, other viral diseases)<br>                Pregnancy (according to the patient's  statement and examination by a doctor)<br>                Breastfeeding (according to the patient's statement)<br>",Serum CRP level. Timepoint: Before-After intervention (14 days). Method of measurement: Biochemical method.;Number of inpatient days. Timepoint: After intervention. Method of measurement: Questionnaire.;Mortality. Timepoint: Daily. Method of measurement: Questionnaire.;Respiratory Rate. Timepoint: Daily. Method of measurement: Observation.;Oxygen saturation (SpO2). Timepoint: Daily. Method of measurement: Pulse Oximeter.;Serum White  Blood Cell count. Timepoint: Before- After intervention (14 days). Method of measurement: laboratory cell counter.,NA,NA,NA,NA,NA,2020-05-21
IRCT20140911019125N6,http://en.irct.ir/trial/46668,Study the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumonia,"Corona virus disease. <br>COVID19, virus identified;U07.1","Intervention group:  The extracted tooth is brought to the lab . After tooth extraction, it is enzymatically digested and cultured. After the cells have reached the required level, 40 million cells are injected intravenously at one time. Patients receive common medications at the same time..",The effect of dental pulp mesenchymal stem cells in treatment of  corona disease,IRCT,2020-04-04,2020-04-04,FALSE,interventional,"Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.",2,10,Kerman University of Medical Sciences,Iran (Islamic Republic of),FALSE,Yes,2020-04-04,2020-04-04,21 April 2020,NA,20200404,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,95 years,Both,Alireza Farsinejad,NA,"Paramedical college, Kerman university of medical science, Haft Bagh Blvd, Kerman, Iran",afarsinejad@kmu.ac.ir,+98 34 3132 5374,Kerman University of Medical Sciences,Inclusion criteria: Patients aged between 18-95 years<br>Patients Approved for Covirus 19 by Laboratory Methods,Exclusion criteria: Patients undergoing other clinical trials<br>Patients with standard and routin treatments show progress in clinical signs,"Pulmonary Condition. Timepoint: Before intervention and 14, 28 days after intervention. Method of measurement: CT scan.;Expression of nucleic acid of virus. Timepoint: Before intervention and 14 and 28 days after intervention. Method of measurement: real time PCR.;Lymphocytes count. Timepoint: Before intervention and 14 and 28 days after intervention. Method of measurement: Flowcytometry.;Patients clinical signs. Timepoint: before intervention and 14 and 28 days after intervention. Method of measurement: Observation.",NA,NA,NA,NA,NA,2020-04-04
IRCT20201016049048N1,http://en.irct.ir/trial/51767,Evaluation of the effectiveness of Iranian Borage Aerial Part infusion on the management of Covid-19 mild to moderate symptoms: a clinical trial,"corona virus (covid-19). <br>COVID-19, virus identified;U07.1",Intervention 1: Intervention group: Patients in the intervention group will receive Iranian Borage Aerial Part infusion (1 g/100 cc water) TID for 5 days in addition to the routine treatment. Intervention 2: Control group: Patients in the control group will receive the placebo (100 cc boiled water) TID for 5 days in addition to the routine treatment.,Effect of Iranian Borage on the management of Covid-19 symptoms,IRCT,2020-11-04,2020-11-07,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization method will be blocked randomization (Quaternary random blocks). Randomization units are individuals. Sixty patients are randomly assigned to one of the two intervention and control groups using Random Allocation Software. This study is a double-blind method and patients in the intervention group will receive the intervention drug in addition to the routine treatment, but in the control group, they will receive the placebo in addition to the routine treatment, Blinding description: The study will be a double-blind trial and only the evaluator knows the results and the code of the intervention or control group. The containers of the drug and placebo are quite similar in appearance. The intervention and control groups will be separated by receiving a code.",0 (exploratory trials),60,Shiraz University of Medical Sciences,Iran (Islamic Republic of),FALSE,Yes,2020-11-04,2020-11-07,30 November 2020,NA,20201104,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,no limit,Both,Mohammad mehdi Zarshenas,NA,"Shiraz school of pharmacy, Karafrin Street",zarm@sums.ac.ir,+98 71 3242 4127,Shiraz University of Medical Sciences,"Inclusion criteria: Patients with COVID-19 confirmed by RT-PCR and Ground glass view on CT scan<br>Patients with COVID-19 symptoms (such as fever, muscle pain, chest discomfort, cough, reduced CBC and platelets, increased CRP and ESR) who have been exposed to suspected people in the last 14 days<br>Having a conscious consent form signed to participate in the study<br>Not participating in similar studies at the same time","Exclusion criteria: People with a history of allergy to herbal medicines<br>Having liver, kidney and cardiovascular diseases<br>Permanent use of psychiatric drugs<br>Pregnant and breastfeeding women<br>People who can't swallow<br>Having endocrine diseases like diabetes",Fever. Timepoint: At the beginning and end of the study. Method of measurement: Digital thermometer.;Respiratory status. Timepoint: At the beginning and end of the study. Method of measurement: Observation.;White blood cell count. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;Platelet blood count. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;Erythrocyte Sedimentation Rate. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;C-reactive protein. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;Vital capacity. Timepoint: At the beginning and end of the study. Method of measurement: Observation.,NA,NA,NA,NA,NA,2020-11-04
ISRCTN13311119,http://isrctn.com/ISRCTN13311119,"The efficacy and safety of Siddha Treatment in Symptomatic Participants with novel coronavirus infectious disease (COVID-19): A Multicenter, Randomized, Open-Label, Active-controlled Randomised Clinical Trial",COVID-19 (SARS-CoV-2 infection) <br>Respiratory <br>COVID-19 (SARS-CoV-2 infection),"<br>                The study consists of the following periods/assessments for participants in both the intervention and control arms.<br>                1. Screening period: -3 to -1 days. This will involve taking informed consent, assessing eligibility and comorbidity (e.g. Hypertension, Diabetes, Cardiovascular disease, etc.) through taking a medical and surgical history, smoking history, previous medication history, demographic history, physical examination, serology, 12-lead ECG, and vital signs.<br>                2. Treatment period: 0 to 14 days<br>                3. Follow-up period: 0 to 28 days. Patients will attend five study assessments at 0 (baseline assessment), 2, 8, 15 and 29 days. If nasal swabs taken at 15 days are negative participants will be invited to return 24 h later on day 16 for a second swab.<br>                4. Safety Follow-up assessment: 28 days after the last dose of the Siddha treatment was received in the event of early termination<br><br>                The patients selected for participation will be assigned randomly to one of the two treatment groups, Siddha treatment regimen + Standard of Care, or Standard of Care only, in 1:1 ratio balancing the stratification factor of co-morbidity status.<br><br>                The stratified permuted block randomization design will be used to randomize the patients in 1:1 ratio among the two treatment groups.<br><br>                Siddha treatment regimen + Standard of care will involve Siddha treatment with Kabasura kudineer and Brammanandha bairavam where indicated in addition to standard care as per local/government guidance. Kabasura kudineer will be given in the dose of 60 ml, twice a day for 7 days taken 90 minutes before food. Brammanandha bairavam will be given in the dose of 100 mg, three times a day for 7 days, ta",START (Siddha Treatment Accelerating Recovery from SARS-CoV-2 Test) trial of Siddha treatment for patients with novel coronavirus infectious disease (COVID-19),ISRCTN,2020-04-24,2020-04-30,FALSE,Interventional,"A Multicenter, Randomized, Open-Label, Active-controlled Randomised Clinical Trial (Treatment)",Phase II,116,Eminentlabs GmbH,India,FALSE,Yes,24/04/2020,30/04/2020,4 May 2020,NA,20200424,12/3/2020 5:31:55 PM,ISRCTN,Recruiting,No,NA,NA,Both,NA,NA,NA,NA,NA,NA,"Inclusion criteria: <br>                1. Aged between 18 and 75 years<br>                2. Laboratory-confirmed COVID-19<br>                3. Presence of any 2 symptoms of COVID-19: fever, cough, sore throat, myalgia, fatigue, headache or dyspnea<br>                4. Not currently hospitalized or under immediate consideration for hospitalization. Hospitalization is defined as admission where patients require parenteral/Intravenous (IV) medications or IV fluids, oxygen or ventilatory support in hospital. Isolation or quarantine inside the hospital premises alone will not be considered as hospitalization.<br>                5. Meets clinical features of the following grades of severity:<br>                5.1. Suspected/confirmed cases in COVID Care Centres, clinically assigned as mild and very mild, presenting with fever and/or upper respiratory tract illness<br>                5.2. Suspected/confirmed cases in Dedicated COVID Health Centres, clinically assigned as moderate, presenting with  pneumonia with no signs of severe disease (Respiratory Rate 15 to 30 breaths/minute, SpO2 90%-94%)<br>                6. Willing to practice contraception during the entire study treatment period and for 3 months after the last treatment of IMP is administered, using either double barrier contraception or sexual abstinence (when this is in line with the preferred and usual lifestyle of the participant)<br>                7. Patients or their legal representatives have personally signed and dated signed the informed consent form (ICF) before completing any study-related procedure, which means before any assessment or evaluation that would not have formed a part of his normal medical care<br>                8. Willing to adhere and comply with the protocol-related procedures<br>                9. Willing to take Siddha drug regimen for COVID-19 infection<br>                10. Willing to not participate in other clinical studies within 30 days after the last administration from the first administration of the study drug<br>","Exclusion criteria: <br>                1. Viral pneumonia with cause other than SARS-CoV-2<br>                2. Severe or critical COVID-19 infection<br>                3. Taken antibiotics/antivirals in the past 1 week<br>                4. History of Asthma, COPD or any other chronic lung disease<br>                5. Active malignancy<br>                6. Received organ transplantation in the past 6 months or planning surgery<br>                7. Unable to take food or drugs orally<br>                8. Malabsorption or GI abnormalities which may affect drug absorption<br>                9. Severe underlying diseases affecting survival, including but not limited to: blood diseases, dyscrasia, active bleeding, severe malnutrition, etc.<br>                10. Subjects who are pregnant or lactating, have a pregnancy plan (including plans for sperm donation or egg donation), or who may fail to take effective contraceptive measures within the next 6 months<br>                11. Allergic constitution, or known allergy to investigational products<br>                12. Testing positive for HIV, Hepatitis B and Hepatitis C at screening<br>                13. Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper limit of normal.<br>                14. Requiring Extracorporeal Life Support Program (ECLS), i.e. Extracorporeal Membrane Oxygenation (ECMO), Extracorporeal carbon dioxide removal (ECCO2R) or Registered Respiratory Therapist (RRT)<br>                15. Life expectancy < 48 h<br>",Proportion of patients confirmed as negative for COVID-19 in 2 consecutive throat/nasal swabs (taken 24 hours apart) at 15 and 16 days,NA,26/06/2020,NA,NA,NA,2020-04-24
ISRCTN88057279,http://isrctn.com/ISRCTN88057279,PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT),"COVID-19 (SARS-CoV-2 infection) in dialysis, vasculitis, and kidney transplant patients <br>Infections and Infestations","<br>                Patients will be randomised to receive either 1:1 oral hydroxychloroquine (HCQ) or standard care (no HCQ). Randomisation will be carried out using a validated bespoke automated randomisation system. Randomisation will be stratified by PROTECT sub-group, age and centre.<br><br>                Haemodialysis subgroup<br>                Dosing: 600 mg per week given as 200 mg three times per week after each haemodialysis session for 6 months<br><br>                Vasculitis and transplant subgroups<br>                Dosing: 800 mg for first 2 days followed by 400 mg once a week for 6 months<br><br>                Duration of follow up (all subgroups):<br>                Until the end of the trial, on average 6 months<br>",Preventative treatment for patients at risk of COVID-19 infection (PROTECT),ISRCTN,2020-05-14,2020-10-01,FALSE,Interventional,<br>                Open-label multi-centre randomized controlled trial<br>                (Prevention)<br>,Phase II/III,500,Cambridge University Hospitals NHS Foundation Trust,United Kingdom,FALSE,Yes,14/05/2020,01/10/2020,10 August 2020,NA,20200514,12/3/2020 5:31:55 PM,ISRCTN,Recruiting,No,NA,NA,Both,Kerry,Brusby,"
                    Cambridge Clinical Trials Unit
                    Box 401 Addenbrookes Hospital
                    Hills Road
",add-tr.protect@nhs.net,+44 (0)1223 25 4472,NA,"Inclusion criteria: <br>                1.1. Dialysis patients receiving in-centre haemodialysis, or<br>                1.2. Diagnosis of vasculitis (according to Chapel Hill Consensus Conference 2012 definitions) and have received immunosuppression (including prednisolone =5 mg daily and/or an immunosuppressive agent (cyclophosphamide (oral or IV), rituximab, azathioprine, MMF, methotrexate, tociluzumab, alemtuzumab, abatacept, leflunomide) in the last 3 years, or<br>                1.3. Transplant patients that have a functional kidney transplant (updated 15/05/2020, previously: Transplant patients)<br>                2. Aged at least 18 years<br>                3. No previous confirmed COVID-19 diagnosis<br>                4. No symptoms highly suggestive of COVID-19 infection at screening or since 1st March 2020<br>","Exclusion criteria: <br>                1. Inability to provide informed consent<br>                2. Hypersensitivity reaction to hydroxychloroquine, chloroquine or 4-aminoquinolines<br>                3. Contraindication to taking hydroxychloroquine as prophylaxis e.g known epilepsy<br>                4. Already taking chloroquine, hydroxychloroquine or 4-aminoquinolines<br>                5. History of any retinopathy including diabetic retinopathy requiring laser therapy<br>                6. Taking medications which are contra-indicated alongside HCQ - digoxin, halofantrine, amiodarone, moxifloxacin, cyclosporin, mefloquine, praziquantel<br>                7. Known history of prolonged QTc<br>                8. eGFR <15 ml/min<br>                9. Multi-organ transplant recipient (added 15/05/2020)<br>",<br>                Time to confirmed COVID-19 diagnosis via online questionnaires at 6 weekly intervals<br>,NA,03/05/2025,NA,NA,NA,2020-05-14
JPRN-jRCTs051200036,https://jrct.niph.go.jp/latest-detail/jRCTs051200036,Efficacy and safety of nintedanib on lung fibrosis in severe pneumonia induced by coronavirus disease 2019: Historical control study.,Severe pneumonia induced by COVID-19 <br>COVID-19;COVID-19,Administration of nintedanib via nasogastric tube,Efficacy  of nintedanib on severe COVID-19 pneumonia.,JPRN,2020-07-27,2020-07-27,FALSE,Interventional,"single arm study, open(masking not used), historical control, single assignment, treatment purpose",2,30,Umemura Yutaka,Japan,FALSE,Yes,27/07/2020,27/07/2020,11 August 2020,NA,20200727,12/3/2020 5:31:55 PM,JPRN,Recruiting,No,>= 20age old,Not applicable,Both,Yutaka,Umemura,"3-1-56, Bandaihigashi, Sumiyoshiku, Osaka, Osaka",plum0022@yahoo.co.jp,+81-6-6692-1201,Osaka,Inclusion criteria: 1) Obtaining sufficient informed consent for this trials from participates or their close relatives<br>2) 20 years or older at the time of informed consent<br>3) Confirmed COVID-19 by PCR assay or LAMP assay<br>4) Respiratory failure requiring mechanical ventilation<br>5) Availability of a nasogastric tube,Exclusion criteria: 1) History of Idiopathic pulmonary fibrosis<br>2) History of chronic liver failure (Child Pugh B or C)<br>3) Breastfeeding and pregnancy <br>4) History or proven risk factors of thrombosis<br>5) Proven risk factors of bleeding<br>6) Unavailable to use enteral tube <br>7) Ineligibility for other reasons,28 days mortality after the initiation of mechanical ventilation,NA,NA,NA,NA,NA,2020-07-27
JPRN-jRCT2031200180,https://jrct.niph.go.jp/latest-detail/jRCT2031200180,A Phase II/III Study of Sargramostim in Patients with Coronavirus Disease-2019 (COVID-19) - NPC-26-1,Coronavirus disease-2019  (COVID-19) <br>Coronavirus,"Randomized, Placebo control, Double blind comparative study",A Phase II/III Study of Sargramostim,JPRN,2020-11-04,2020-11-24,FALSE,Interventional,"randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose",2-3,60,Taniguchi Masaki,Japan,FALSE,Yes,04/11/2020,24/11/2020,1 December 2020,NA,20201104,12/3/2020 5:31:55 PM,JPRN,Not Recruiting,No,>= 20age old,< 80age old,Both,Masaki,Taniguchi,"NMF Kayabacho Bldg., 1-17-24, Shinkawa, Chuo-ku, Tokyo",taniguchi.masaki@nobelpharma.co.jp,+81-3-6670-3800,"Nobelpharma Co., Ltd.",Inclusion criteria: (1) Hospitalized patients under treatment who were severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] positive by polymerase chain reaction (PCR) test.<br>(2) Patients with clinically diagnosed pneumonia and a percutaneous oxygen saturation [SpO2] of 93% or less on breathing of room air at bed rest.<br>(3) Patients for whom written informed consent has been obtained from those themselves or the legally acceptable representatives.<br>(4) Patients aged 20 years or older and younger than 80 years at the time of obtaining informed consent.,"Exclusion criteria: (1) Patients who have been participating in other intervention studies, such as studies on unapproved pharmacotherapy, within 90 days prior to screening.<br>(2) Patients who have experienced off-label use of approved drugs (including those for COVID-19 treatment other than steroids as standard treatment) within 7 days prior to screening. <br>(3) Patients who are not expected to survive longer than 24 hours after commencement of study drug administration.<br>(4) Patients who are using invasive ventilator or extracorporeal membrane oxygenation (ECMO).<br>(5) Patients who have a chronic respiratory disease requiring continuous home oxygen therapy or ventilator use.<br>(6) Patients with an underlying condition that is considered very unlikely to withdraw ventilator (e.g., motor neuron disease, Duchenne muscular dystrophy, rapidly progressive interstitial pulmonary fibrosis).<br>(7)Patients who have a disease including bronchial asthma, lower respiratory tract infections, and interstitial lung diseases that may affect the assessment of the clinical study, since before the symptom onset of COVID-19.<br>(8) Patients who have a disease including leukemia and leukocytosis that causes leukocytosis.<br>(9) Patients who have a chronic kidney disease requiring dialysis.<br>(10) Patients who have severe liver failure (Child Pugh grade C).",Number of days to achieve at least 2-rank improvement on a 7-point ordinal scale from baseline until Day 28,NA,NA,NA,NA,NA,2020-11-04
NL8547,https://trialregister.nl/trial/8547,"REDUCING HOSPITAL ADMISSION OF ELDERLY IN SARS-CoV-2 PANDEMIC VIA THE INDUCTION OF TRAINED IMMUNITY BY BACILLUS CALMETTE-GUÉRIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL",COVID-19,BCG-vaccine,"REDUCING HOSPITAL ADMISSION OF ELDERLY IN SARS-CoV-2 PANDEMIC VIA THE INDUCTION OF TRAINED IMMUNITY BY BACILLUS CALMETTE-GUÉRIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL",NTR,2020-04-22,2020-04-16,FALSE,Interventional,"
                        Randomized: No, 
                        Masking: Single, 
                        Control: Placebo, 
                        Group: undefined, 
                        Type: 2 or more arms, randomized
",NA,1600,Radboudumc,The Netherlands,FALSE,No,22/04/2020,16/04/2020,30 November 2020,NA,20200422,12/3/2020 5:31:55 PM,Netherlands Trial Register,Recruiting,No,NA,NA,NA,Simone,Moorlag,NA,Simone.Moorlag@radboudumc.nl,+31-24-3667218,NA,Inclusion criteria: •	Adult (= 60 years),"Exclusion criteria: <br>•	Fever (>38 ºC) within the past 24 hours <br>•	Suspicion of current active viral or bacterial infection <br>•	Expected vaccination during the first three months of the study period<br>•	Severely immunocompromised subjects. This exclusion category comprises: a) subjects with known infection by the human immunodeficiency virus (HIV-1); b) neutropenic subjects with less than 500 neutrophils/mm3; c) subjects with solid organ transplantation; d) subjects with bone marrow transplantation; e) subjects under chemotherapy; f) subjects with primary immunodeficiency; g) severe lymphopenia with less than 400 lymphocytes/mm3; h) treatment with any immunosuppressant drugs such as anti-cytokine therapies, and treatment with oral or intravenous steroids defined as daily doses of 10mg prednisone or equivalent for longer than 3 months, or probable use of oral or intravenous steroids in the following four weeks <br>•	Active solid or non-solid malignancy or lymphoma within the prior two years<br>•	Active participation in another research study that involves BCG administration<br>",•	SARS-CoV-2 related hospital admission,NA,NA,NA,NA,NA,2020-04-22
PACTR202006760881890,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12168,"A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Clinical Trial of the Safety and Efficacy of Convalescent Plasma for the Treatment of COVID-19 in Hospitalized Patients in Lagos State
",<br>Covid-19;Covid-19,;Convalescent Plasma;Normal saline,Lagos Covid-19 Convalescent Plasma Trial (LACCPT),PACTR,2020-06-23,2020-08-01,FALSE,Interventional,"Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Simple randomization using a randomization table created by a computer software program,Sealed opaque envelopes",Phase-2,100,Lagos State Government,Nigeria;Nigeria;Nigeria;Nigeria;Nigeria;Nigeria,FALSE,Yes,23/06/2020,01/08/2020,30 November 2020,NA,20200623,12/3/2020 5:31:55 PM,PACTR,Recruiting,No,19 Year(s),44 Year(s),Both,Hussein,AbdurRazzaq,"Block 4, State Secretariat, Alausa",Hussein.abdur-razzaq@lagosstate.gov.ng,+2348099355417,Head Health Research,"Inclusion criteria: A. Moderate to Severe COVID-19 disease cases<br>1. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. <br>2. Understands and agrees to comply with planned study procedures.  <br>3. Agrees to the collection of N-P, OP swabs, sputum and venous blood per protocol.  <br>4. Male or non-pregnant female adult =18 years of age at time of enrolment.  <br>5. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen <7 days prior to randomization. <br>6. Illness of any duration, and at least one of the following: > 50% radiographic infiltrates by imaging (chest x-ray, CT scan, etc.) OR Clinical assessment (evidence of rales/crackles on exam) AND SpO2 = 94% on room air OR requiring mechanical ventilation and/or supplemental oxygen. <br>7. If female of childbearing age, should agree to use at least one primary form of contraception for the duration of the study (acceptable methods will be determined by the site)","Exclusion criteria: 1.	ALT/AST > 5 times the upper limit of normal.  <br>2.	Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30)  <br>3.	Pregnancy or breast feeding.  <br>4.	Anticipated transfer to another hospital which is not a study site within 72 hours.  <br>5.	Allergy to any study medication","1. SARS-CoV-2 detectable in NP, OP or sputum samples at days 1, 3, 5, 7, 9, & 11.<br>2. Clinical status of subject at day 11 (on a 7-point ordinal scale)<br>•	Not hospitalized, no limitations on activities  <br>•	Not hospitalized, limitation on activities <br>•	Hospitalized, not requiring supplemental oxygen <br>•	Hospitalized, requiring supplemental oxygen <br>•	Hospitalized, on non-invasive ventilation or high flow oxygen devices  <br>•	Hospitalized, on invasive mechanical ventilation <br>•	Death.",NA,NA,NA,NA,NA,2020-06-23
RBR-876qb5,http://www.ensaiosclinicos.gov.br/rg/RBR-876qb5/,Eculizumab for the treatment of Covid-19 severe cases - : Eculizumabe for COVID,"Coronavirus disease <br>Coronavirus infection, unspecified ;A00-B99;Coronavirus infection, unspecified","This project will recruit 10 individuals of both sexes, with age between 18 and 80 years old, who have been diagnosed with COVID-19 infection confirmed by RT-PCR and with severe respiratory failure. All 10 patients will receive eculizumab intravenously once a week, at approximately the same time each day of application. The administered dose will be 900mg (each ampoule has 300mg in the concentration of 10mg / mL) every 7 days, in a 30 minute intravenous infusion without the need for an infusion pump, for 3 weeks (total of 3 doses of 900mg applied).<br>Laboratory tests will be performed weekly on all participants, before each dose of the drug (biochemical tests, blood count, inflammatory tests and complement dosage). For these tests, we will try to use the blood samples already collected to perform routine hospital tests, requested by the attending physician, in order to avoid additional venipuncture. Inflammatory tests will also be evaluated daily (according to the institutional protocol, in tests already collected in the care routine of Hospital das Clínicas). After finishing the treatment with the intervention, we will reassess the patients clinically weekly, during 4 weeks. This reassessment will be based on an interview, physical examination and laboratory tests.<br>There will be no control group in the study.;Drug;Complement Inactivator Proteins",Treatment of severe cases of Covid-19 with Eculizumab,RBR,2020-06-08,2020-05-27,FALSE,Intervention,"Clinical trial treatment, single-group, open label, single-arm",1-2,10,"Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo - Ribeirão Preto, SP, Brazil",Brazil,FALSE,No,08/06/2020,27/05/2020,4 November 2020,NA,20200608,12/3/2020 5:31:55 PM,REBEC,Recruiting,No,18Y,80Y,-,Bruno,Pires,"Avenida Bandeirantes, 3900. Campus Universitário, Monte Alegre",brunogarciapires@gmail.com,+55(16)3602-2294,Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo,"Inclusion criteria: COVID-19 diagnosis confirmed by RT-PCR. Age between 18 and 80 years. Severe form of SARS-CoV-2 infection. ECOG prior to infection < ou igual a 2.<br><br>","Exclusion criteria: Age less than 18 years or more than 80 years. Known hypersensitivity and / or previous eculizumab therapy; septic shock and / or multiple organ failure syndrome; hstory of infection by human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C (HCV) (with the exception of chronic infections treated or cured for HBV and HCV, which will be accepted); neoplasms in activity or under treatment, except for basal cell carcinomas; any major surgery, extensive radiation therapy, delayed toxicity chemotherapy, biological therapy, or immunotherapy within 6 weeks prior to clinical trial screening; any investigational medication other than the study drugs in the 6 weeks before the first dose of the study drug; history of chronic liver disease (Child-Pugh B or C); hystory of chronic kidney disease (glomerular filtration rate <30 mL / min / 1.73 m²); any contraindication to the use of penicillin for bacterial meningitis's prophylaxis during the use of eculizumab; any contraindications to the use of contraceptive methods in childbearing age women.","Overall survival of patients who started treatment, assessed using Kaplan-meier curves and comparison with the historical survival of other patients affected by the severe form of COVID-19 in other studies.",NA,NA,NA,NA,NA,2020-06-08
RPCEC00000321,https://rpcec.sld.cu/en/trials/RPCEC00000321-En,Expanded clinical use of CIGB-258 in the treatment of serious or critically ill patients by COVID-19 (COVID-19),COVID-19 respiratory distress <br>COVID-19;Respiration Disorders;COVID-19,"- Patients WITH invasive mechanical ventilation, CIGB-258 Peptide: 1 mg intravenously until extubation of the patient. Subsequently, the same dose and route is continued, every 24 hours, for three days. If there is no clinical, gasometric and radiological improvement after 72 hours, the dose may be increased to 2 mg, with a frequency of 12 hours (at the discretion of the physician). Never exceed 4 mg daily. - Patients WITHOUT invasive mechanical ventilation, CIGB-258 Peptide: 1 mg intravenously 1 mg every 24 hours until the patient reverses his condition (that is, that he does not require oxygen therapy and there are no signs and / or symptoms of acute respiratory failure). In case of unfavorable evolution and need for mechanical ventilation, the CIGB-258 therapeutic scheme is modified every 12 hours, detailed above (for patients with invasive mechanical ventilation).;Peptides;Peptide CIGB-258,        Jusvinza",VIDA study,RPCEC,2020-06-22,2020-04-27,FALSE,Interventional,Allocation: N/A: single arm study. Masking: Open. Control group: Uncontrolled. Assignment: Single group. Purpose: Treatment,N/A,All patients meeting selection criteria,"Center for Genetic Engineering and Biotechnology (CIGB), in Havana",Cuba,FALSE,No,22/06/2020,27/04/2020,30 November 2020,NA,20200622,12/3/2020 5:31:55 PM,RPCEC,Recruiting,No,19 years,None,Male/Female,Verena,Muzio Gonzalez,"Ave. 31 entre 158 y 190, Cubanacan, Playa.",verena.muzio@cigb.edu.cu,+53-72716022,Center for Genetic Engineering and Biotechnology (CIGB).,"Inclusion criteria: 1) Virological diagnosis by PCR-RT of infection to SARS-CoV-2. 2) Patients with confirmed respiratory distress / multifocal interstitial pneumonia. 3) Need for oxygen therapy to maintain SO2> 93%. 4) Worsening of lung involvement, defined as one of the following criteria: a) Worsening of oxygen saturation > 3 percentage points or decrease in PaO2 > 10%, with stable FiO2 in the last 24 hours; b) Need to increase FiO2 in order to maintain stable SO2 or new need for mechanical ventilation in the last 24 hours; c) Increase in the number and / or extension of the lung consolidation areas. 5) Patients in whom a clinical condition prior to hyperinflammation is suspected, according to the following criteria: a) sustained fever above 38 combined with criteria 2 or 3 and 4; b) dyspnea requiring oxygen therapy by mask or nasal fork, to maintain an oxygen saturation above 93; c) polypnea greater than 25 ventilations per minute, requiring oxygen therapy by mask or nasal fork, to maintain an oxygen saturation above 93; d) choppy language that does not allow you to count to 10. 6) Express voluntariness of the patient, family member or impartial witness.",Exclusion criteria: 1) Known hypersensitivity to any of the components of the formulation. 2) Pregnancy or lactation.,Reduction of the deterioration of the pulmonary function (Proportion of patients that did not require increasing FiO2 to maintain stable SO2 and without the need for intubation and / or Percentage of patients that decrease the values of positive pressure at the end of expiration [PEEP]). Measurement time: On the 7th day after starting the treatment.,15/09/2020,30/08/2020,NA,NA,NA,2020-06-22
